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ABSTRACT 
Purpose 
Quality assurance (QA) for intensity modulated radiotherapy (IMRT) has evolved substantially. In 
recent years, various ionization chamber or diode detector arrays have become commercially 
available, allowing pre-treatment absolute dose verification with near real-time results. This has led 
to a wide uptake of this technology to replace point dose and film dosimetry and to facilitate QA 
streamlining.  However, arrays are limited by their spatial resolution giving rise to concerns about 
their response to clinically relevant deviations. The common factor in all commercial array systems is 
the reliance on the gamma index (γ) method to provide the quantitative evaluation of the measured 
dose distribution against the Treatment Planning System (TPS) calculated dose distribution. The 
mathematical definition of the gamma index presents computational challenges that can cause a 
variation in the calculation in different systems. The purpose of this thesis was to evaluate the 
suitability of detector array systems, combined with their implementation of the gamma index, in 
the verification and dosimetry audit of advanced IMRT. 
 
Method 
The response of various commercial detector array systems (Delta4®, ArcCHECK®, and the PTW 2D-
Array seven29™ and OCTAVIUS II™ phantom combination, Gafchromic® EBT2 and composite EPID 
measurements) to simulated deliberate changes in clinical IMRT and VMAT plans was evaluated. The 
variability of the gamma index calculation in the different systems was also evaluated by comparing 
against a bespoke Matlab-based gamma index analysis software. A novel methodology for using a 
commercial detector array in a dosimetry audit of rotational radiotherapy was then developed. 
Comparison was made between measurements using the detector array and those performed using 
ionization chambers, alanine and radiochromic film. The methodology was developed as part of the 
development of a national audit of rotational radiotherapy. Ten cancer centres were asked to create 
a rotational radiotherapy treatment plan for a three-dimensional treatment-planning-system 
(3DTPS) test and audited. Phantom measurements using a commercial 2D ionization chamber (IC) 
array were compared with measurements using 0.125cm3 ion chamber, Gafchromic film and alanine 
pellets in the same plane. Relative and absolute gamma index (γ) comparisons were made for 
Gafchromic film and 2D-Array planes respectively. A methodology for prospectively deriving 
Abstract  
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appropriate gamma index acceptance criteria for detector array systems, via simulation of deliberate 
changes and receiver operator characteristic (ROC) analysis, has been developed. 
 
Results 
In the event of clinically relevant delivery introduced changes, the detector array systems evaluated 
are able to detect some of these changes if suitable gamma index passing criteria, such as 2%/2mm, 
are used. Different computational approaches can produce variability in the calculation of the 
gamma index between different software implementations. For the same passing criteria, different 
devices and software combinations exhibit varying levels of agreement with the Matlab predicted 
gamma index analysis. This work has found that it is suitable to use a detector array in a dosimetry 
audit of rotational radiotherapy in place of standard systems of dosimetry such as ion chambers, 
alanine and film. Comparisons between individual detectors within the 2D-Array against the 
corresponding ion chamber and alanine measurement showed a statistically significant concordance 
correlation coefficient (ρc>0.998, p<0.001) with mean difference of -1.1%±1.1% and -0.8%±1.1%, 
respectively, in a high dose PTV. In the γ comparison between the 2D-Array and film it was found 
that the 2D-Array was more likely to fail in planes where there was a dose discrepancy due to the 
absolute analysis performed. A follow-up analysis of the library of measured data during the audit 
found that additional metrics such as the mean gamma index or dose differences over regions of 
interest can be gleaned from the measured dose distributions.  
 
Conclusions 
It is important to understand the response and limitations of the gamma index analysis combined 
with the equipment and software in use. For the same pass-rate criteria, different devices and 
software combinations exhibit varying levels of agreement with the predicted γ analysis. It has been 
found that using a commercial detector array for a dosimetry audit of rotational radiotherapy is 
suitable in place of standard systems of dosimetry. A methodology for being able to prospectively 
ascertain appropriate gamma index acceptance criteria for the detector array system in use, via 
simulation of deliberate changes and ROC analysis, has been developed. It has been shown that 
setting appropriate tolerances can be achieved and should be performed as the methodology takes 
into account the configuration of the commercial system as well as the software implementation of 
the gamma index. 
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1 INTRODUCTION 
1.1 BRIEF OVERVIEW OF RADIOTHERAPY 
Radiotherapy is the use of ionising radiation to treat benign and malignant (cancerous) superficial 
and deep-seated tumours within the human body. Throughout history, cancer has been a major 
cause of morbidity, but is now the second biggest cause of death in the western world. It has been 
estimated that one in two people in the UK born after 1960 will develop cancer at some stage in 
their lives due to increased life expectancy [1]. More than 200 different types of cancer have been 
identified to date, all cancers however are basically similar; they all result from uncontrolled cell 
growth causing tumours. The four most common cancers, which make up over 50% of all cancer 
incidences, are breast, lung, bowel (including anus) and prostate cancer. Radiotherapy plays an 
important role in curative and palliative treatment of cancer, sometimes in conjunction with other 
therapeutic agents such as surgery, chemotherapy and hormonal therapy.   
 
Until recently the standard technique for treating cancer using radiotherapy in the UK was Three 
Dimensional Conformal Radiotherapy (3DCRT). This technique uses 3-4 beams of uniform intensity 
shaped around the tumour. As technology advanced so had the ability to develop more accurate 
techniques of delivering radiotherapy. Advanced techniques such as Intensity Modulated Radiation 
Therapy (IMRT) and more recently Volumetric Modulated Arc Radiation Therapy (VMAT) have 
recently been introduced into clinical practice and are quickly becoming the ‘gold standard’. These 
techniques use multiple beams of varying intensity therefore better  conforming the high doses to 
the tumour and resulting in better normal tissue avoidance. 
 
1.2 OVERVIEW OF IMRT TECHNOLOGY 
Intensity-Modulated Radiation Therapy can be typically described as ‘a radiation treatment 
technique with multiple (radiation) beams in which at least some of the beams are intensity-
modulated and intentionally deliver a non-uniform intensity to the target. The desired dose 
distribution in the target is achieved after superimposing such beams from different directions. The 
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additional degrees of freedom are utilised to achieve a better target dose conformity and/or better 
sparing of critical structures’ [2]. A lower dose is therefore delivered to normal tissues around the 
tumour target. Figure 1.1 shows a comparison between a three-dimensional conformal radiotherapy 
(3DCRT) prostate treatment plan and an IMRT treatment plan. It can be clearly seen that the 3DCRT 
plan results in a high dose to the rectum whereas better sparing is achieved in the IMRT plan. Better 
conformity to the target can also be seen in the IMRT plan. 
 
 
Figure 1.1 Comparison of conventional (3 field), left, and an IMRT (5 field) plan, right.  
 
The early history of the concept of IMRT began in 1982 when Brahme et al [3] published their 
landmark paper on ‘Solution of an integral equation encountered in radiation therapy’. The paper 
looked at an idealised case with rotational symmetry. This was a doughnut-shaped target volume 
with a circular critical structure in the middle. The integral solution calculated the beam intensity 
profile that delivers the doughnut shaped distribution through a full rotation of the beam and 
therefore showing that a highly non-uniform intensity profile was needed to produce a uniform dose 
distribution in the doughnut-shaped target volume. 
 
The practical formulation of the inverse solution was developed by Webb [4]. The inverse problem 
has no exact solution as there are no physical intensity modulated profiles that deliver the full 
prescription dose to the tumour and no dose to surrounding critical structure.  It is desirable to 
therefore design an IMRT treatment plan such that it comes as close as possible to the ideal 
prescription. This has become the basis of the optimisation solutions used in modern IMRT planning. 
 
Before the advent of multi-leaf collimators many researchers and investigators of IMRT in the late 
1980’s/early 1990’s assumed that many more than 10 beams were required to simulate a rotational 
treatment. Bortfeld et al. [5] realised that less than 10 radiation fields were often enough to provide 
Rectum 
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clinically acceptable dose conformity and OAR sparing and therefore his work paved the way for 
motor-driven MLCs to be practically implemented in IMRT. 
 
There are currently two distinct methods of delivering static gantry IMRT. This collaborative PhD was 
based at the Royal Surrey County Hospital NHS Foundation Trust (RSCH) where the sliding window 
technique is used; see Figure 1.2 for a schematic. In the sliding window technique the radiation 
beam is constantly on while the MLCs move across the field at a defined speed such that the 
intensity of the beam is modulated. The MLC leafs conventionally move from left to right. The sliding 
window IMRT is typically used by the Varian Linear Accelerators (Varian Medical Systems, Palo Alto, 
CI).  At other centres, IMRT may be delivered using the step-and-shoot method, typically found on 
Elekta Linear Accelerators (Elekta Ltd, Crawley, UK).  
 
 
Figure 1.2 Schematic of IMRT delivery for prostate cancer. 
 
1.3 ROTATIONAL IMRT 
The term rotational IMRT may be used to classify techniques that deliver a modulated dose with a 
constantly rotating gantry. The concept of delivering radiation treatment through an arc existed 
years before the introduction of 3DCRT and IMRT. Conformal modulated arc therapy was first 
suggested in 1965 [6]. In the last 30 years, significant developments such as computer-controlled 
1. Introduction 
4 
 
MLCs, IMRT, and the ever increasing power of desktop computer processing speed and memory 
have been achieved to bring the technology from research labs and into the clinic. These include 
Tomotherapy [7], Intensity Modulated Arc Radiotherapy (IMAT); [8], and Volumetric Modulated Arc 
Radiotherapy (VMAT) [9].  
 
 
Figure 1.3 Schematic showing difference between static IMRT (left) and rotational IMRT (right). 
 
1.3.1 Tomotherapy 
In Tomotherapy [7], the linear accelerator head is mounted in a CT scanner style gantry. Radiation is 
delivered as a rotating fan-beam. Intensity modulation is achieved by means of a binary collimator 
which either opens or closes. In the initial research system, a slice-by-slice approach was used; 
however this required precise indexing of the table from one slice to the next slice.  Tomotherapy 
was subsequently developed as a helical delivery system. This included the development of a slip-
ring rotating gantry to achieve more efficient dose delivery by simultaneous gantry rotation and 
couch translation. Tomotherapy’s triumvirate of a rotating fan beam, couch translation, and binary 
MLCs allows for highly complex distributions to be achieved. In addition, long volumes can be 
treated. For example it has been demonstrated that Total Bone Marrow Irradiation can be achieved 
successfully by conforming the high dose to the marrow whilst sparing surrounding normal tissue 
[10]. On a conventional Linac, a comparable plan would require multiple isocentres. 
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1.3.2 Intensity modulated arc radiotherapy (IMAT) 
IMAT was proposed as an alternative to Tomotherapy [8] using a conventional ‘C-arm’ linear 
accelerator. IMAT uses a rotating cone-beam with varying shapes and dose weightings to achieve 
modulation. The full arc is first approximated as a series of evenly spaced fixed fields, yielding 
multiple intensity patterns. The strategy in IMAT is to convert those patterns into multiple segments 
delivered with multiple overlapping arcs.  
 
As the gantry moves from one angle to the next, MLC speed restrictions must be taken into account; 
i.e. an optimal field shape may need to be altered to allow for a smooth delivery. This may reduce 
plan quality in complex situations [11]. IMAT does not need to move the patient during treatment 
and also allows for non-coplanar delivery. 
 
Although IMAT was first demonstrated in 1995 [8], the concept did not advance commercially and 
there was limited clinical uptake. There may be a few reasons for this. Firstly, there was no efficient 
optimisation algorithm available and the burden of optimising individual segments within the arcs 
would have been computationally expensive, and therefore time consuming.  Secondly, the inability 
of linacs, at the time, to vary dose-rate dynamically meant that equally spaced angles had to be used 
and combined with the technical limitations of the MLC, plan quality for complex cases was 
degraded. Thirdly, it was necessary to deliver IMAT through multiple overlapping arcs, which may 
have been unattractive compared to static IMRT due to the increased delivery time. 
 
However, it had been predicted that a single arc with a sufficient number of aperture shape 
variations could create an optimal treatment plan [8]. Various works have been performed that have 
attempted to use a single arc for IMAT and have been reviewed [11]. The major commercial 
breakthrough came after Otto [9] developed a single-arc IMAT algorithm by assuming that the dose-
rate could be varied. This was referred to as volumetric modulated arc therapy (VMAT). 
 
1.3.3 Volumetric modulated arc radiotherapy (VMAT) 
In VMAT,  the dose rate and gantry speed variation as well as MLC modulation is performed within 
the optimisation algorithm [9]. This uses progressive beam angle sampling to optimise a large 
number of apertures (~1 aperture / 2° gantry angle). Aperture shapes and weights are optimised 
initially for a number of coarsely spaced gantry angles and, as the solution converges, additional 
gantry angles are inserted. In the initial steps, aperture connectivity is ignored, giving the algorithm 
more freedom to find an optimal solution. As the angular spacing becomes finer, aperture shapes 
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are linearly interpolated from their angular neighbours. The result is a smooth transition from one 
aperture shape to the next meaning the gantry can be continuously rotating. This allows for delivery 
time within 2 minutes for a standard 2Gy/# treatment regime. This contribution and others [8,9,12–
24] has paved the way for a rapid clinical and commercial uptake.  
 
Varian Medical Systems adopted Otto’s VMAT solution and marketed it with the trademark name 
RapidArc™ in 2007 (Varian Medical Systems Ltd, Palo Alto, CL). The main change made by Varian was 
that the Linac control was updated to allow variable dose rate and gantry rotation. Shortly after, 
Elekta (Crawley, UK) marketed their solution with the trademark name VMAT™. Various third party 
manufactures have created a VMAT solution that can be used on either Varian or Elekta machines, 
for example Philips Medical Systems developed a VMAT algorithm known as SmartArc™ [25]. 
 
A search for peer-reviewed articles in Scopus using the keywords Volumetric Modulated Arc 
Therapy, RapidArc, SmartArc, returned 822 literature citations between 1st January 2008 and 31st 
December 2014. In 2008 there were just 7 papers but by the end of 2010 there were 122, and 228 
by the end of 2011. This dramatic increase in the number of publications within a short space of time 
(particularly when one considers the timescales involved in the peer review process, which can take 
a few months for a paper to be published) demonstrates the remarkable speed of the clinical uptake 
of this technology.  
 
For a clinical perspective on VMAT, the reader is referred to the comprehensive review that has 
been conducted by Teoh et al [26]. This gives a detailed account of the clinical use of VMAT in a 
range of different cancer sites. A systematic review of treatment planning studies has been 
published in the journal Radiotherapy & Oncology [27] which the reader is also referred to. 
 
1.4 QUALITY ASSURANCE AND VERIFICATION FOR ADVANCED RADIOTHERAPY 
The advancing rate of radiotherapy technology necessitates the need for extra quality assurance 
[28]. As the complexity of treatment technology continues to increase so do the potential 
uncertainties and inaccurate dose delivery can have clinical implications [29,30]. Additionally, 
radiotherapy dosimetry audits allow for the testing of procedures and the identification of errors 
[31–43].  
 
The complexity of the 3D dose distributions in IMRT treatments requires careful quality assurance. 
IMRT distributions are characterised by numerous steep dose gradients in order to conform as 
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tightly as possible to the target volume whilst minimising the dose to normal tissue. Conventional 
3DCRT treatments are composed of relatively large uniform beams and therefore patient-specific 
quality assurance consisted of simple independent dose and monitor unit verification calculations 
which are supplemented by routine machine specific QA (which includes basic checks such as output 
constancy, energy, beam flatness & symmetry etc.). In IMRT, the complex MLC pattern means that 
an independent dose calculation alone is not sufficient as these methods, even at the time of 
writing, estimate a point dose. In IMRT, the dose at any point is delivered by a fraction of the total 
modulated field. The MLC pattern varies from patient to patient and the number of MUs is heavily 
linked to the complexity of this pattern. Therefore it is necessary to perform a patient-specific QA 
measurement to verify the fluence from the IMRT beams to ensure the suitability of the MLC 
pattern. Traditionally this has been done using ionisation chambers and film within cubic or semi-
anthropomorphic phantoms. An example is given in the next paragraph, however the interested 
reader is referred to the review by Low et al [44] which gives a detailed account of these early IMRT 
QA methods. 
 
Once an IMRT treatment plan for a patient is complete it is possible in radiotherapy treatment 
planning systems to create a verification plan. Essentially, a verification plan is a copy of the same 
geometry, dynamic MLC, and monitor units calculated on a CT scan of the physical phantom to be 
used for performing the verification measurement. This plan can be used to generate a predicted 
dose for comparison against the measurement. For ionisation chamber measurements, the 
predicted dose can be typically calculated by creating a contour on the CT dataset that simulates the 
collecting volume of the chamber (see Figure 1.4). The mean dose to this structure is then recorded. 
It was often necessary to move the isocentre position relative to the phantom in order to position 
the ion chamber in regions of the dose distribution that are of interest, e.g. in the high dose PTV 
region. It is also necessary to set the position so that the dose across the chamber is homogeneous 
and to avoid areas of high dose gradient as a minor error in the setup of the phantom can result in 
large dose measurement error. For comparison against film measurements (see schematic in Figure 
1.5), a dose plane can be exported from the TPS at the same plane as the film within the phantom. 
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Figure 1.4 Coronal image showing three regions (shown as blue rectangles) for measuring 
ionisation chamber dose points in a clinical prostate & nodes IMRT treatment plan. 
In this example the rectangle drawn represent the collection volume of a Farmer 
type 0.6cm3 ionization chamber and are sampling the (1) high dose PTV, (2) the 
elective nodal PTV, and (3) a low dose sparing region. 
 
Figure 1.5 Schematic representation of typical setup for film irratiation in cubic solid water 
phantom. The film is represnented as yellow sheets sandwiched between individual 
layers of solid water. 
 
In this example, the ion chamber provides an absolute point dose measurement and the film 
provided a relative 2D measurement of the IMRT fluence. These methods however are time 
consuming, particularly for film measurements which require heavy resources for calibration, 
processing, and analysis as well as the costs of single-use films requiring multiple batches to be 
purchased, which also require physical archiving. Radiographic or radiochromic film suffers from 
variation in the sensitivity from one batch to another and non-linear dose response resulting in 
measurement uncertainties that render them unsuitable for routine absolute dose checks. These 
resource costs have historically limited the number of patients that could be treated with advanced 
IMRT. Therefore a new measurement methodology was needed.   
 
In recent years, various commercial 2D and 3D ionization chamber or diode detector arrays have 
become available. These electronic devices have allowed for verification of absolute dose in 2D or 
1 
2 
3
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3D with near real-time results. This allows for analysis to be performed in the IMRT QA 
measurement session and therefore out of tolerance results can be investigated immediately. At the 
time of writing, conventional methods such as ionization chamber point dose measurements and 
film dosimetry are gradually being replaced by detector arrays. 
 
International recommendations, such as from the European Society for Radiotherapy & Oncology 
(ESTRO), advise that 3D measurements for pre-treatment QA should be performed for every patient. 
The International Commission on Radiation Units and Measurement (ICRU) recommends that for 
low gradient regions (<20% per cm) of the dose distribution, the dose difference normalised to the 
prescribed point should be no more than ±3.5% and for high gradient regions (>20%/cm) the dose 
points should have a distance to agreement of ≤3.5mm. However the most common quantitative 
technique used is called the gamma index analysis which combines dose difference and distance to 
agreement into a single dimensionless metric [45]. A gamma index of less than 1 indicates that the 
measurement point lies within the dose difference and/or distance to agreement passing criteria. A 
common acceptance threshold is that ≥95% of measured points should pass with a gamma index of 
<1 for passing criteria 3% dose difference and 3mm distance to agreement [46]. Further information 
on the theory of this metric is given in Chapter 2. 
 
1.5 SCOPE OF THIS RESEARCH 
Detector arrays are limited by their detector spacing, as shown in Figure 1.6, giving rise to concerns 
about their sensitivity to errors. Understanding the limitations of these devices is therefore critical.  
 
 
Figure 1.6  Schematic representation of film resolution (left) vs detector array resolution (right). 
In the latter case, individual detectors are shown as grey squares. 
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The aim of this PhD is to conduct a critical appraisal of this new measurement technology for the 
verification of IMRT and VMAT. The main research questions are: 
 
1. How do detector arrays respond to known changes in treatment plan delivery? 
2. How is the gamma index calculation affected by the limited detector spacing and the 
different available commercial configurations? 
3. Are there software and/or hardware, or both, effects on the gamma index calculation? 
4. Can a detector array be used in a dosimetry audit in place of standard methods such as ion 
chamber and film? 
5. What optimal tolerances should be used? 
 
The following gives an outline of the topics discussed in the different chapters of this thesis: 
 
 The theoretical background behind the gamma index method of quantitative evaluation in 
IMRT QA, which is a significant theme throughout this thesis, is the focus of Chapter 2.  
 Chapter 3 gives a review of detector array technology and the various options that are 
available, and those used in this thesis.  
 A methodology developed for characterising and critically evaluating commercial detector 
arrays for IMRT/VMAT pre-treatment verification is developed in Chapter 4. This work has 
been published in the Journal of Applied Clinical Medical Physics 1. This chapter addresses 
research question number 1 by using clinical treatment plans with deliberately introduced 
changes. 
 Chapter 5 introduces a bespoke gamma index software written in Matlab (MathWorks Inc.) 
by the author which has been developed to investigate the computing challenges of the 
gamma index calculation and to look at the impact of different software implementations on 
its calculation. Chapter 5 addresses research question number 2. 
 Chapter 6 focuses on a comparison between three commercial detector array systems in 
terms of the combined hardware and software effect on the gamma index calculation. This 
work has been published as a research paper in Radiotherapy & Oncology 2. It has also been 
presented orally at the 2nd ESTRO Forum in Geneva 2013 and as an invited talk in the IPEM-
RTSIG IMRT Verification Meeting in London 2012. Chapter 6 addresses research question 
number 3. 
                                                          
 
1 Hussein M et al. Journal of Applied Clinical Medical Physics 2013;14:4460. Copyright retained by 
author. 
2 Hussein M et al. Radiotherapy & Oncology 2013;109:370-6. Copyright was required to be 
transferred to Elsevier for publication; however permission has been granted by Elsevier to 
reproduce work in this thesis. 
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 The effect on 2D and 3D gamma index calculations of the spacing of detector arrays is 
investigated and discussed in Chapter 7. This work has been partially presented as poster 
presentation at the ESTRO 33 Conference in Vienna April 2014. Chapter 7 addresses research 
question numbers 2 and 3. 
 Work has been carried out to develop a methodology for a National Rotational Radiotherapy 
Audit in the UK in collaboration with the National Physical Laboratory (NPL), National Cancer 
Research Institute Radiotherapy Trials Quality Assurance group (NCRI RTTQA), and Institute 
of Physics and Engineering in Medicine (IPEM). The details of this work are discussed in 
Chapter 8. This work has been published as an original research paper in Radiotherapy & 
Oncology 3 and has been presented orally at the ESTRO 31 conference in Barcelona 2012, 
and the IPEM Biennial Radiotherapy Meeting in Oxford 2012. Chapter 8 addresses research 
question numbers 4. 
 Chapter 9 focuses on methodologies for deriving optimal acceptance criteria for detector 
arrays for use in benchmarking studies. . Chapter 9 addresses research question numbers 4. 
 Chapter 10 gives the overall discussion and conclusions 
 Chapter 11 discusses the prospects for future research directions respectively. 
 
A full list of papers and presentations arising from this work are listed in Appendix B. 
                                                          
 
3 Hussein M et al. Radiotherapy & Oncology 2013;108:78-85. Copyright was required to be 
transferred to Elsevier for publication; however permission has been granted by Elsevier to 
reproduce work in this thesis. 
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2 EVALUATION OF DOSE DISTRIBUTIONS: THE 
GAMMA INDEX ANALYSIS TECHNIQUE 
This chapter reviews the different methods for comparing dose distributions that have been 
published in the literature. Initially, these methods were developed to be able to compare measured 
water phantom data for basic photon fields against 3D treatment planning system calculations as 
part of the commissioning process. The methods have then naturally been adopted in IMRT QC. This 
chapter  focuses in detail on the most commonly used technique, the gamma index [45]. The 
following published terminology is used to distinguish between the two dose distributions that are 
being compared [45]: 
  
 The reference dose distribution is generally taken as the ‘gold standard’, e.g. it could be the 
dose distribution that has been measured. In theory this could be a single point 
measurement, 1D (e.g. a line profile), 2D (e.g. film measurement), or 3D (e.g. gel dosimetry, 
Monte Carlo simulation).   
 The evaluated dose distribution is what is being compared. In most cases this will be the 
predicted TPS dose distribution that is being checked for accuracy. 
 
2.1.1 Dose difference 
The most basic evaluation method is to take the dose difference between the two datasets and 
check if each point agrees within a specified tolerance value. This works well in regions where there 
is a low dose profile gradient. However, in regions of high dose gradient (as would be expected with 
IMRT) techniques, this evaluation method can report a large dose error due to a small misalignment 
which may not be clinically significant; see schematic representation of this in Figure 2.1. The dose 
difference is calculated using equation 2.1: 
 
          
             
      
    (2.1) 
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Where        is the dose at a point in the evaluated dose distribution,   , and        is reference 
point dose.  
 
Figure 2.1 Diagrammatic representation of the concept of dose difference and DTA. In this 
example, the reference distribution is shown as the blue line and the evaluated as 
the red line. 
 
2.1.2 Distance-to-agreement 
The distance-to-agreement (DTA) is another simple method that can be used. Ideally the spatial 
discrepancy between two distributions needs to be known and this tool was developed for such a 
purpose  [47]. The DTA is the closest distance between the reference point and the point in the 
evaluated distribution that has the same dose value. In contrast to the dose difference test, the DTA 
test works better in high dose gradient regions where it can be interpreted as the spatial offset 
between the two distributions. It should be noted that the offset could be due to experimental setup 
error rather than inaccuracy of the evaluated dose distribution. DTA is very sensitive in low dose 
gradient regions. As shown in Figure 2.1, it is possible in a shallow dose region for the distance 
between two dose points of the same value to be large, and lead to a clinically insignificant error as 
the dose difference in that region may be small. 
 
2.1.3 The composite index 
As outlined above, the dose difference and DTA tests have advantages and disadvantages associated 
with them. The dose difference test is useful in low dose gradient regions but overly sensitive in high 
dose gradient, whereas the opposite is true for DTA. Therefore the ‘composite index’ was developed 
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as a combination of the two tests, such that one can test both the dose and spatial agreement of 
two distributions, see Equation 2.2. The user sets pass/fail criteria for the dose difference and DTA. 
 
                     {
                       
                       
   (2.2) 
 
Where    is the dose difference criterion and    is the distance difference criterion. 
 
2.1.4 The gamma index 
The gamma index (γ) evaluation [45] has become a standard technique used to evaluate measured 
distributions in commercial detector systems against the dose distribution predicted by commercial 
treatment planning systems. It combines    and    to calculate a dimensionless metric for each 
point in the evaluated distribution. A γ of < 1 indicates that points lie within the   /   passing 
criteria. In a QA scenario, the total percentage of points that have achieved γ<1, for a given   /   
criteria, is calculated and a pass/fail threshold is set [48]. 
 
Figure 2.2 Diagrammatic representation of the gamma index method in 1D. Adapted from Low 
et al (1998). The y-axis is Dose, D, and the x-axis is distance, r. In this schematic, the 
reference point is illustrated by the cross at the origin of the graph. The blue line 
represents the evaluated dose distribution with individual points represented by 
blue dots. 
 
r 
D 
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In practice the gamma index is calculated based on finding the minimum Euclidean distance for each 
reference point, see Figure 2.2. For each reference point in the dose distribution, calculate against 
each point in the evaluated distribution: 
 
1. the distance between reference to evaluated point:           
2. the difference between the reference and evaluated dose;           
 
Then for each point in the evaluated distribution, calculate the gamma index using the following 
equation: 
 
         √
          
   
 
          
   
    (2.3) 
 
Where    is the distance criterion and    is the dose difference criterion. 
 
The gamma index is then taken as the minimum value calculated over all evaluated points. 
 
         {        } {  }     (2.4) 
 
An array of gamma index values for all of the points within the reference dose distribution can be 
constructed. It is then common to report the percentage of points passing with a γ < 1. This is called 
the gamma index passing rate. For nomenclature it is standard to report the passing criteria in the 
format            ⁄ ; for example, 1%/1mm. This standard nomenclature is used throughout 
this thesis. In order to eliminate dose in the out-of-field region where a large relative dose difference 
can be calculated and skew the gamma index result, it is typical to set a lower dose threshold below 
which the gamma index result is ignored. Therefore, it is common to limit the gamma index 
calculation to all points that are ≥10-20% of the maximum dose value within the dose distribution 
[49]. 
2.1.4.1 Global & local gamma index calculations  
Typically the gamma index calculations are categorised into two different types; local and global. The 
contrast between the two types is the way the dose difference is calculated. For a local gamma 
index, Equation 2.1 gives the definition for a local dose difference. For global gamma, Equation 2.1 
has to be modified to become: 
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    (2.5) 
 
Where      is a normalisation dose value which can be defined as any value, and is usually defined 
as the maximum dose within the reference dose distribution or a point selected in a high dose low 
gradient region. The two types of gamma index reporting have advantages and disadvantage. The 
local gamma index will tend to highlight failures in high dose gradient regions and in low dose 
regions, whereas the global gamma index will tend to mask these errors but show the errors within 
the higher dose regions within the dose distribution. The choice of the type of gamma index will 
depend on the need of the test. Most published works within the reference list report global gamma 
index. In most of this thesis, much of the focus is on global gamma index, and is discussed further in 
the next few chapters.  
2.1.4.2 Advantages and disadvantages of the gamma index  
It is common to report the results of a gamma index analysis as the number points that achieved 
gamma index <1; i.e. the gamma index passing rate. The main characteristic of this metric is that it 
can condense a verification measurement into a single unit; this is both the advantage and pitfall of 
this metric. If implemented carefully, it can be used to streamline QA by making it possible to choose 
decision thresholds for a passing rate, thereby reducing the analysis time. The disadvantage is that 
the passing rate does not provide any details of where failed points are. Another disadvantage is 
that the gamma index itself is inherently an absolute metric, i.e. it provides no information on 
whether a failed point is due to positive or negative dose or distance fluctuations. For example, it is 
possible for there to be a failed point in an OAR region where the measurement is lower than the 
predicted dose by more than the dose difference criterion. In this case, the failed point is clinically 
acceptable as the OAR is receiving a lower than expected dose and the aim of radiotherapy is to 
keep dose to an OAR region as low as possible. Conversely, it is possible to have a failed point in a 
PTV region where the measured dose is higher which would also be acceptable. 
 
The most common passing criteria being used is 3%/3mm which was originally recommended in the 
work by Low et al [45]. The gamma index was originally designed to compare measured water tank 
beam data against a treatment planning system algorithm. The criteria of 3%/3mm were used due to 
the limitations of computing capability at the time (1998).  
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The choice of appropriate passing criteria are investigated and discussed further throughout this 
thesis. The potential limitations of the gamma index are also discussed further. 
 
2.2 LITERATURE REVIEW 
2.2.1 Prevalence of the use of the gamma index 
The prevalence of the use of the gamma index was investigated through a literature search. 
Unfortunately a search on Scopus and PubMed for “gamma & index & radiotherapy” returned some 
papers that were unrelated to radiotherapy measurement as the use of “gamma” is common in 
other scientific fields such as cancer biochemistry. However, all uses of the index in the literature 
should have cited the original publication by Low et al in Medical Physics in 1998 and therefore 
Scopus was used to investigate citations to this article and what time trend there has been since its 
initial publication. A search on PubMed was attempted for this article but gave no citations before 
2006 and therefore was abandoned. 
 
In the Elsevier Scopus abstract and citation database, (as of March 2015) it was found that the 
gamma index paper has been cited 865 times in the literature since it was published. Of these, there 
were 775 original research articles; the remainder were composed of 65 conference proceedings, 19 
review papers and the remainder as book chapters or Editorials. The breakdown by scientific journal 
shows Medical Physics publishing ~33% of all research papers that made use of the gamma index. 
The top 15 citing journals which represent some of the major journals in the field are shown in Table 
2.1. This shows that the use of the gamma index is not limited to specialist medical physics journals 
but also journals such as Radiotherapy & Oncology which are aimed at a wider community which 
also includes other members of the radiotherapy multidisciplinary team such as clinicians and 
radiographers.  
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Table 2.1 List of top 15 citing journals for the gamma index. 
Journal Citing articles % of total 
Medical Physics 258 33.3 
Physics in Medicine and Biology 140 18.1 
Journal of Applied Clinical Medical Physics 74 9.5 
Radiotherapy and Oncology 41 5.3 
International Journal of Radiation Oncology Biology Physics 40 5.2 
Medical Dosimetry 26 3.4 
Journal of Physics Conference Series 26 3.4 
Radiation Oncology 24 3.1 
Australasian Physical and Engineering Sciences in Medicine 16 2.1 
Zeitschrift Fur Medizinische Physik 14 1.8 
Physica Medica 14 1.8 
Journal of Medical Physics 12 1.5 
British Journal of Radiology 11 1.4 
Acta Oncologica 11 1.4 
Strahlentherapie Und Onkologie 11 1.4 
 
 
Figure 2.3 The number of citations per year (blue solid line) and the cumulative citations (black 
dashed line) for the original gamma index paper by Low et al [45]. 
 
2. The gamma index theory 
19 
 
2.2.2 The computing challenge of the gamma index 
The gamma index is a computationally expensive process due to the need to search all points in the 
evaluated distribution. This becomes more complex when comparing two 3D dose distributions. 
Ideally the gamma index would be calculated quickly to give a result within a reasonable time. The 
computer hardware used will have an impact on the speed of the γ calculation. Given previous 
limitations with computer technology, a number of studies in the literature have focussed on ways 
to mathematically decrease the calculation time of the gamma index. A common feature when 
reading through manufacturer manuals is that there is seldom detailed information on the way the 
gamma index calculation has been performed, with often the ‘go-to’ solution being to simply cite the 
original paper by Low et al. A true gamma index calculation can take from a few minutes up to 
potentially days for complex 3D dose distributions, which is clearly unacceptable from a clinical point 
of view [50]. This section gives a brief description on some of the methodologies and also discusses 
the future trend in this area. 
2.2.2.1 Mathematical techniques to refine/speed up the gamma index calculation  
A refinement of the gamma index was proposed by Depuydt et al [48]. In their work, the authors 
introduced a filter cascade of multiple levels that were designed to speed up the comparison.  The 
focus of this algorithm is whether or not a point passes or fails the gamma index criteria rather than 
calculating an absolute gamma index value for each point in the reference distribution. The 
algorithm employs 3 levels in the calculation. In the first level, the minimum gamma index is 
searched within a limited distance to reduce the calculation time. As soon as an evaluated point is 
found where          < 1 then the calculation is stopped and the algorithm moves on to the next 
reference point, starting at Level 1. If there are no evaluated points where          < 1 then the 
algorithm moves on to Level 2. In the second level, the algorithm searches for at least 2 evaluated 
points in the vicinity of the reference point where the           for the two points is of opposite 
signs. In this scenario it is assumed that the evaluated distribution must intersect the region defined 
by the passing criteria and therefore the reference point is classified as passed. Failing this, the 
algorithm moves to the third and last level. In most cases, reference points rejected in Level 2 
because the evaluated points are truly outside the pseudo-space defined by the passing criteria. 
However, there may be rare occasions when the reference points should not have failed because of 
the discrete nature of the evaluated distribution. This is because it is possible for two discrete 
evaluated points at the outside edge of the passing region to produce a failed result, but 
interpolating between them means that there is an intersection with the passing region. Therefore 
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Level 3 is designed to take these possibilities into account. If the reference point fails level 3 then it is 
classified as having failed the test.  
 
Chen et al [50] consider the possibility to speed up the search distance algorithm by using fast 
Euclidean distance transform and predict a speedup of the order of tens of thousands for 3D gamma 
index calculations. Bakai et al [51] published a revision of the original gamma index formalism which 
considered gradient-dependent local acceptance thresholds. The actual number calculated by the 
Bakai method is called the χ index and is defined using the following equation: 
  
             
√               
     (2.6) 
 
In this method, one begins by calculating the local gradient for each point in the reference 
distribution,        , to build a gradient map or cube. The numerator part of equation 2.6 means 
that this method only works when the reference and the evaluated dose distributions have the same 
array sizes. This formulism means that a χ distribution can be calculated efficiently using simple 
matrix operations which are optimised for speed in numerical analysis coding software such as 
Matlab, or could be programmed in other languages using existing libraries and utilising multiple 
threads in the computer processing unit (CPU). The χ index retains the sign, unlike the gamma index. 
The value of |χ| is also approximately equivalent to the gamma index [51]. 
 
Wendling et al [52] developed a fast algorithm through speeding up the search routine by pre-
sorting the distance from the reference point to evaluated points within a fixed search circle or 
sphere, for 2D and 3D respectively. The theory is that the search loop should be stopped when there 
is a low chance that evaluated data points will reach the minimal Γ. In their approach, the calculation 
starts at the reference point and increases outwards and terminating when the condition defined by 
equation 2.7 is met [52]: 
          
   
                   (2.7) 
 
The possible limitation of this technique is that there is potential for overestimation of the gamma 
index when dose differences are very large within the search region and then sharply drop off just 
outside this region. If an exhaustive search was performed in this scenario it would likely find the 
minimum gamma index in this region where the calculation has stopped.  
 
Ju et al [53] propose a re-interpretation of the gamma index to avoid the need to interpolate the 
evaluated distribution to a finer grid, thus reducing the calculation time.  For 1D, 2D, and 3D 
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distributions the evaluate distribution is divided into line segments, triangles and tetrahedral 
respectively. The closest distance between any reference point and these simplexes is calculated 
using matrix multiplication and inversion. The finding is that the method is as accurate as 16 times 
finer linear interpolation of the evaluated dose distribution with an order of ~20 times speedup in 
calculation time. 
2.2.2.2 Future trends in computational techniques 
As hardware continues to progress, the speed of the gamma index calculation will naturally continue 
to be quicker. In the last few years there have been innovative approaches to utilising the processing 
power provided by graphical processing units (GPU). Traditionally programs are calculated on the 
CPU, however the number of cores is limited with standard desktop PCs at the time of writing 
offering dual core processors and quad core at the higher price range. However, GPUs have been 
designed to handle complex graphics particularly in modern 3D video games where intensive tasks 
such as rendering and in-game physics simulations are required. The GPU is otherwise left unused 
when graphics intensive programs are not running. The parallel computing platform, called Compute 
Unified Device Architecture (CUDA), was developed by NVIDIA Corporation (Santa Clara, California, 
USA) which was first made available on compatible NVIDIA GPU cards in 2006 [54]. The CUDA 
platform can be implemented in standard programming languages such as C, C++ and Fortran, and 
software such as Matlab has implemented support for it. OpenCL™ (Open Computing Language, 
developed by Apple Inc., California) is a similar platform that has the advantage in not being vendor 
specific, although CUDA can work on AMD (Advanced Micro Devices Inc., California) GPU cards 
which represent the other major manufacturer. Driven by the video gaming industry, GPU cards are 
now routinely available with highly parallel multiple cores that are in the region of 1000+. This allows 
for significant potential for parallel computing in areas such as Monte Carlo calculations or in this 
case, fast gamma index calculations. For the gamma index, it would be possible to utilise the GPU to 
perform the otherwise computer intensive task of the minimum distance search by searching and 
calculating γ for each reference in parallel.  
 
Gu et al [55] studied accelerated gamma index calculations by combining the geometric technique 
proposed by Ju et al [53] and the pre-sorting technique described above by Wendling et al [50] and 
by implementing the calculation onto the GPU. They found a 45 – 70 times speedup of the 
calculation compared to the traditional implementation on the CPU. Peerson et al [56] found a 
speedup of 57 ± 15 for patient cases when using the GPU against the CPU.  
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3 DETECTOR ARRAY TECHNOLOGY 
 
3.1 WHAT IS THE IDEAL DETECTOR ARRAY? 
It is best to start by thinking about what would make an ideal detector array. There are many 
systems that have been researched and investigated in the literature that ultimately aim to come as 
close as possible to the ideal condition. The following is essentially a wish list of criteria for an ideal 
detector: 
 
1. Have a high resolution which is comparable to or better than the resolution of the grid 
spacing used for the dose calculation in the TPS 
2. Be able to measure a true 3D dose distribution; i.e. detectors arranged in a 3D lattice 
3. Have no angular dependence 
4. Have linear dose, energy and dose rate response 
5. Be water equivalent 
6. Be a robust system; i.e. suffer from no leakage during measurement sessions and have 
perfect short and long term reproducibility 
7. Be easy to calibrate 
8. Be able to perform real-time measurements so that a diagnosis of out-of-tolerance events 
can be made immediately 
 
Of course all of the above cannot be easily achieved in a cost-effective manner. The only dosimeters 
currently available that have been able to measure a true 3D dose distribution are polymer gel 
dosimeters. The advantage of these is that they are tissue-equivalent and can be moulded into an 
anthropomorphic shape. After irradiations the dosimeter requires scanning using MRI, optical CT, or 
X-ray CT and then processing of the measured signal. It has been estimated that the entire process 
from fabrication to analysis can take up to 45 hours, rendering this unsuitable for routine 
3. Detector array technology 
23 
 
measurement [57]. It has potential to be used as a benchmarking tool for a commissioning 
treatment plan. Currently this technology has been mainly confined to research institutions and the 
current processing and analysis timescales have meant that there is a limited market. However with 
research into optimisations and more cost-effective scanning techniques this may become more 
available in the future [57].  
 
Manufacturers have attempted to fulfil as many of the above wish list by developing electronic 
detector arrays within the limits of technology and cost. Engineering challenges with building a 3D 
detector array include ensuring that the detectors respond equally from any direction in addition to 
ensuring that the circuitry required causes negligible perturbation in the dose. The following section 
outlines the available commercial electronic detector arrays and those that were investigated in this 
thesis. 
 
3.2 BRIEF HISTORY OF DETECTOR ARRAYS 
The first commercial detector array was the MapCHECK® (Sun Nuclear Corp., Melbourne, FL) which 
was a 2D array utilising 445 n-type diodes [52]. The diodes had a spacing of 7.07 mm in the central 
10 cm x 10 cm area and 14.14 mm in the outer regions up to an area of 22 cm x 22 cm. This has since 
been superseded by the MapCHECK® 2 which increased the number of detectors to 1527 and 
maintained a uniform spacing of 7.07 mm to have an active area of 32 cm × 26 cm. Development of 
ionisation chamber arrays followed soon after with PTW (Freiburg, Germany) producing a 2D Array 
which initially had 256 vented ion chambers with cross-sections of 8 x 8 mm2 spaced 1.6 cm centre-
to-centre. This was then upgraded to the newer model seven29 which has 729 chambers with cross-
sections of 5 x 5 mm2 and spacing of 1 cm. The latter implementation is still in use; however it has 
recently been replaced commercially by the OCTAVIUS® 729 which has increased radiation shielding 
of the electronics.  
 
These devices were originally developed to be able to measure per-beam fluence. In other words 
they were designed to be set up normal to the beam direction. At the time that detector arrays were 
becoming commercially available, electronic portal imaging devices (which had started being 
developed in the early 1980s) had matured with linac vendors, by 2001, using active matrix flat-
panel arrays incorporating amorphous silicon (aSi) photodiodes [59]. These devices were designed to 
measure the MV beam transmission through the patient to be used for imaging and patient setup 
verification. However concurrently with ongoing imaging developments of EPIDs, it was recognised 
that with appropriate calibration they could also be used for dosimetry [60,61]. With sub-millimetre 
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resolution, they started to be used routinely for IMRT fluence verification. Therefore the use of 
detector arrays for these kinds of measurements became uncompetitive almost immediately and 
adaptations were made in hardware and software to be able to measured composite dose 
distributions. For the PTW 2D-ARRAY 729, this involved the development of the OCTAVIUS Phantom 
which was designed to reduce the angular dependence of the array at non-normal beam incidences 
[62]. For other planar detector arrays, cubic phantoms were used but developments in the 
calibration procedure were made such that the user is able perform measurements with their 
equipment to characterise the angular dependence which can then be corrected out of the 
composite measurement; this requires the use of an inclinometer to monitor the gantry angle for 
each beam delivery [63]. 
 
Other commercial detector arrays available are the Delta4® (ScandiDos AB, Uppsala, Sweden), 
ArcCHECK® (Sun Nuclear Corp., Melbourne, FL) and I’mRT MatriXX (IBA Dosimetry GmbH, 
Schwarzenbruck, Germany. Table 3.1 gives a summary of the main characteristics of commercial 
detector arrays that are currently available for IMRT and VMAT QA.  
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Table 3.1 Summary of characteristics of the available commercial detector arrays (as of March 2015).  
 PTW 2D-ARRAY 729 
seven29 / OCTAVIUS® 
729 Detector Array * 
PTW OCTAVIUS® 
1500 § 
PTW OCTAVIUS® 
1000 SRS 
IBA I’mRT  
MatriXX® 
Scandidos Delta4® 
Sun Nuclear 
MapCHECK® 2 
Sun Nuclear 
ArcCHECK® 
Array configuration Planar Planar Planar Planar Cross-plane Planar Helical 
Detector type and 
shape 
Plane-parallel vented 
ion chambers; cubic 
Plane-parallel 
vented ion 
chambers 
Liquid-filled ion 
chambers; cubic 
Vented pixel ion 
chambers; disc 
shaped 
p-type Diode; disc 
shaped 
SunPoint® n-type 
Diodes; cubic 
SunPoint® n-type 
Diodes; cubic 
Detector size (mm) 5.0 × 5.0 × 5.0 4.4 × 4.4 × 3.0 2.3 × 2.3 × 0.5 
4.5 diameter × 5 
height 
1.0 diameter × 
0.05 height 
0.8 × 0.8 x 0.03 0.8 × 0.8 x 0.03 
Detector volume 
(cm
3
) 
0.125 0.058 0.0026 0.08 0.000039 0.000019 0.000019 
Detecor spacing 
(centre-to-centre) 
10 mm 7.1 mm 
2.5 mm in central 
5.5 x 5.5 cm and 5 
mm elsewhere 
7.62 
5 mm in central 6 
× 6cm; 10 mm to 
outer 20 × 20 cm 
7.07 mm 10 mm 
Maximum field size 
(cm) 
27 × 27 27 × 27 10 × 10 24.4 × 24.4 20 × 32 × 26 21 × 21 
Number of 
detectors 
729 1405 977 1020 1069 1527 1386 
Housing material 
PMMA / Glass-
reinforced plastic 
PMMA 
Glass-reinforced 
plastic 
Tecaran ABS 
buildup, RW3 
backscatter 
PMMA or Plastic 
Water® 
PMMA (Acrylic) PMMA (Acrylic) 
Weight (kg) 3.2 / 5.7 6.0 5.4 10.0 24.0 7.1 15.4 
Phantom shape for 
composite dose 
measurement 
Octagonal (2D) 
Cylindrical (3D dose 
reconstruction) 
Octagonal (2D) 
Cylindrical (3D 
dose 
reconstruction) 
Cylindrical (3D 
dose 
reconstruction) 
Cubic Cylindrical Cubic 
Cylindrical (hollow 
central cavity) 
Separate 
CavityPlug™ 
available 
* Note that the PTW 2D-ARRAY 729 seven29 has been discontinued commercially and replaced by the OCTAVIUS 729. It is included here as it has been used in this thesis 
§ Commercially available from October 2014 
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The PTW 2D-ARRAY 729, Delta4 and ArcCHECK were used in this thesis. Most of the experimental 
work in this thesis was on the PTW OCTAVIUS 2D-ARRAY 729 seven29 as this was the initial device 
available to the author and is featured in Chapters 4, 6 – 9. The Delta4 was owned by the Royal 
Surrey County Hospital and the ArcCHECK was kindly loaned by Imaging Equipment Ltd on behalf of 
Sun Nuclear Corporation for a limited time period. A fuller description of these devices is given 
below. These devices represent the three main device configurations as shown in Figure 3.2; these 
are planar (e.g. PTW 2D-ARRAY 729), helical (ArcCHECK) and cross-plane (Delta4). The PTW 
OCTAVIUS® 4D was recently developed which uses 2D measured data from any of the PTW detector 
arrays to reconstruct a 3D dose cube [64,65]. This, along with the OCTAVIUS 1000SRS detector array 
were loaned from PTW on a research collaboration agreement to investigate the differences in 
hardware resolution as described in Chapter 7.  
 
 
Figure 3.1  Schematic showing different types of detector array configurations. Planar (left), 
helical arrangement (middle) and cross-plane (right). 
 
3.2.1 Review of detector array characterisation studies for IMRT and 
VMAT QA 
Various studies have previously been performed to assess the suitability of detector arrays for IMRT 
and VMAT QA. Letourneau et al [66] evaluated the dosimetric characteristics of the first commercial 
MapCHECK and found a linear dose response up to 2.95Gy, reproducibility within ±0.15%,  
calibration of the diodes to within ±1% of each other was achievable, and there was reported ‘good 
agreement’ with ion chamber and film results.  Li et al [67] performed a comparison between the 
MapCHECK and the MatriXX for IMRT QA and reported ‘excellent passing rates’ for a set of 6MV and 
18MV IMRT fields. Buonamici et al [68] performed an intercomparison between film dosimetry and 
the MapCHECK and reported the detection of deliberate deviations was as good as film, therefore 
their overall conclusion was that the MapCHECK was suitable as a replacement for film dosimetry in 
routine IMRT QA. Yan et al [63] compared the sensitivity of the MapCHECK against radiochromic 
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films for detecting deliberate MLC deviations and found that using a gamma index passing criteria of 
2%/2mm showed the strongest sensitivity for detecting MLC changes and that the sensitivity of the 
MapCHECK was larger than radiochromic film. Masi et al [70]  compared the 2D-ARRAY 729 with 
other systems of dosimetry, including Delta4 and MapCHECK, in the detectability of MLC positional 
deviations in 50 Elekta™ VMAT plans in different cancer sites and found high pass-rates for 3%/3mm 
gamma index, and suggested possibly moving to 3%/2mm for the arrays studied. Spezi et al. [71] and 
Poppe et al. [72] found that for step-and-shoot IMRT, 1mm MLC deviations could be detected for 
per-beam planar verification using the PTW 2D-ARRAY 729. Myers et al [73] performed a comparison 
between the PTW seven29 and the Delta4 for 15 clinical Tomotherapy QA plans and >90% gamma 
index passing rates for 3%/3mm for both systems. These were considered clinically acceptable; 
therefore the conclusion was that they were suitable as replacements for ion chamber and film 
dosimetry in routine QA. Syamkumar et al [74] characterised the response of the 2D-ARRAY 729 
seven29 in 10 clinical RapidArc QA plans and using 3%/3mm gamma index criteria, concluded that it 
was suitable to use for routine QA. Chandraraj et al [75] compared EDR2 film, IBA I’mRT MatriXX, 
PTW seven29 and Delta4 for RapidArc and IMRT QA.  They found that all 4 techniques yielded 
equivalent results with all achieving 3%/3mm passing criteria. The gamma index results of the 3 
detector arrays were found to be within 5% of film [75]. Heilemann et al [76] used the PTW seven29 
and Delta4 to assess the sensitivity of the gamma index to MLC misalignments in RapidArc QA and 
recommended that 2%/2mm should be used as passing criteria for these devices instead of 3%/3mm 
but stress that visual inspections should be made as 2%/2mm did not pick up all clinically significant 
errors. Van Esch et al [77] described a formalism for RapidArc clinical implementation and have 
evaluated the PTW seven29 and Delta4 as suitable dosimeters for routine patient QA. Zhu et al [78] 
compared the ion chamber, EPID, seven29, MatriXX and Delta4 in the verification of 12 VMAT plans 
of different sites and complexity. Ion chamber measurements were within 3% and the detector 
arrays passed the 3%/3mm criteria at >90%. Letourneau et al [79] evaluated the ArcCHECK for VMAT 
QA and found good passing rates for 3%/2mm criteria and that it was able to sufficiently detect 
small gantry rotation changes (up to 3°) and phantom setup errors of 1mm. It was also found to be 
suitable for evaluating individual control points in the VMAT delivery. Lin et al [80] also validated the 
suitability of using the ArcCHECK for VMAT verification; in this work, ArcCHECK measurements for 
plans with deliberate translational and rotational errors were compared against the TPS and an 
independent Monte Carlo model. Lang et al [81] made use of the MatriXX, Delta4, and ArcCHECK for 
pre-treatment QA of flattening filter free VMAT to assess dosimetric accuracy and Petoukhova [82] 
reported on HybridArc verification using the ArcCHECK. Bedford et al [83] performed benchmarking 
measurements for the introduction of the Delta4 into clinical use for IMRT and VMAT verification. 
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The study found that the Delta4 measured a dose within 2.5% of an ion chamber and a slightly 
higher passing rate for 3%/3mm gamma index than film. Feygelman et al [84] evaluated the Delta4 
for Tomotherapy QA with mean passing rate of 97% for 3%/3mm in 9 clinical plans and 
recommended the use of MVCT imaging for phantom alignment. Fredh et al [85] performed a 
comparison of the Delta4, OCTAVIUS 729, COMPASS and Epiqa™ to assess their response to 
deliberate errors in VMAT patient-specific QA and found considerable variation in the types of errors 
that could be detected by the different systems, as well as poor correlation between the gamma 
index results and DVH deviations. Zhen et al. [86] performed a theoretical evaluation of three 
detector geometries: ‘X’, ‘O’, and spiral shapes which simulated modifications by modifying the 
beam models to introduce MLC transmission and penumbra errors, in order to create ‘virtual 
measurements’ at the treatment planning system resolution. These were compared against error-
free calculations. This method meant uncertainties in delivery and devices were removed. A similar 
methodology was used by Nelms et al [87].  
 
3.3 DESCRIPTION OF DETECTOR ARRAYS USED IN THIS THESIS 
Basic commissioning tests of the detector arrays were performed on a Varian Clinac iX (Varian 
Medical Systems, Palo Alto, CI). The Clinac incorporates the Millennium 120 leaf MLCs, with the 
central 80 MLCs covering 20x20cm each having a 0.5cm width at the isocentre; the remaining MLCs 
have 1cm width. The methodology used was in keeping with previously published reports 
[60,66,74,88–94]. All systems were used according to individual manufacturer recommendations. 
The tests performed for the basic commissioning of detector arrays are discussed in Appendix A, 
with the PTW 2D ARRAY used as an example. 
 
3.3.1 The PTW OCTAVIUS® Series 
3.3.1.1 VERISOFT® 
For all of the different detector array systems offered by PTW, the software required is PTW 
VERISOFT® which is used to acquire and analyse measurements. Various versions became available 
throughout the duration of this PhD research. Versions 4.0 - 6.0 were therefore used at various 
times and the particular version is specified at the appropriate points. All versions shared the same 
gamma index implementation and mainly interface and upgrades to the handling of DICOM objects 
were the principal modifications between different versions. 
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3.3.1.2 2D-ARRAY 729 seven29 / OCTAVIUS 729 
The PTW 2D-Array consists of a matrix of 729 cubic vented ionization chambers with 0.5cm x 0.5cm 
cross-section, spaced 1cm centre-to-centre, giving a total area of 27cm x 27cm [89]. The upper 
electrode layer sits below a 0.5cm PMMA build-up layer whereas the lower electrode layer lies on 
top of a 0.2cm thick electrode plate which itself is mounted on a 1cm PMMA base plate. The 
nominal effective point of measurement (EPOM) is located at 0.75 cm from the surface. The 
OCTAVIUS phantom has an octagonal shape in its cross-section, and is designed to allow composite 
rotational IMRT plan verification. The phantom is made of polystyrene which has a physical density 
of 1.04g/cm3.  Its dimensions are 32 cm width, 32 cm length, 32cm height, and has a 30x30x2.2 cm3 
central cavity for the 2D-ARRAY 729 [62].  
 
 
Figure 3.2  The PTW Ocavius II phantom with 2D-ARRAY 729 detector array in situ. 
 
The OCTAVIUS phantom was CT scanned twice with both the 2D-ARRAY 729 in situ and with a 
homogeneous insert for comparison, see Figure 3.3. For composite field measurements, the base of 
the OCTAVIUS contained a semi-circular air gap to correct for the inherent under-response of the 
2D-ARRAY 729 when the radiation field is incident posteriorly, as described by Van Esch et al [62]. 
For planning, the phantom was scanned with a solid base. 
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Figure 3.3 CT scan of the OCTAVIUS phantom with (left) 2D-ARRAY 729 in situ, and (right) 
homogeneous insert. 
 
3.3.1.3 PTW OCTAVIUS Detector 1000SRS 
The OCTAVIUS Detector 1000SRS consists of a matrix of 977 liquid-filled ion chambers with 2.3 mm  × 
2.3 mm ×  0.5 mm volume and 2.5 mm centre-to-centre detector spacing in the central 55 cm x 55 
cm area and 5 mm in the outer 110 x 110 mm area. The nominal EPOM is located at 0.9 cm from the 
surface. 
 
 
Figure 3.4 The PTW OCTAVIUS Detector 1000SRS. 
 
 
3. Detector array technology 
31 
 
In a separate collaborative study [95], the 1000SRS array has been compared against Monte Carlo 
simulations, Gafchromic film, glass optical fibres, and glass beads in measuring small open field sizes 
down to 1 x 1cm and showed excellent response in this study. 
 
 
Figure 3.5 Profiles acquired with the BEAMnrc/ DOSXYZnrc Monte Carlo simulation code (MC), 
Gafchromic film (GF), ionization chamber (IC), glass beads (GB) and optical fibre (OF) 
for the 10 × 10 cm, 4 × 4 cm, 3 × 3 cm, 2 × 2 cm and 1 × 1 cm field sizes at 5 cm water 
depth and normalized to the dose at the central axis for a 10 × 10 cm field size 
defined at the surface. From Jafari et al [95], with permission. 
 
3.3.1.4 PTW OCTAVIUS® 4D system 
The OCTAVIUS 4D phantom is made of polystyrene.  It is cylindrical and has dimensions 32 cm 
diameter and 34.3 cm length, and has a 30 x 30 x 2.2 cm3 central cavity to accommodate the 
detector arrays. The phantom makes use of an inclinometer which is attached to the linac gantry to 
allow synchronous rotation of the OCTAVIUS 4D with the linac, see Figure 3.6. In this situation the 
detector array is always perpendicular to the radiation beam.  
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Figure 3.6 The OCTAVIUS4D phantom setup on a Varian Clinac iX at the Royal Surrey County 
Hospital. 
 
For predicted TPS dose calculation, a homogeneous cylinder of the same physical size as the 
phantom was used with a relative electron density in Eclipse set to 1.016 (~1.05 g/cm3). The 
required Verisoft software version was at least 5.1 and over in order to be able to perform 3D dose 
reconstruction; version 6.0 was used when measurements were carried out. Time integrated dose 
measurements at each gantry angle are acquired and the software uses the data to reconstruct a 3D 
dose distribution; the algorithm for this has been previously discussed [65,96]. To be able to perform 
the reconstruction, the software requires percentage depth dose (PDD) in water data for each beam 
energy used in the measurements for 85cm FSD and for square field sizes 2cm – 26cm. The PDD in 
water is converted to PDD in polystyrene (assuming relative electron density of 1.016). Generally 
speaking, for each gantry angle, the detector array measures the beam and calculates the effective 
field size using the detectors. Using the appropriate PDD for the effective field size, the dose plane is 
reconstructed at intervals along the ray line for that gantry angle; see schematic in Figure 3.7. This is 
done for all gantry angle measurements and summed together. Then the dose values are sorted into 
a 3D dose grid with a default spacing of 2.5 mm using linear interpolation [96].  
 
 
Inclinometer 
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Figure 3.7 Schematic representation of the 3D dose reconstruction algorithm used for the 
OCTAVIUS 4D. The red line indicates the measured dose plane. The blue lines 
indicate the reconstructed dose planes at intervals along the ray line for the gantry 
angle. 
 
 
3.3.2 Scandidos Delta4® 
The Delta4® phantom consists of 1069 disc-shaped p-Si diodes, 1 mm diameter x 0.05 mm thick, 
arranged in a cross-plane configuration and housed in a PMMA cylindrical phantom. The dimensions 
of the phantom are 22 cm diameter and 40 cm length. The spacing of the detectors is 0.5 cm centre-
to-centre in the central 6 cm x 6 cm area and 1 cm spacing in the outer 20 cm x 20 cm area. 
Measurements were performed with the inclinometer and synchronized to the linac trigger pulse as 
recommended [83]. A virtual CT cylindrical phantom with the same dimensions as the Delta4 was 
used according to the manufacturer specification. The software associated with this system carries 
the same name (Delta4 Software version: February 2012 release). Each detector board within the 
Delta4 had a relative uniformity calibration. An absolute dose calibration was performed against a 
Farmer-type ionization chamber. Both procedures followed the detailed instructions in the technical 
manual. The daily correction factor (DCF) procedure was used to normalise the output on the day of 
measurements as recommended [83]. 
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Figure 3.8 The Scandidos Delta4 detector array which uses p-Si diodes setup in a bi-plane 
configuration. 
 
3.3.3 SunNuclear ArcCHECK® 
The ArcCHECK® consists of 1386 n-Si diodes (0.8 x 0.8 mm) arranged in a helical shape at 3cm depth 
along the long-axis of a cylindrical phantom made of PMMA acrylic. The dimensions of the cylinder 
are 21 cm length and 21 cm diameter. The detectors are spaced 1cm centre-to-centre and measure 
an exit and entrance dose during delivery. All measurements were performed with 15 cm diameter 
CavityPlug™ homogeneous PMMA cylinder. A CT-scan of the ArcCHECK phantom was used for 
verification plan calculations. The scan was overridden where artefacts were caused by the diode 
detectors.  The associated software used for acquisition and analysis was SunNuclear SNC Patient™ 
version 6.1. The methodology described in the technical manual was followed to calibrate the 
ArcCHECK. This involved; a background correction, a uniformity correction, an angular correction 
and an absolute dose calibration against a Farmer-type ionization chamber. The absolute calibration 
was done on the day of plan measurements. 
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Figure 3.9 The SunNuclear ArcCHECK detector array which uses diodes set up in a spiral 
configuration. 
 
 
3.4 THE NEW TREND TOWARDS MEASUREMENT GUIDED 3D DOSE 
RECONSTRUCTION USING DETECTOR ARRAYS 
There is a growing trend in measurement guided 3D dose reconstruction in patient anatomy. The 
basic premise is to use the dose measured by detector arrays to either back-project a dose onto the 
patient or to use the measurement to effectively ‘correct’ the TPS dose distribution according to the 
measured deviation. This then allows for a direct comparison between the reconstructed 
distribution and the TPS distribution in the patient anatomy and therefore DVH comparisons can be 
performed for volumes of interest. Recently, software algorithm and hardware improvements have 
led to the possibility of this technique. All of the main detector array manufacturers listed in Table 
3.1 have focussed on implementing this technique and at the time of writing, all had introduced at 
least an early version of software for this kind of analysis.   
3.4.1.1 The IBA Solution: COMPASS® 
The MatriXX system can be adapted to be attached directly onto the Linac gantry head. The device 
has the addition of a digital inclinometer to monitor the gantry angle. This upgrade to the device has 
been branded MatriXXEvolution®. The device measures the actual beam fluence and then uses that to 
3. Detector array technology  
36 
 
calculate a dose distribution in the patient anatomy. This is achieved using the IBA COMPASS® 
software which has been developed in partnership with RayStation Laboratories (RaySearch 
Laboratories AB, Stockholm, Sweden). The software uses a collapsed cone convolution algorithm to 
calculate the dose (in fact as the software has its own algorithm it can be used as an independent 
dose check system of the TPS). Studies have been performed on evaluating this system; Boggula et al 
[97] evaluated the performance of the COMPASS system by comparing the reconstructed dose 
against Monte Carlo calculations and Godart et al [98] reported on the MLC error detection ability of 
the COMPASS software.  
3.4.1.2 The PTW solution: DVH 4D 
The PTW DVH 4D module relies on the use of the OCTAVIUS 4D’s 3D reconstruction dose algorithm 
which has been described in section 3.3.1.4. The CT data along with the RT structures are imported 
into Verisoft. The dose reconstruction in the CT anatomy follows the same principle as the dose 
reconstruction in the OCTAVIUS phantom, except that instead of assuming uniform density for the 
dose reconstruction along each ray line, the Hounsfield Units in the CT data are converted to relative 
electron densities [96]. The PDDs are converted to Tissue Phantom Ratios (TPR) according to the 
recommendations in BJR Supplement 11 [99]. For each detector along the ray line the water 
equivalent depth in the OCTAVIUS phantom is calculated;     .  For the CT voxels along the ray line, 
the water equivalent depth in the patient is calculated;    . Then the geometrical distance between 
the linac focus and the detector,      and the CT voxel     respectively is determined. The dose at 
each voxel along the ray line,    is then calculated as follows [96]: 
 
        (
      
       
) (
    
   
)
 
     [3.1] 
 
This algorithm only requires the CT data and therefore is independent of the TPS system; however 
the dose calculation is fairly basic and doesn’t take into account scatter effects. At the time of 
writing there have been no published reports on this as it was released in late 2014. 
3.4.1.3 The Sun Nuclear solution: 3DVH® 
This module works with MapCHECK for fixed field IMRT [86] or with ArcCHECK for IMRT or VMAT 
measurements. In both cases the measured dose is used to perturb the TPS dose distribution on the 
patient anatomy [100]. This method uses the Planned Dose Perturbation (PDP) [86] and ArcCHECK 
Planned Dose Perturbation (ACPDP) that has been described by Nelms et al [100]. In the ArcCHECK, 
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the author’s interpretation of this algorithm is as follows: firstly, time stamped entrance & exit dose 
measurements are used to discretise the treatment delivery into finite control points. Each control 
point is essentially the measured gantry angle using the ArcCHECK inclinometer as a function of 
time. These control points are used to modify the DICOM Plan file (which specifies the beam 
geometry, MU and planned control points for the MLC motion) to ‘synchronise’ the planned control 
points with what is actually measured; i.e. by modifying the planned gantry angle header with the 
measured value. The modified DICOM RT Plan is then processed by ACPDP which first generates a 
relative 3D dose distribution with a grid spacing of 2mm through fast Fourier transform (FFT) 
convolution of the time resolved control points, the total energy released per unit mass (TERMA) in 
the ArcCHECK and a 3D pencil beam dose kernel. For each sub-beam the x-ray beamlet is projected 
from the entry and exit surfaces of the ArcCHECK to achieve perturbation factors which are 
interpolated from entrance and exit values. The final absolute 3D dose distribution is then the 3D 
relative dose convolved with the scaling factors. Because of the way the perturbation factors are 
derived, only the TPS dose that lies within the dimensional space of the ArcCHECK can be perturbed; 
for regions outside this space, the software simply retains the original TPS dose value.  
 
The disadvantage with this kind of implementation is that it relies heavily on information provided 
by the TPS and therefore there is an argument that it is not fully independent. Watanabe and 
Nakaguchi [101] evaluated the accuracy of the 3DVH module by comparing the 3D dose distribution 
reconstructed by the ArcCHECK with that measured using a polymer gel dosimeter. The gel was 
manufactured into a cylinder with similar dimensions to the ArcCHECK. In this study it was concluded 
that the 3DVH module produced an accurate 3D dose distribution when compared against the 
measured distribution in the gel dosimeter. 
3.4.1.4 The Scandidos solution: Delta4DVHAnatomy® 
The Delta4DVH® implementation is analogous to the ArcCHECK methodology, i.e. it is also a TPS dose 
perturbation algorithm. Hauri et al [102] performed an evaluation of the Delta4DVH Anatomy 
module for VMAT QA. However they found that the dose calculation algorithm was inferior to the 
TPS algorithm that they used in the study (Varian Eclipse AAA 8.9). This uses a pencil beam 
algorithm. 
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3.4.1.6 EPID based systems for in vivo dosimetry 
As previously mentioned, EPIDs have been in use for per-beam IMRT QA measurements since the 
early 2000s. In recent years there have been developments in performing 3D in vivo dosimetry using 
these systems [61]. The general principle is that by measuring the exit fluence through a patient 
using the EPID, it is possible to back-project that fluence and, through convolution with an 
appropriate energy deposition kernel, perform a 3D dose calculation in the patient CT data. This 
dose distribution can then be compared directly against the TPS distribution. Whilst the detector 
array system implementations highlight if there has been any error in the transfer of the treatment 
plan to the delivery system, EPID-based systems allow up to a day-to-day monitoring and 
additionally can be used to highlight any major changes to the patient anatomy that may have a 
clinical impact. At the time of writing, commercial systems for EPID dosimetry included Dosimetry 
Check™ by Maths Resolutions, Epiqa™ by EPIdos, and Sun Nuclear EPIDose™. However, only 
Dosimetry Check at the time was able to perform a 3D calculation in the patient and currently uses a 
pencil beam algorithm. The Netherlands Cancer Institute (NKI) in Amsterdam [103] and the 
MAASTRO Clinic in Maastricht [61,104] have performed extensive research on non-commercial 
systems. The NKI implementation uses a 3D back-projection algorithm and the MAASTRO 
implementation uses a Monte Carlo dose calculation algorithm to re-calculate the dose on patient 
anatomy. Strong commercial interest will likely lead to significant developments and competition in 
the next few years with systems utilising more accurate dose calculations, and with continuing 
advancements in Linac technology, the improvements in quality of on board image leading to the 
possibility of accurately calculating on the images will give rise to routine dose-guided-adaptive 
radiotherapy.   
 
 
3.5 SUMMARY 
Detector array technology offers the potential for novel approaches in complex radiotherapy QA. 
The technology continues to advance at the rate of advancement in the therapeutic systems. Various 
studies in the literature report that detector arrays are suitable for routine use in IMRT and VMAT 
QA. One aim in this thesis was to build on and add to that knowledge. At the time of the research 
work, some aspects of the above review had not been extensively looked at. For example, a 
comprehensive critical appraisal of the PTW 2D ARRAY 729 response to  plan delivery deviations for 
VMAT had not been carried out; a methodology for this purpose was developed and published in the 
Journal of Applied Clinical Medical Physics [94], and is described in Chapter 4. A common theme in 
the review was the prevalent use of 3%/3mm gamma index passing criteria. There had been no 
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study investigating whether this analysis was consistent between different commercial systems. 
Additionally there had been no studies looking at the combination of the software and hardware 
design effect on the consistency of the analysis. This research was carried out and published in 
Radiotherapy & Oncology [105], and is described further in Chapter 5 and 6. Additionally this work 
was extended to compare 2D planar gamma analysis and 3D volumetric analysis in Chapter 7, as well 
as the impact of the analysis on the resolution of detector arrays. At the time of this research, the 
majority of literature reports focussed on appraising detector arrays for routine QC. However, no 
study had investigated the suitability of a detector array in an audit setting. This was investigated as 
part of this thesis. The work is described in Chapter 8 and was published in Radiotherapy & Oncology 
[106]. Finally, alternative metrics to using the gamma index passing rate with detector arrays are 
investigated in Chapter 9, along with discussions about the methodology to establish appropriate 
acceptance thresholds.  
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4 DEVELOPMENT OF METHODOLOGY TO 
CHARACTERISE DETECTOR ARRAY 
TECHNOLOGY 
4.1 INTRODUCTION 
The purpose of this study was to develop a methodology to systematically characterize the response 
of a commercial detector array system for optimal use in composite clinical dynamic IMRT and VMAT 
verification. This study focussed on developing tests to evaluate the PTW OCTAVIUS II phantom and 
2D-ARRAY 729 combination against the EPID and EBT2 Gafchromic film. The intention was then to 
use some of the tests developed to test the other commercial hardware and software combinations 
as discussed in chapter 6. 
 
4.2 MATERIALS AND METHODS 
4.2.1 EBT2 Gafchromic Film 
Gafchromic EBT2 20 cm x 25.4 cm film sheets were used. Measurements were performed in a 30 cm 
x 30 cm x 20 cm solid water cubic slab phantom (Gammex Inc., Middleton, WI). The orientation of 
the film was consistent for all measurements; each film had a mark from manufacture to allow 
consistency in setup. All Gafchromic films were processed and analysed at least 24 hours after 
exposure. Films were scanned using the Epson Espression 10000 XL flatbed (Seiko Epson Corp., 
Nagano, Japan) colour scanner at a resolution of 75 dpi, using the red channel [91]. The films were 
all scanned in the same orientation and a jig was used to place the films in the same part of the 
scanner to minimize any displacement effects and to use the optimum part of the scanner which was 
determined through the commissioning process. A uniformity correction was applied by scanning a 
blank film from each batch. A calibration curve for the Gafchromic film batch was determined for a 
range of doses between 0 and 600 cGy. For analysis, the IBA OmniPro I’mRT v.7.0. software was 
used. 
4. Methodology for detector array characterisation  
 
41 
 
 
4.2.2 Varian Electronic Portal Imaging Device (EPID) 
The Varian EPID system used was the aS1000 version which is a panel of amorphous silicon diode 
with a resolution of 0.392 mm. The measuring area of the EPID was 40cm x 30cm. Varian Portal 
Dosimetry software v.10 was used for analysis. In this software there was an option to create a 
composite of all individual fields. For consistency against the other systems this option was used for 
analysis. The EPID underwent a dark field correction (to correct for background noise), a flood field 
uniformity correction and an absolute calibration. The absolute calibration was done by delivering a 
10x10 cm field size 6MV beam for 100 MU for a source-to-imager distance of 100 cm. The measured 
response was then set as 1 calibrated unit (CU) according to the definition in the Varian AM 
Maintenance imager calibration software.  
 
4.2.3 Comparisons of using the OCTAVIUS scan with 2D-ARRAY 729 in 
situ vs homogeneous scan. 
Calculating on the scan of the OCTAVIUS with the 2D-ARRAY 729 in situ with an advanced calculation 
algorithm may result in perturbation of the predicted dose by the air filled ionization chambers, 
which may add to uncertainties in dose, with impact when using gamma index analysis [45]. 
Therefore, a dosimetric comparison was performed between using the OCTAVIUS scan with the 2D-
ARRAY 729 in situ and a homogeneous insert. All clinical plan composite measurements, described 
below in section 4.2.5, were evaluated using predicted doses calculated on both scans to compare 
the sensitivity of the gamma index analysis. 
 
4.2.4 Multiple acquisition modes in the 2D-Array 
In the PTW Verisoft software it is possible to merge multiple measurement acquisitions as proposed 
by Spezi et al [107]. The sequence of measurements is as follows: 
 
1. a measurement is performed at the central axis, then 
2. the 2D-Array is moved 0.5cm inferior, then 
3. the 2D-Array is shifted 0.5cm to the right, then 
4. the 2D-Array is shifted 0.5cm superior 
 
By performing the above sequence and merging the measurements, it was possible to effectively 
increase the total number of measurement points four-fold from 729 to 2916, and improve the 
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detector spacing from 1cm to 0.5cm centre-to-centre. For planar measurements, this can be easily 
achieved by automated couch movements. However, for composite measurements using the 
OCTAVIUS phantom, the 2D-Array must be shifted within the phantom and an insert is available to 
facilitate this. It may not be practical to perform this for every clinical plan verification, therefore the 
effect of different acquisition techniques was compared. All of the test fields and clinical plans 
described below were measured using the multiple acquisition technique. Comparisons were then 
performed between: 
 
a) Single acquisition 
b) Merging in the lateral direction only (by performing 2 acquisitions) 
c) Merging in the longitudinal direction only 
d) Full merge after four acquisitions 
 
The gap between each ion chamber in the 2D-Array is 5mm wide as can be seen in the schematic in 
Figure 4.1. Suppose that only a single 5mm MLC leaf was being sampled. In this case three 
possibilities may occur for a collimator rotation of 0 degrees: 
 
i. Direct overlap between the leaf and a line of detectors 
ii. Partial overlap with a line of detectors 
iii. Complete miss if the leaf aligns with the gap between the lines of detectors 
 
In normal situations, whereby the setup is such that the field’s cross-hairs align with the marks on 
the 2D-Array and OCTAVIUS phantom, the central axis will intersect the central detector. In this case, 
scenario 2 will occur and is illustrated in Figure 4.1 for static gantry IMRT where the collimator is 
typically set to 0 degrees and for RapidArc where the collimator angle may be typically set to 30 
degrees. However scenario [i] and [iii] above would occur if a superior-inferior movement of 0.5cm is 
performed. In this case, every other MLC leaf will directly overlap with a row of detectors for a 
collimator angle of 0 degrees, and the remainder will be missed.  This effect is minimised where 
there is a collimator rotation.  Therefore in order to test the limits of the 2D-Array, comparisons 
were also performed using acquisition number 2 in the measurement sequence described above. 
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Figure 4.1 Schematic of the overlap between the 5mm Varian Millenium MLCs and ion 
chambers within the 2D-Array for a collimator rotation of 0° (as typically used for 
static gantry IMRT) and 30° (as typically used for RapidArc). The dashed line indicates 
the central axis. 
 
4.2.5 Deliberate plan modification tests 
The resolution and sensitivity of the 2D-ARRAY 729 was tested by a number of methods. All plans 
described in the following sub-sections were created using Eclipse™ and calculations were 
performed using the analytical anisotropic algorithm (AAA) with a 0.25cm grid spacing. The AAA is 
categorised as a 3D convolution-superposition dose calculation algorithm [108]. This type of 
algorithm computes dose as the superposition of the total energy released per unit mass (TERMA) 
with an energy deposition kernel which represents the spread of energy from the primary photon 
interaction site throughout the volume. The kernel is pre-calculated using Monte Carlo and in the 
case of the AAA, is a pencil beam type kernel. For further detailed information on the AAA, the 
interested reader is referred to the literature such as [108] and [109]. 
 
Measurements were performed on the same Varian Clinac iX over two sessions. Plans were 
generated to make optimal use of the 0.5cm MLCs.  The array was cross-calibrated in the morning 
and afternoon of each session to account for any output fluctuation. In all cases the normal plan (i.e. 
with no modifications) was measured for baseline. Measurements were also performed using 
Gafchromic EBT2 film in the OCTAVIUS phantom in the same plane as the 2D-ARRAY 729, using the 
film insert provided with the phantom. In the case of the film measurements, the solid OCTAVIUS 
base was used and plans were calculated on a homogeneous scan. Gafchromic films were processed 
and analysed 24 hours after exposure. Films were scanned using the Epson Espression 10000 XL 
flatbed colour scanner at a resolution of 75 dpi, using the red channel [91]. 
Central Ion chamber 
5mm 
5mm 
5mm 
Collimator rotation 30° Collimator rotation 0° 
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In all cases, the gamma index (γ) method of evaluation was used with a 20% lower dose threshold 
[45]. Various criteria for γ were analysed, including the commonly used 3% dose difference and 3mm 
distance-to-agreement (DTA) criteria. For the 2D-ARRAY 729, analysis was performed using the PTW 
Verisoft software version 4.1. For film, analysis was performed using the Scanditronix Wellhöfer 
OmniPro™ I’mRT software version 1.7. Both the film and plan data were normalized at 100% to a 
point in a high-dose low-gradient region, to perform a relative comparison. This procedure is 
commonly used for film analysis due to the known difficulty in performing an absolute dose 
calibration for film [68]. In order to maintain a consistent comparison, the 2D-ARRAY 729 data was 
also re-scaled in the same way as the film. In both cases, the normalization point for the gamma 
analysis was kept consistent for any particular set of measurement; for example in the prostate 
IMRT plan with different changes introduced, the normalization value was always kept the same to 
avoid bias. 
 
4.2.6 Gantry angle 0 degree test fields 
As a starting point, it was necessary to understand the limitations of the 2D-Array in its basic IMRT 
measuring mode; that is setting the Gantry to 0 degrees and delivering a modulated field such that 
the 2D-Array is orthogonal to the beam. The aim was to investigate the two following questions: 
 
 How does the detector spacing of the 2D-Array affect the measurement and visualization of 
a highly modulated field? 
 How does the detector spacing affect the sensitivity of the gamma index in a modulated 
field? 
 
Therefore, two individual planar test fields were designed specifically with the aim of addressing 
these questions. The test fields described below were also measured using the Varian aS1000 
Electronic Portal Imaging Device (EPID) and Gafchromic film. 
 
The first test field was designed to test the sensitivity of the gamma index analysis calculated in the 
2D-Array using a modulated field with regions ranging from subtle to significant. This test will be 
referred to as the sensitivity test. The test had 54 regions of varying width and dose difference 
introduced into an open 15x15cm field using the fluence dose painting tool in Eclipse as shown in 
Figure 4.2 (left). The minimum spot size that the fluence painting tool allowed was 3mm width and 
5mm height. As such, the columns in the test varied between one to six adjacent fluence spots (i.e. 
the width varied from 3mm in the first columns up to 15mm in the last column). Each row had a 
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height of 5mm and corresponded to a MLC leaf and the gap between each region was 5 mm.  The 
difference in dose between each row and the high dose background ranged between 1% and 10%. 
The measurement of the field was compared to the open field predicted dose to determine the 
minimum detectable error by means of the gamma index analysis. Parameters for the analysis were 
varied from 1–10% dose difference, and 1–3mm DTA. 
 
In the second test, a highly modulated field was created by dose painting varying dose and spatial 
positioning into an initially uniform field as shown in Figure 4.2 (right). This field is more complex 
than a field encountered clinically and tests the limits of the 2D-Array. The first two lines in the field 
were offset from each other by 5mm. This meant that due to the design of the 2D-Array, the 
resolution in the lateral direction could be tested. The third line increased in size in the longitudinal 
direction, and therefore the resolution could be tested in this direction. The remaining six lines were 
used as a combined spatial and dose resolution test. This test will be referred to as the resolution 
test. The field was delivered to the 2D-Array to test how well it performs in distinguishing the 
regions.  
 
Figure 4.2 Single gantry test fields for sensitivity (left) and resolution (right) assessment. In the 
sensitivity test the regions vary in width from left to right between 3mm and 15mm 
and the dose difference relative to the background varies from top to bottom by 1% 
to 10%. In the resolution test the values in the lower half represent difference in % 
dose between the regions and the background (lime green) area. In both tests, each 
row represents a single MLC leaf. 
 
4.2.7 Test clinical plans with deliberate modifications 
In order to evaluate the variability of the gamma index analysis in the different QA systems 
described above, changes were deliberately introduced to clinical treatment plans as has been used 
1% 
10% 
Dose 
difference 
3mm 15mm 
Lateral 
resolution test 
 Longitudinal 
resolution test 
  Combined 
dose and 
spatial 
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+25% 
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by others [86,87,110,111]. Previous studies have simulated deliberate delivery errors by introducing 
MLC leaf bank changes or modifications to MLC transmission and penumbra [76,85,86,111]. In this 
study an alternative approach was employed. Single MLC leaf positional deviations of 1mm, 2mm, 
and 5mm were introduced, across the entire field, into pelvic and head & neck IMRT and RapidArc 
clinical plans by editing each control point within the RT Plan DICOM files. The plans which the MLC 
deviations were introduced into were: a 5-field prostate dynamic IMRT plan, a 6-field Head & Neck 
dynamic IMRT plan, a single 360° arc prostate RapidArc plan and a 2-Arc Head & Neck RapidArc plan. 
In the prostate plans the leaf chosen in all plans was such that the deliberate modification intersects 
the high-dose prostate region. In the head & neck plans the modification intersected the high dose 
region and the spinal cord sparing region. These were chosen as a relatively simple prostate plan and 
a complex head & neck plan to test how the arrays performed in those diverse scenarios.  Deliberate 
collimator rotation changes of 1, 2 and 5 degrees were also introduced into a 2-Arc prostate & pelvic 
nodes RapidArc plan; this plan was chosen to give a large error as the area of the dose distribution 
covered most of the detector arrays. A further test was created using the fluence editing tool in 
Eclipse to manually dose paint hot and cold dose spots (ranging from -10% to +10% dose regions) of 
varying dimensions (0.5 cm x 0.5 cm to 2 cm x 2 cm) into all the fields in a 5-field prostate & pelvic 
node dynamic IMRT plan. These significant modifications were randomly introduced and were 
designed to be able to test both the resolution and response of the different systems. In this case a 
re-calculation of the leaf sequence was required. In total, 22 plans were created (5 of which had no 
modifications). This number of plans was practical to be able to perform measurements in each QA 
system in a few measurement sessions as described further below. To ensure that the fields were 
deliverable, all plans were re-calculated in Varian Eclipse v.10 using the analytical anisotropic 
algorithm (AAA). 
 
4.2.8 Effect of normalisation point 
The effect of choosing a point for the gamma index evaluation was investigated to assess whether 
this would influence the results. The analysis described above was repeated by deliberately choosing 
a dose point in a region where there was an MLC deviation, and by choosing the dose based on a 
mean value over the high dose region. In order to facilitate the latter, a custom spreadsheet was 
generated in Microsoft Excel 2007 (Redmond, Washington, US). The spreadsheet was created such 
that it was possible to import the 2D-ARRAY 729 measurement and predicted dose. The local % dose 
difference was calculated on a per detector basis, by comparing the measurement against the 
corresponding predicted dose. Customisable thresholds were also written into the spreadsheet such 
that the user may choose a lower and upper threshold for any value between 0% and 100%. The 
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maximum dose point was taken as 100%; assuming that the ICRU Report 83 [112] conditions were 
met for the high dose region, the coverage would range between 95% to 107% of the prescribed 
dose, i.e. a range of 12%. Allowing for changes in the homogeneity when the plan was transferred to 
the OCTAVIUS phantom, a lower threshold of 85% was used to ensure complete sampling of the 
primary PTV region. This spreadsheet was generated as it was found that the commercial systems 
(Verisoft and Omnipro) limited the lower threshold to a maximum of 30%, whether for dose 
difference or gamma analysis. It was then possible to acquire various statistics such as the mean of 
all the dose differences and standard deviation. The spreadsheet was also setup in a way that a 
comparison may be performed between one predicted dose plane and another. 
 
4.2.9 Dosimetric and radiobiological evaluation of clinical plan 
modifications 
The dosimetric impact of the subtle MLC positional modifications was assessed using the 
spreadsheet described in section 4.2.8. The predicted dose due to a MLC positional modification was 
exported to compare against the unperturbed predicted dose. The expected local dose difference 
caused by the deliberate MLC positional modification was calculated and compared to that found by 
the 2D-ARRAY 729. Additionally, the mean dose difference over a high dose region was also 
calculated. 
 
In addition to the dosimetric impact, it was also possible to determine whether there is a theoretical 
radiobiological effect due to the changes introduced into the clinical plans as described by Carver et 
al [113]. Tumour control probability (TCP) calculations and normal tissue complication probabilities 
were performed in BIOPLAN  [114]. TCP was calculated using the mechanistic Poisson-based TCP 
model [115]. The following input parameters for the TCP models for prostate tumours were used: 
radiosensitivity parameter α=0.29 Gy-1, inter-patient variation in radiosensitivity parameter 
σα= 0.07 Gy
-1, clonogenic cell density ρc=10
7 cm-3 as well as an α/β ratio of 10Gy [114]. For squamous 
cell carcinoma parameters were chosen as α/β=10 Gy, α=0.305Gy-1, σα=0.07Gy
-1, ρc=10
7 cm-3  [116]. 
 
In the prostate cases, NTCP calculations were performed for the rectum using the Lyman-Kutcher-
Bauman model [117–119], generalised uniform dose concept [120] and QUantative Analysis of 
Normal Tissue Effects in the Clinic recommended best parameter estimates of α/β=3 Gy, volume 
effects parameter (n) =0.09, slope parameter (m) =0.13, and the dose for 50% complication 
probability (TD50)=76.9 Gy. For the bladder, there is limited NTCP parameter data due to difficulties 
in fitting parameters to genitourinary toxicity [121]. The general consensus is to use the parameters 
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of n=0.5, m=0.11, and TD50=80 Gy, in conjunction with α/β=3 Gy [122]. In the head & neck plans, 
NTCP values were calculated for spinal cord and parotids. For spinal cord, parameters for 
myelopathy were taken as α/β=3Gy, n=0.05, m=0.175, TD50=66.5Gy [122]. For xerostomia 
α/β=3 Gy, n=0.7, m=0.18, TD50=46Gy [122]. 
 
4.2.10 Data and statistical analysis 
To perform a quantitative analysis between the different permutations described above, a range of 
gamma index [45] passing criteria were recorded, including the commonly used 3%/3mm. For each 
passing criteria, the percentage of detectors with γ<1 was recorded. To compare the response of the 
different systems, cumulative histograms were plotted for the percentage of detectors/pixels 
passing with γ<1, for specified passing criteria, for a given plan; i.e. the number of plans where the 
percentage of points passing with γ<1 was 95%, 96%, 97% and so forth. It was possible to use the 
plots to illustrate the trend and agreement of the different systems against the independent 
predicted γ. See the schematic in Figure 4.3. 
 
 
Figure 4.3 Schematic diagram of cumulative histogram analysis for evaluating the gamma index 
response of different systems. On the y-axis is a plot of the percentage of all 
measured distributions and on the x-axis is plotted the percentage of measured 
points with γ<1. For a range of measured plans with no delivery errors one would 
expect all measured distributions to achieve 100% of measured points to pass with 
γ<1 for a given passing criteria. If a range of plans with known delivery ‘errors’ are 
measured, one would expect an ideal system to demonstrate a range of failures and 
produce a trend such as that illustrated by the solid blue line. As such the response 
of different systems can be tested by comparing their results against a baseline 
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trend. Measured trends that tend to the left of the baseline have greater response 
and those to the right have a lower response. This type of graph allows for a 
comparison between different systems and can be used to compare different 
passing criteria. 
 
In addition to the above analysis method, agreement between passing rates in the different 
measurement permutations and the 2D-ARRAY 729 measurement in single acquisition mode was 
statistically assessed using the concordance correlation coefficient, ρc  [123]. In the case of poor 
agreement, the statistical significance of any difference was assessed using the Wilcoxon signed rank 
test with p<0.05 as the threshold for significance.  
 
4.3 RESULTS 
4.3.1 Gantry angle 0 degree test fields 
Measurements of the resolution test field for the 2D-ARRAY 729 in single acquisition and full merge 
mode, Gafchromic film and EPID are shown in Figure 4.4. The array was able to distinguish dose 
differences, but there was a smoothing effect in the single acquisition which improved when the 
effective resolution was reduced to 5 mm.  
 
 
Figure 4.4 (Left to right) Gafchromic film of highly modulated test, 2D-ARRAY 729 measurement 
(single acquisition), 2D-ARRAY 729 measurement (fully merged), EPID measurement. 
 
Passing rates for the sensitivity test using varying gamma index criteria are shown in Figure 4.5. The 
data have been plotted for the 2D-ARRAY 729 in single and full merge acquisition modes, film, EPID, 
and the expected passing rate. It can be seen that the DTA criteria had a minimal impact in this test 
field for all the permutations, except for the Gafchromic film. The single acquisition 2D-ARRAY data 
can be seen to be the least sensitive when compared to the expected passing rate.  Spatial 
resolution was significantly affected; however dose resolution was less affected. This was due to the 
sparse resolution of 1cm. Improvements were found when a full merge acquisition was performed. 
As the dose difference criterion was increased, the different systems began to converge. The 
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Gafchromic film measurement, although very good spatially, appears to give false negative results 
when compared to the expected passing rate. This is due to intrinsic film heterogeneity causing 
minor artefacts combined with processing uncertainty, which were enough to disrupt the gamma 
index analysis passing rate, and are some of the known limitations of film dosimetry [124]. The EPID 
was found to be have the closest agreement to the predicted gamma index passing rate.  
 
 
Figure 4.5 Gamma index passing rates for the sensitivity test field for different measurement 
permutations. Points have been linked to provide a visual guide. 
 
4.3.2 Dosimetric and radiobiological impact of the deliberate clinical plan 
modifications 
The ability of the 2D-ARRAY 729 to detect local dose differences caused by the MLC positional 
modifications is shown in Figure 4.6. There was a statistically good agreement between the dose 
difference detected by the 2D-Array and the expected difference (ρc=0.96). A 1mm MLC deviation 
caused up to a 1% local dose difference, whereas for a 2mm deviation this was between 1% - 3%, 
and for a 5mm MLC deviation, a local dose difference of between 3% – 6% was observed.   
 
In the prostate IMRT plan, a 5mm MLC positional modification resulted in a 0.4% NTCP increase, 
whereas in the RapidArc plan, this was 1.2%. For a 2mm change, the increase in the IMRT and 
RapidArc plan was 0.3% and 0.9% respectively. In the prostate & nodes plan with collimator rotation 
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changes, a 1 and 2 degree deviations resulted in an increased rectal NTCP of 3.0% and 3.2% 
respectively. In all prostate plans, bladder NTCPs were found to be 0%, although this may not be 
clinically relevant and is due to the difficulty of fitting parameters to genito-urinary toxicity [121].  In 
the head & neck plans, NTCP values for spinal cord did not increase and were 0.2% for all IMRT plans 
and 0.1% for all RapidArc plans; these values are in keeping with published data on the incidence of 
myelopathy at the 45 Gy level [125]. Similarly for the parotids, the maximum increase was limited to 
0.2%. As expected, TCP values increased in all plans due to the increase in local dose from the MLC 
positional modifications. This was as high as an increase of 3% for a 5mm MLC modification and a 
collimator rotation deviation of 2 degrees. 
 
 
Figure 4.6 Expected vs measured local dose difference due to the MLC positional modifications. 
 
4.3.3 Composite verification of clinical plans 
All the unperturbed plans had a γ<1 passing rate of 100% using 3%/3mm. When using 2%/2mm, the 
passing rate for all the plans was greater than 97%. The 5mm systematic MLC positional 
modifications were detected using 3%/3mm in the 2D-ARRAY 729 in the IMRT plans and in the 
prostate single-arc RapidArc plans. However, the 2mm systematic deviations were difficult to detect 
using 3%/3mm; the γ in the region where the deviations occurred was increased in comparison to 
the surrounding area but was still <1, and hence would not be detected as a fault; the deviation was 
detectable at 2%/2mm. For the head & neck 2-arc RapidArc plan, none of the MLC deviations were 
visible in the measurement and were also found to have a low impact in the expected gamma index 
maps. This is due to the plan having opposing collimator rotations on each arc to minimise the 
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tongue and groove effect and the errors may have been largely cancelled out. For the prostate & 
pelvic nodes RapidArc plan with collimator rotation changes, 3%/3mm gave a passing rate of >99% 
for deliberate 1 and 2 degree changes, and reduced to 92% in the presence of a 5 degree collimator 
angle deviation. The 1 degree change would have still passed at 2%/2mm with a passing rate of 
99.3%. The 2 degree deviation, however, resulted in a passing rate of 94.1% and would have failed if 
a 95% threshold was used. At 2%/2mm, the passing rate for the 5 degree rotation plan was 74.6%. In 
the cases where the deliberate deviations were detectable using 2%/2mm, a passing criteria of 
3%/2mm would have passed if a passing threshold of 95% was used; however, had a passing 
threshold of 98% been used then these measurements would have failed. Table 4.1 gives a summary 
of the average and minimum percentage of detectors/pixels passing with γ<1 in all the plans, for 
3%/3mm, 3%/2mm and 2%/2mm passing criteria for the different acquisition permutations. 
 
The analysis of the effect of choosing a normalization point found that there was no significant 
difference between choosing a point in an unperturbed region, a point in a deviation region, or 
mean dose within the 85% isodose at 3%/3mm or 3%/2mm. At 2%/2mm there was a reduction in 
the passing rate in the analysis based on mean dose by 0.5% compared to the other two 
normalization techniques. This reduction was small but statistically significant (p<0.001).  
  
4.3.4 Comparison between expected gamma index passing rates in 
Verisoft and OmniPro 
There was good statistical agreement between the expected gamma index passing rates calculated 
in Verisoft and OmniPro as indicated by the concordance correlation coefficient (ρc > 0.90 for all 
passing criteria). The average difference between the passing rates calculated by Verisoft and 
OmniPro was 0.5% and 1.1% for 3%/3mm and 2%/2mm criteria respectively. The difference was 
found to be statistically not significant (p>0.20 for all). It was therefore reasonable to use the 
average passing rate for the expected gamma index calculated by both software for each clinical 
plan to compare against that measured by 2D-ARRAY 729 and Gafchromic film. 
 
4.3.5 Comparison between evaluations using CT scan with 2D-ARRAY 729 
in situ vs homogeneous insert. 
As shown in Figure 4.7 (a) and Table 4.1, there was a small difference between passing rates using a 
criteria of 3%/3mm, however at 2%/2mm using the scan with the 2D-ARRAY 729 in situ appeared to 
be more sensitive to deviations than comparing against the predicted dose calculated on the 
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homogeneous scan; where at 2%/2mm the average passing rate was 95.7% compared to 88.5% in 
the array scan.  
 
 
Figure 4.7 (a) Cumulative histogram of gamma index passing rates at 3%/3mm predicted doses 
calculated using 2D-ARRAY 729 in situ and homogeneous scan. (b) Cumulative 
histogram of multiple acquisition analysis calculated at 3%/3mm (solid lines) and 
2%/2mm (dashed lines). (c) Cumulative histogram of 2D-ARRAY 729 versus 
Gafchromic film gamma index analysis calculated at 3%/3mm and 2%/2mm.  
 
(c) 
(b) (a) 
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Table 4.1  Summary of mean and minimum gamma index passing criteria for all various measurement permutations. A lower number indicates greater response to deviation 
detection. The concordance correlation coefficient, ρc, is also given assessing agreement with single 2D-Array acquisition. 
Device Acquisition 
% detectors/pixels passing with γ<1 and ρc 
3%/3mm 3%/2mm 2%/2mm 
Mean Min ρc Mean min ρc Mean min ρc 
2D-Array 
Single 98.9 92.0 - 97.9 82.6 - 94.7 74.6 - 
Merged lateral 98.8 91.3 0.984 97.8 82.0 0.979 95.0 74.0 0.957 
Merged longitudinal 98.6 88.8 0.948 97.6 80.9 0.967 94.6 72.3 0.966 
Merged full 98.6 89.5 0.922 97.5 80.9 0.941 94.8 72.1 0.912 
Shift 5mm 
longitudinal‡ 
98.5 85.7 0.875 97.8 79.2 0.959 95.1 69.9 0.910 
Homogeneous scan 99.0 91.8 0.851 98.3 86.6 0.795 96.1 74.6 0.703 
Gafchromic film 98.5 95.5 0.204 95.4 87.8 0.060 92.1 81.3 0.062 
‡ acquisition (b) as described in section 4.2.4. 
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4.3.6 Single vs multiple 2D-ARRAY 729 acquisition modes. 
There was no significant difference in the gamma index passing rate at either 3%/3mm or 2%/2mm 
between performing a single or multiple acquisitions, as shown in the cumulative histogram in Figure 
4.7 (b) and Table 4.1. It appears that performing a single acquisition is comparable to multiple 
acquisitions.  
 
Figure 4.8 shows the gamma index maps and passing rates for the prostate IMRT plan with a 5mm 
single MLC leaf deliberate change. The first panel, Figure 4.8a, shows how the predicted gamma 
index distribution should look as a result of the deliberate change. The deliberate MLC change was 
systematic in all fields of the IMRT plan, however it should be noted that due to the variation of the 
modulation in the field, the variation of the leaf gap will result in a non-linear dosimetric impact. 
Therefore the band of raised gamma index values will not be homogeneous. 
 
It can be seen that performing a merged lateral acquisition (Figure 4.8c) is visually comparable to a 
single acquisition (Figure 4.8b), whereas slightly improved resolution is achieved by either merging 
longitudinally (Figure 4.8d) or performing a full merge of four acquisitions (Figure 4.8e). The effect of 
the finite composition of the air filled ionisation chambers within the array can be seen in the 
measurements. It can also be seen in Figure 4.8 and Table 4.1 that the single acquisition was 
comparable to the acquisition shifted 5mm on the longitudinal axis (Figure 4.8f), demonstrating no 
reduction in response to delivery changes. Overall the acquisition shifted 5mm longitudinal was 
found to be the most responsive acquisition position based on the gamma index passing rates 
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Figure 4.8 Gamma maps using 3%/3mm criteria showing the effect of multiple acquisition 
modes for prostate IMRT plan with 5mm MLC positional modification. (a) predicted 
gamma index distribution; 99.5%, (b) Single acquisition; passing rate 96.8%, (c) two 
merged acquisitions with array shifted lateral for second acquisition; 97.0%, (d) two 
merged acquisitions with array shifted longitudinal for second acquisition; 96.2%, (e) 
four merged acquisitions to give effective 5mm resolution; 96.8%, (f) acquisition with 
5mm shift in the longitudinal direction 96.1%. 
 
4.3.7 2D-ARRAY 729 vs Gafchromic film. 
Figure 4.9 shows a comparison between the gamma index distribution (using 3%/3mm) in the 2D-
ARRAY 729, Gafchromic film and expected gamma index distribution for the head & neck IMRT plan 
with a 5mm MLC positional modification and prostate & nodes with randomly distributed changes. 
Regions of failure were comparable between the 2D array and Gafchromic film, with the array 
exhibiting the blurred effect due to its resolution. Neither system picked up all the modifications in 
the prostate & nodes plan with random changes. 
 
Average and minimum gamma index passing rates using criteria of 3%/3mm were comparable for 
the 2D array and film as shown in Table 4.1 and the cumulative histogram in Figure 4.7(c). At 
2%/2mm the 2D array appears to have resulted in a higher overall passing rate. For a passing rate of 
85% or below the 2D array and Gafchromic films were comparable at 2%/2mm. For passing criteria 
(a) (b) 
(c) (d) 
(e) (f) 
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of 3%/3mm, all film planes achieved 95% passing rate or above, for the 2D array this was found to be 
90.5% of measured planes. At 2%/2mm 33.3% of film planes achieved a passing rate of 95% or 
above, whereas for the 2D array it was 66.7%. Statistically, there was a poor agreement between 2D 
array and film as given by ρc for each passing criteria. The difference between 2D array and 
Gafchromic film was statistically significant for passing criteria 3%/3mm or 3%/2mm (p=0.048 and 
0.001 respectively), however it was not significant for 2%/2mm (p=0.11). When compared against 
the expected gamma passing rate, the 2D array result had a statistically more significant agreement 
(ρc = 0.91 for 3%/3mm, and 0.79 for 2%/2mm) than Gafchromic film (ρc = 0.35 for 3%/3mm, and 0.22 
for 2%/2mm).   
 
 
Figure 4.9 Comparison between gamma index distribution at a passing criteria of 3%/3mm for 
the head & neck IMRT plan with 5mm MLC positional modification (a) predicted, (b) 
2D-ARRAY 729, (c) Gafchromic film and prostate & nodes plan with randomly 
distributed fluences modifications for (d) predicted, (e) 2D-ARRAY 729, (f) film. 
 
4.4 DISCUSSION 
For planar measurements of IMRT fields, the 2D-ARRAY 729 in single acquisition mode performed 
the worst in measuring the sensitivity and resolution test fields. Spatial resolution was significantly 
affected; however dose resolution was less affected. This was due to the sparse resolution of 1cm. 
Improvements were found when a full merge acquisition was performed. In measuring individual 
IMRT fields with the 2D-ARRAY 729 orthogonal to the beam, the resolution may be more influenced 
  
(a) (b) (c) 
(d) (e) (f) 
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by the modulated nature of the fields. This may have less significance in a prostate plan than in a 
head & neck cancer case. It appeared that the Gafchromic film measurement, although very good 
spatially, was giving false negative results in the sensitivity test. This is due to intrinsic film 
heterogeneity causing minor artefacts combined with processing uncertainty, which were enough to 
disrupt the gamma index analysis passing rate, and are some of the known limitations of film 
dosimetry [124]. The EPID was found to be the most effective of the different devices. In this regard, 
if using a 2D-Array for planar field measurement, it would be advisable to consider performing a full 
merge acquisition when measuring very complex planar fields.  
 
In composite plan verification, the 2D-ARRAY 729 demonstrated good sensitivity to subtle MLC 
positional modifications. There was a reasonable comparison between the gamma index 
distributions generated by the 2D-Array and Gafchromic film. At 3%/3mm, passing rates were similar 
between the two systems. The 2D-Array did exhibit a higher passing rate at 2%/2mm compared to 
film. However, it was also interesting to see that the passing rates from the 2D-Array agreed better 
with the expected passing rates than Gafchromic film, consistent with the static gantry planar test 
fields. The effect of manually choosing a normalization point was found to be minimal but there was 
a statistically significant small difference between normalising based on a mean dose and a point in 
the measured distribution. Performing a normalization based on a mean dose would provide more 
consistency. 
 
Performing a merged lateral acquisition was visually comparable to a single acquisition, whereas 
slightly improved resolution was achieved by either merging longitudinally or performing a full 
merge of four acquisitions. This is because, in the case of a lateral shift, resolution is only gained 
along the MLC leaf path, whereas merging in the longitudinal direction perpendicular to the MLCs 
allowed more sampling of the leaf bank. The single acquisition was also comparable to the 
acquisition shifted 5mm on the longitudinal axis, demonstrating no significant reduction in response 
to delivery deviations. The lack of difference between the different acquisition modes can be 
explained by the fact that on Varian linear accelerators, MLCs are arranged either side of the central 
axis. However, the 2D-ARRAY 729 is setup such that the central detector is aligned directly with the 
central axis. Therefore each chamber is always sampling two 5mm MLC leaves simultaneously. A 
5mm offset in the longitudinal direction would result in every other MLC potentially being missed. It 
would therefore be recommended that if a longitudinal shift is required (e.g. for a long IMRT field 
where it is necessary to avoid irradiating the electronics) that the shift be made in whole 
centimetres. It also appears that calculating the expected dose on a homogeneous scan may be less 
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sensitive to errors than calculating on a scan with the 2D-Array in situ. This is due to underestimation 
of the dose from the lateral and oblique directions when using the homogeneous scan.  
There appears to be an international trend to use 3%/3mm with a 95% passing threshold. In this 
study, it was found that in terms of passing rate, the criteria of 3%/3mm masked deviations caused 
by deliberate collimator rotation changes of 1 and 2 degrees, as well as 2mm MLC positional 
modifications. The collimator rotation changes introduced in the prostate & nodes RapidArc plan 
caused the rectal NTCP to increase by about 3% which may be clinically significant. The 2mm 
positional modifications increased the rectal NTCP up to 0.9% in the prostate plans. These deviations 
were detectable using passing criteria of 2%/2mm with a 95% threshold or using passing criteria of 
3%/2mm with a 98% passing threshold. For this system, these may be the recommended criteria to 
be used in order to detect deviations that may cause a clinically significant increase in NTCP. The 
changes introduced all increased local dose difference and therefore the TCP was increased. One 
limitation of this study would be that none of the plan modifications resulted in a reduction of TCP. 
All the MLC positional modifications were designed to increase the leaf gap. Errors with closed leaf 
gaps were not created as there was a risk of causing MLC collisions. MLC positional modifications 
with narrower leaf gaps would have been expected to cause dose reductions. It was shown in Figure 
4.6 that the 2D-ARRAY 729 was able to detect the dose differences caused by the MLC positional 
modifications and the strong linear relationship between the expected dose difference and the 
measured difference suggests that dose reductions may have been detected equally. It is suggested 
that the gamma index passing thresholds be used for guidance, but also be combined with a visual 
inspection of the gamma index distribution and calculation of the dose difference to assess whether 
there may be a clinical impact in failed regions. 
 
4.5 CONCLUSIONS 
Tests have been employed to characterise the sensitivity and resolution of the PTW 2D-ARRAY 729 
and OCTAVIUS II phantom combination. The 2D-Array in single acquisition mode was comparable to 
multiple acquisition modes and Gafchromic film for composite IMRT and RapidArc plan verification. 
A gamma index criterion of 3%/3mm may potentially mask clinically relevant deviations. A criterion 
of 3%/2mm with a passing threshold of 98% or 2%/2mm with a passing threshold of 95% was found 
to be more sensitive in conjunction with an evaluation of the gamma index distribution. These tests 
have resulted in an understanding of the 2D-Array’s limitations and increased confidence in its use 
for clinical IMRT and RapidArc verification.  
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5 EVALUATION OF THE IMPACT OF THE GAMMA 
INDEX CALCULATION APPROACH: A BESPOKE 
MATLAB SOFTWARE 
5.1 INTRODUCTION 
As described in Chapter 2, the gamma index is a computationally expensive process due to the need 
to search all points in the evaluated distribution. This becomes more complex when comparing two 
3D dose distributions. Ideally the gamma index would be calculated quickly to give a result within a 
reasonable time. The computer hardware used will have an impact on the speed of the γ calculation. 
Given previous limitations with computer technology, a number of studies in the literature have 
focussed on ways to mathematically decrease the calculation time of the gamma index.  
 
In order to investigate the different approaches that can be used to calculate the gamma index, a 
software tool was written and implemented in Matlab v2012a – 2014a (Mathworks Inc.). Some open 
source tools are available online, however these are limited. Matlab uses some in-built functions for 
manipulation of matrices that can simplify the coding of the gamma index algorithm, but require the 
two compared datasets to have the same matrix size. This new software was written so that it could 
accept two datasets with different resolution and matrix sizes, and by default it was set up to 
perform no interpolations on the reference dataset. This tool was implemented as a graphical user 
interface (GUI) for user-friendliness as shown in Figure 5.1.  
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Figure 5.1  Screenshot of the gamma index calculation software implemented in Matlab. 
 
The current features of the software are: 
 Able to handle 2D or 3D DICOM dose distributions, Excel, or PTW 2D-ARRAY 729 
measurement format 
 Datasets do not have to have the same resolution/matrix size as each other  
 For 3D DICOM, can visualise axial, coronal, or sagittal viewing plane 
 Display dose profiles 
 Perform 2D plane vs 2D plane γ analysis 
 2D plane vs 3D volume γ analysis 
 3D volume vs 3D volume γ analysis 
 Specify whether to search the whole evaluated distribution, or limit the search to a user-
defined distance from each reference point 
 Perform global or local γ calculation, with ability to set dose difference and distance 
criterion. 
 Allows the user to set lower and upper dose thresholds (a yellow outline is given to visualise 
this; can be used e.g. to focus on a high dose region) 
 Allows the user to specify interpolation factors for either dataset 1 or dataset 2 and also to 
specify the type of interpolation algorithm; linear or cubic spline. 
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 Allows the calculation of different gamma index metrics; % of points passing with γ<1, mean 
γ, median γ, maximum γ, or the minimum gamma index in the top X% pixels (e.g. minimum γ 
in the top 1% pixels; γ1%). 
 Calculate mean, median, and standard deviation dose difference within the user defined 
threshold. 
 Toggle between displaying gamma index dose distribution, gamma index histogram, or dose 
difference distribution. 
 Batch analyse PTW 2D-ARRAY 729 measurements 
 
By default, the dataset 1 was designated as the evaluated distribution, and dataset 2 was designated 
as the reference distribution (according to the definitions specified in Chapter 2).  
 
5.2 OPTIMISING THE SOFTWARE 
5.2.1 Impact of Limiting the Search Distance on Calculation Time 
A global 3%/3mm gamma index comparison of 2D matrices both with 81 x 81 points at 2.5mm 
spacing took ~380s to complete on a PC desktop with a quad-core Intel i7 4GHz CPU, and 16GB of 
RAM. One simple way to speed up the γ calculation significantly is to limit the search in the 
evaluated dose distribution to a certain distance around each reference point. An interesting 
observation made in the study by Wendling et al [52] is that by setting a limited maximum search 
distance, it is only necessary to calculate the distance between a reference point and all the 
evaluated points bound by the search distance once; this can be defined as a 2D or 3D array,  . 
Similarly, it would then be possible to calculate the dose difference between the reference point and 
all the evaluated points which can be defined as an array   which has the same size as  . This 
significantly reduces computing overhead and makes it possible to perform matrix operations which 
are optimised for speed in programmes such as Matlab by calculating all elements using 
parallelisation. Equations 3.2 and 3.3 can then be used to calculate the gamma index for the 
reference point. 
 
To evaluate the suitability of using a limited search distance, a two 360° arc Head & Neck RapidArc 
treatment plan was calculated using the Varian Eclipse Treatment Planning System (TPS) using the 
Analytical Anisotropic Algorithm (AAA) v11 for a dose grid of 2.5mm. The head & neck RapidArc plan 
was then copied and a collimator angle change of +5 degrees was introduced to the two Arcs. This 
changed plan was compared against the normal plan using the software. The changed and normal 
plans were exported in DICOM format to be evaluated against each other in the software. The 
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reason for the choice of a large collimator change was that this would introduce a range of failed and 
passing points with varying levels of dose gradient as shown in Figure 5.2.  
 
 
Figure 5.2 Gamma index map for the deliberate 5° collimator rotation change distribution 
against the normal distribution, showing failed points expected in the 2.5mm pixel 
spacing distribution. 
 
For global gamma index passing criteria 3%/3mm, 3%/2mm, 3%/1mm and 2%/2mm, the search 
distance was linearly increased starting from no limitation. In this case the most informative 
parameter is the maximum calculated gamma index value as this will be affected by limited search 
distances. The calculation time was also measured for each permutation. As the distance criterion is 
varied, the physical search distance will have a different impact depending on the number chosen 
for   . Therefore rather than plotting the maximum gamma index against search distance it was 
more meaningful to plot against the ratio of the search distance divided by    as shown in Figure 
5.3. In this graph it can be seen that for different passing criteria there was a consistent trend 
towards the maximum gamma index having no variation once the ratio of search distance /    
became ≥1.5. The maximum gamma index was the same above the threshold as that where the 
entire evaluated distribution was searched. Even up to a higher ratio of 5 the calculation time was 
still significantly small at ~0.4s. Given these results, the search distance was by default set to be 
3    taking into account the use of the software for 3D data. 
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Figure 5.3 Comparison of the maximum gamma index as a function of varying the search 
distance for global gamma passing criteria 3%/3mm, 3%/2mm, 3%/1mm, and 
2%/2mm. The average calculation time taken is plotted against the right axis. 
 
5.2.2 Data Interpolation techniques 
A fundamental issue with the gamma index calculation is that the result will be influenced by the 
data point spacing of the evaluated dose distribution. There can be inaccuracies when the pixel 
spacing is ≈ distance criterion and can lead to overestimation of the gamma index. Previously Low et. 
al. [45] recommended that the pixel spacing should be   ⁄   . More recently, Wendling et. al. 
concluded that the spacing should be of the order of    ⁄    [52]. In order to achieve a smaller 
point spacing, it is necessary to interpolate the evaluated dose distribution to a finer grid size.  
 
In the software, the in-built 2D and 3D interpolation functions (called interp2 and interp3 
respectively) in Matlab were used. The software was designed so that it is possible to interpolate 
either dataset 1 or 2 for investigative purposes (dataset 2 was always defaulted to have no 
interpolation unless the user specified otherwise). The interpolation options available were to use 
(1) a linear interpolation, (2) nearest neighbour, (3) cubic method or (4) spline method.  In order to 
test the different interpolation techniques available, the head & neck RapidArc treatment plan was 
calculated in the Eclipse TPS using 1.25mm, 2.5mm and 5mm grid spacing. Each individual grid size 
calculation was exported in DICOM format. The 2.5mm and 5mm grid calculations were then 
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interpolated to a grid size of 1.25mm grid size using the different interpolation techniques and 
compared directly against the 1.25mm dose calculation using global gamma index and 1% / 1mm 
passing criteria. The % points passing with γ<1, and mean gamma index were quantified as well as 
visual inspection of the gamma map for each interpolation technique. No lower threshold was used 
for the γ calculation. 
 
Figure 5.4 shows the calculated gamma index maps for the four different interpolation techniques 
and Table 5.1 shows the % points passing γ<1 and mean gamma index results. It was found that the 
spline algorithm gave the closest agreement. Errors mainly occurred at the penumbral edges which 
have been highlighted using 1%/1mm criteria and is therefore within acceptable uncertainty. For the 
purposes of this software the spline algorithm was therefore deemed to be appropriate.  
 
 
Figure 5.4 Comparison of different Matlab interpolation algorithms; (a) spline, (b) linear, (c) 
cubic and (d) nearest neighbour. 
 
  
Spline Linear 
Cubic Nearest neighbour 
(a) (b) 
(c) (d) 
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Table 5.1 Comparison of different interpolation techniques using global 1%/1mm, 0% 
threshold. 
Interpolation type Passing rate (%) Mean gamma index 
Spline 96.6 0.25 
Linear 94.4 0.30 
Cubic 96.4 0.26 
Nearest neighbour 83.4 0.47 
 
After confirming the spline algorithm for interpolation, it was necessary to benchmark how much 
interpolation is needed. The Head & Neck RapidArc plan used previously was employed again. The 
normal plan was again set as the evaluated distribution and the gamma index was calculated by 
varying the level of interpolation. In Matlab an integer interpolation factor,  , is specified. This 
changes the original spacing, x0, by: 
 
  
  
      (5.1) 
For passing criteria of 3%/1mm, 3%/2mm, 3%/3mm,   was varied from 0 to 7 in increments of 1. For 
each passing criteria the following ratio was calculated: 
 
  
  
       (5.2) 
 
For each calculation, the mean gamma index was calculated and the time taken for the calculation 
was recorded. The results of this are shown in Figure 5.5 where it can clearly be seen that the mean 
gamma varies sharply when the ratio of    and    are close to 1 and begins to stabilise by the time 
the ratio has become 10. This is in keeping with the recommendations by Wendling et al [51]. Up to 
this ratio, the calculation time was only of the order of 1 second and therefore as the default for 
further evaluations using the software the interpolation factor was set so that the ratio of equation 
5.2 was ≥10. 
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Figure 5.5 Comparison of the maximum gamma index as a function of varying the interpolation 
factor for global gamma passing criteria 3%/3mm, 3%/2mm, 3%/1mm, and 
2%/2mm. The calculation time taken is plotted against the right axis for each passing 
criteria. 
 
5.3 COMPARISON AGAINST TWO COMMERCIAL SOFTWARE 
The bespoke Matlab software was tested against two other established commercially available 
software; namely the PTW Verisoft v5.1 package and IBA OmniPro v7.0. The same combination of 
the normal and changed head & neck RapidArc plan was used. In order to test the software, the 
changed plan was calculated and exported as 2.5mm, 5mm and 10mm dose grids to compare 
against the 2.5mm grid normal plan. Global gamma index comparisons were made using 3%/2mm 
passing criteria and no lower dose threshold. The mean gamma and % passing rates were compared. 
Figure 5.6 shows gamma index maps for the 10mm grid spacing changed plan against the normal 
plan.  
 
The top two images are from OmniPro and Verisoft respectively. It is clear that the OmniPro 
software prefers to plot the gamma index map as an intensity image where each pixel is given a 
discrete colour based on the gamma index. The Verisoft software uses a colour contour approach 
which is visually easier to interpret. The two styles were replicated in Matlab and the maps are given 
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for the bespoke software below the respective commercial software maps. The figure shows good 
visual agreement in the gamma index maps between the bespoke software and the commercial 
packages. 
 
 
 
Figure 5.6 Gamma index map for the 10mm resolution reference distribution from (a) OmniPro, 
(b) Verisoft, (c) Matlab plotted using the imagesc function, and (d) Matlab plotted 
using the contourf function. 
 
The comparison between the γ passing rate in the Matlab software, OmniPro and Verisoft is shown 
in Figure 5.7. This shows very good agreement between the Matlab and Verisoft calculations for all 
the different grid spacing of the deliberately changed plan.  
(a) (b) 
(c) (d) 
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Figure 5.7 Comparison of % points passing with γ<1  between (top graph) Matlab, Verisoft and 
OmniPro analysis for reference distributions with 2.5mm, 5mm and 10mm pixel 
spacing, and (bottom graph) repeated using Matlab with no interpolation setting. 
Analysis used global 3%/2mm with no lower dose threshold.  
 
Interestingly, if the Matlab software is re-run with no interpolation setting, there is excellent 
agreement against OmniPro. Clearly this shows evidence that Verisoft interpolates the evaluated 
dose distribution into finer grid spacing, whereas OmniPro does not. A similar trend was found with 
the mean gamma index shown in Figure 5.8. This is a good example of how there can be variability in 
the implementation of the gamma index calculation. This brief study focussed purely on the 
software side, however most commercial systems are designed taking into account the associated 
detector array configuration and therefore a more robust analysis will include an evaluation of the 
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combined hardware and software. This topic is addressed further in chapters 6 and 7 of this thesis. 
An extract of the code is provided in Appendix C, the entire code for the GUI consisted of ~4600 
lines.  
 
 
 
Figure 5.8 Comparison of mean gamma index between (top graph) Matlab, Verisoft and 
OmniPro analysis for reference distributions with 2.5mm, 5mm and 10mm pixel 
spacing, and (bottom graph) repeated using Matlab with no interpolation. Analysis 
used global 3%/2mm with no lower dose threshold. 
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6 A COMPARISON OF THE GAMMA INDEX 
ANALYSIS IN VARIOUS COMMERCIAL 
IMRT/VMAT QA SYSTEMS 
6.1 INTRODUCTION 
Previous studies have been performed to inter-compare different commercial detector arrays and 
the response of γ IMRT and/or VMAT simulated errors. Zhen et al. [86] performed a theoretical 
evaluation of three detector geometries: ‘X’, ‘O’, and spiral shapes which simulated errors by 
modifying the beam models to introduce MLC transmission and penumbra errors, in order to create 
‘virtual measurements’ at the treatment planning system resolution. These were compared against 
error-free calculations. This method meant uncertainties in delivery and devices were removed. A 
similar methodology was used by Nelms et al. [87].  However, detector arrays are limited by their 
sparse spatial resolution which may affect the response of the gamma index analysis due to under-
sampling [126].  
 
It is, therefore, of interest to understand the variability in gamma index analysis between different 
commercial QA systems, including their shape, configuration and detector resolution, and their 
associated software. Hence, the purpose of this study was to compare the gamma index analysis in 
the commercial 2D and 3D detector arrays to assess the impact of low resolution in combination 
with the gamma calculation implementation. This study made use of the methodology developed in 
Chapter 4 to evaluate the variability of the resulting gamma index assessment across the systems.  In 
keeping with the methodology proposed by Nelms et al. [87] and Zhen et al. [86], the predicted 
gamma index was calculated by comparing high resolution calculation of the deliberate errors in the 
different commercial 2D and 3D detector configurations against the error-free calculation, in each 
respective commercial software.  The predicted calculation in each software was also compared 
against the calculation in the Independent Matlab Software (Chapter 5). The final goal of this study 
was to compare the gamma index calculated based on experimental measurements in the 
commercial systems against the predicted gamma index. 
6. Comparison of the gamma index in commercial systems 
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6.2 DETECTOR ARRAY SYSTEMS INTER-COMPARED 
The commercial detector arrays used in this study were the PTW 2D-Array in the OCTAVIUS II 
phantom, SunNuclear ArcCHECK, and Scandidos Delta4. These are representative of each of the 
currently available detector array configurations which are: planar (2D-Array), cross-plane (Delta4) 
and helical (ArcCHECK). In addition, in-phantom EBT2 Gafchromic film was used as well as the Varian 
Electronic Portal Imaging Device (EPID) to provide high resolution measurements to experimentally 
compare against the potential under-sampling effects from using sparse detector arrays. 
 
6.3 VIRTUAL PLAN MEASUREMENTS TO CALCULATE PREDICTED γ IN 
COMMERCIAL SOFTWARE 
The influence of the hardware and linac delivery on the γ calculation was removed using a similar 
methodology to that employed by Nelms et al. [87] and Zhen et al. [86], which allows for a 
theoretical direct comparison between different commercial software as well as different array 
configurations and shapes. To perform this analysis, all the test plans developed in Chapter 4 with 
the deliberately inserted modifications, were calculated on the respective phantom CT scan in 
Eclipse, in addition to the original unperturbed plans. This effectively meant that it was possible to 
simulate the predicted gamma index pass rate in ‘ideal’ conditions as it was possible to remove any 
inherent QA hardware uncertainty, any inherent mechanical effects on the other unperturbed MLC 
leaves and no output fluctuations would be present. Additionally, this method removes the effect of 
under-sampling and/or blurring effects that are inherent in array designs. 
 
The original dose distribution, in DICOM RT Dose format, was then imported into each of, Verisoft, 
OmniPro I’mRT, and SNC Patient and Portal Dosimetry, as the ‘reference’ data set and the perturbed 
dose was imported as ‘measurement’ dataset. It was then possible to calculate a predicted γ. This 
was not possible in the Delta4 software as there is no straightforward way to replace the measured 
dose with virtual data. Each system was used to process the predicted doses as they normally would 
in the presence of a measurement. For example in the ArcCHECK the dose cylinder is unrolled to 
compare against the unrolled measured dose [92]. For Verisoft and OmniPro, coronal planes 
corresponding to the position of the 2D-Array or Gafchromic film were chosen for this analysis. For 
Portal Dosimetry, a two-dimensional predicted dose was calculated using the algorithm within 
Eclipse, and the predicted plane with no modification was compared against the predicted plane 
from the modified treatment plan.  
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To perform a consistent evaluation, an independent gamma index calculation using a code 
developed in MATLAB [127]4, was also performed. This was a 2D calculation. For independence, the 
plans were calculated on a separate virtual phantom which was a water equivalent cylinder with 
30cm diameter and 30cm length, and a coronal plane through the axis of the phantom was used. 
The purpose of the independent calculation was to remove the impact of software-specific gamma 
calculations. 
 
For the Delta4 software, it was not possible to directly inter-compare two dose cubes against one 
another. However, it was possible to compare the normal plan measurement against the 
deliberately changed plan. Since the measurements were carried out sequentially, any inherent 
systematic uncertainties will be present in both the normal and changed plan measurements and 
consequent differences will be minimised.  Whilst this was not an ideal comparison, it allowed the 
software to be evaluated. To ensure the validity of this, a similar comparison was made using the 
2D-Array data and compared with the results from the Delta4 and the independent gamma index 
calculation. 
 
6.4 EXPERIMENTAL PLAN MEASUREMENTS 
Following on from the theoretical derivation of the predicted gamma index, experimental 
measurements on the linac using the QA systems were performed. All test plans were delivered 
using the same monitor units (MU) as the original plan and compared against the original unedited 
plan. In order to ensure that there would be no problem when delivering the deliberately introduced 
changes, each plan was first delivered to the EPID and compared with the calculated version of that 
plan. The same 22 plans were measured by each of the five QA systems. All measurements were 
undertaken on the same Varian Clinac iX. The linac incorporates the Millennium 120 leaf MLCs, with 
the central 80 MLCs covering a 20x20cm area each having a 0.5cm width at the isocentre; the 
remaining MLCs have 1cm width. Due to the number of plans, it was not possible to perform 
measurements by all the different QA systems on the same day. However, measurements were 
performed on sequential days and routine dynamic MLC quality control (QC) checks using the EPID 
were performed each day, to minimize uncertainty. The routine tests include the picket fence, 
                                                          
 
4 This study was performed before the author fully developed a gamma index Matlab code. In the 
interest of time and in order to publish in the high impact journal, Radiotherapy & Oncology [105], a 
fruitful collaboration was set up with Dr Pejman Rowshanfarzad and Professor Martin Ebert 
(University of Western Australia) who, after being sent the DICOM files, performed the independent 
calculations using their own already developed Matlab code. 
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sweeping gap, and MLC speed test, which have been described in the literature for IMRT and 
RapidArc [128–130]. Measurement of the QC tests were compared directly against a baseline 
measurement taken at linac commissioning using gamma index with strict criteria of 2% dose 
difference (DD) and 1mm distance-to-agreement (DTA) criteria and 95% passing threshold. 
 
6.5 DATA AND STATISTICAL ANALYSIS 
In all theoretical and experimental cases, the global γ were calculated with a 20% threshold relative 
to a point selected in the centre of the high dose region, with low dose gradient. For 2D-Array, 
Delta4, ArcCHECK and film measurements, the gamma index evaluation was performed taking into 
account the 3D dose distribution; i.e. the complete TPS dose cube, not just the dose distribution of 
the measured plane. Various γ criteria were analysed, including the commonly used 3%/3mm.  
 
In addition to the cumulative histograms, the statistical agreement between the predicted γ 
calculated in the different systems was assessed using the concordance correlation coefficient, ρc  
[123]. The Pearson correlation coefficient assesses whether there is a linear trend between two 
datasets, but does not indicate whether they agree. However, ρc assesses the correlation between a 
trend on a scatter plot against the 1:1 trend expected if two measured datasets agreed.  The 
agreement between measured γ and the predicted γ was also evaluated using ρc. 
 
6.6 RESULTS 
6.6.1 Predicted γ based on virtual measurements  
 
There was statistically good agreement between the predicted γ from each software and the 
independent calculation (all ρc>0.92), also shown in the scatter plot in Figure 6.1 and the cumulative 
histogram plotted in Figure 6.2. A summary of the predicted mean and minimum percentage of 
detectors/pixels passing with γ<1 is given in Table 6.1 for 3%/3mm, 3%/2mm and 2%/2mm for each 
system. The plot for the Delta4 is, as described in the methodology section, given for the comparison 
between the experimental measured plan with and without error as it was not possible to compare 
two calculated dose distributions. This was shown to be valid as this approach tested with the PTW 
2D-Array measured data gave ρc against the independent calculation of 0.96, whereas for Delta4 this 
was 0.93, for passing criteria 2%/2mm. This is further supported as the corresponding PTW VeriSoft 
virtual measurement result was 0.95.    
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Table 6.1 Summary of the mean and minimum measured gamma index passing criteria for 
each system. The concordance correlation coefficient, ρc, is also given assessing 
agreement with independent gamma index. The software are listed in the same 
order as the associated measurement system. 
System 
% detectors/pixels passing with γ<1 and ρc 
3%/3mm 3%/2mm 2%/2mm 
Mean Min ρc Mean min ρc Mean min ρc 
Software predicted 
Verisoft v5 99.0 89.9 0.97 98.4 83.9 0.95 97.2 75.4 0.95 
SNC Patient v6 98.7 84.5 0.97 98.0 78.5 0.99 96.4 70.0 0.96 
Delta4 software 98.8 89.4 0.96 98.3 84.9 0.93 97.3 77.3 0.93 
OmniPro I’MRT v7 98.7 82.6 0.95 97.9 73.8 0.97 96.2 57.1 0.92 
Portal Dosimetry v10 98.7 84.7 0.97 98.0 73.6 0.96 97.5 68.2 0.92 
Independent 
predicted 
98.8 87.0 - 97.9 78.0 - 96.4 58.1 - 
Measured 
PTW 2D-Array 98.0 86.3 0.87 96.2 79.3 0.86 90.7 70.9 0.61 
ArcCHECK 98.4 87.2 0.96 97.2 81.6 0.95 93.9 74.1 0.83 
Delta4 96.2 86.6 0.53 93.4 78.5 0.58 85.5 68.8 0.33 
Gafchromic 98.1 88.2 0.81 94.6 76.5 0.62 91.2 70.1 0.54 
EPID 97.7 77.4 0.82 96.2 66.3 0.84 93.6 59.1 0.82 
 
The Delta4 measurement showed the lowest concordance correlation with the predicted gamma 
index. Given this difference, the Delta4 was re-analysed using 4%/3mm and 4%/4mm to see if there 
is better agreement to passing criteria of 3%/3mm in the other systems and the predicted 
evaluation.  
 
 
 
 
 
6. Comparison of the gamma index in commercial systems 
76 
 
 
Figure 6.1 Cumulative histogram of gamma index analysis using passing criteria of 3%/3mm for 
(a) comparison of different software against the independent predicted calculation 
and (b) comparison of the measurements by the QA systems against the 
independent prediction. The software in the figure legend in (a) is listed in the same 
order as the associated hardware in (b). 
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Figure 6.2 Scatter plot of gamma index analysis for each plan using passing criteria of 2%/2mm 
for (a) comparison of different software against the independent predicted 
calculation and (b) comparison of the experimental measurements by the QA 
systems against the independent prediction. The dashed line gives a 1:1 trend that 
would be expected for perfect agreement. The software in the figure legend in (a) is 
listed in the same order as the associated hardware in (b). 
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6.6.2 Calculated γ based on experimental linac measurements  
All of the normal (unperturbed) plan measurements had a γ<1 passing rate of >98% using 3%/3mm 
in all systems. When using 2%/2mm, the passing rate for all the normal plans was greater than 93%. 
The 5mm systematic MLC positional modifications showed a visible strip of γ>1 for passing criteria 
3%/3mm in all QA systems.  
 
For the experimental measurements the trend against the predicted independent calculation is 
shown in the cumulative histogram in Figure 6.1b and the scatter plot in Figure 6.2b. For the 
measurements, a lower mean passing rate indicates greater response. Additionally, ρc, is given for 
the comparison between the measured plans and the independent predicted γ for each system in 
Table 6.1. 
 
Figure 6.3 shows the  cumulative histogram of the 4%/4mm, 4%/3mm, and 3%/3mm analysed in the 
Delta4 alongside the 3%/3mm results from the predicted gamma index calculation, and in Figure 6.4 
the ρc for the Delta4 vs the predicted is shown for the different passing criteria compared against the 
3%/3mm ρc for the other systems. 
 
 
Figure 6.3 Concordance correlation coefficients for the different systems for 3%/3mm. For the 
Delta4, the coefficient is also given for 4%/3mm and 4%/4mm. 
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Figure 6.4 Cumulative histogram of gamma index analysis for the Delta4 using passing criteria 
of 3%/3mm, 4%/3mm and 4%/4mm against the predicted 3%/3mm results. 
 
 
Figure 6.5 shows a comparison between the gamma index distribution (using 3%/3mm) for the head 
& neck IMRT plan with a 5mm MLC positional modification measured by the 2D-Array, Delta4, 
ArcCHECK, EPID, and Gafchromic film and predicted by the independent gamma index calculation. 
For comparison separately, the predicted gamma index distribution in the SNC software vs the 
ArcCHECK measured gamma index map is shown in Figure 6.6. 
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Figure 6.5 Gamma index distributions for the head & neck IMRT plan with 5mm MLC deliberate 
change. The passing criteria shown is 3%/3mm. Distributions are shown for the 
independent gamma index calculation, and the measured plans using the 2D-Array, 
Gafchromic film, EPID, ArcCHECK and Delta4.  
 
The 2mm systematic MLC positional modifications were difficult to detect using 3%/3mm but were 
detectable for criteria of 2%/2mm. For the head & neck 2-arc RapidArc plan, none of the deviations 
were visible in the measurement and were also found to have a low impact on the expected gamma 
index maps. This is due to the plan having opposing collimator rotations on each arc to minimise the 
addition of inter-leaf leakage in the same spots, and therefore the deviations may have been largely 
masked. For the prostate & pelvic nodes RapidArc plan with collimator rotation changes, 
Predicted 2D-Array Gafchromic 
EPID 
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measurements by all the QA systems at 3%/3mm gave a passing rate of >95% for deliberate 1 and 2 
degree collimator rotation changes, and ranged from 77.0% - 88.2% in the presence of a 5 degree 
change.  
 
 
 
Figure 6.6 Predicted vs measured gamma index points with γ>1 for the ArcCHECK. 
 
Figure 6.7 shows a comparison, for the measurements, of the percentage of detectors/pixels passing 
with a gamma index < 1, for passing criteria 2%/2mm, for the prostate IMRT plan with 2mm MLC 
positional modification, head & neck IMRT plan with 2mm MLC positional modification, prostate 
RapidArc with 2mm MLC positional modification, head & neck RapidArc with 2mm MLC positional 
modification and the prostate and pelvic nodes RapidArc plan with a collimator rotation error of 1 
degree. 
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Figure 6.7 Percentage of detectors/pixels passing with a gamma index < 1, for 2%/2mm, for the 
prostate IMRT plan with 2mm MLC positional modification, head & neck (H&N) IMRT 
plan with 2mm MLC positional modification, prostate RapidArc (RA) with 2mm MLC 
positional modification, H&N RA with 2mm MLC positional modification and the 
prostate and pelvic nodes (PPN) RA plan with a collimator (col.) rotation error of 1 
degree. 
 
6.7 DISCUSSION 
This study has shown that various commercial software agree well with each other in calculating the 
predicted gamma index passing rates when delivery fluctuations and under-sampling effects due to 
the sparse detector resolution are removed, even at tight passing criteria of 2%/2mm (as shown in 
Table 6.1). Figure 6.1a illustrates the agreement for a passing rate of 3%/3mm using the cumulative 
histogram. The scatter plot in Figure 6.2a is given for tighter passing criteria of 2%/2mm and shows 
the trend against the expected 1:1 trend for perfect agreement. The trend at 2%/2mm shows that 
the software calculation tends to slightly over-estimate the passing rate with respect to the 
independent calculation, with the exception of one point where OmniPro predicted a lower passing 
rate for the prostate and pelvic node RapidArc plan with 5° collimator angle rotation change. Overall, 
the agreement is encouraging given the variability in detector array design from planar (2D-Array, 
EPID), helical (ArcCHECK) and cross-plane (Delta4) configurations as well as potential variation in 
implementing the gamma index calculation in the various software. There was also a good 
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agreement (ρc > 0.92 in all cases) against the independent 2D gamma index calculation. This 
agreement in the virtual calculation may be explained by the fact that none of these systems 
perform a true 3D gamma index calculation. Instead, generally the 3D dose cubes are re-sampled 
into 2D planes to compare against the measurements which are effectively 2D data. For example, in 
the ArcCHECK the measurement by the helical diode array is unrolled into a 2D plane and likewise 
the same is done with the predicted dose. In Verisoft there is a 3D option, but this takes into account 
the predicted dose planes above and below the measured 2D dose plane. 
 
For the measured data it can be seen in Table 6.1 that the agreement against the predicted γ 
reduces with tightening passing criteria and the variability between the different systems increases. 
This indicates that detector configuration and resolution have greater impact on the experimental 
calculation of γ. This is also seen in Figure 6.2b where there is more spread in the data compared to 
the graph for the predicted software analysis. This can be caused either by under-sampling of the 
dose distribution, blurring effects, or noise, or a combination of all. Moreover, in the theoretical 
approach, the high resolution combined with the comparison of two distributions with the same 
resolution mean that interpolations are not required. In particular the cases with fine resolution 
mean that for the DTA criteria used, the ratio between the grid spacing and the DTA will be less than 
the recommended one third [45]. For a real measurement using a sparse detector array, 
interpolation to a finer resolution will be required and/or re-sampling of the 3D dose distribution to 
the configuration of the detector array (as mentioned above) is required. These processes can 
introduce uncertainties particularly for a complex array configuration such as the Delta4. Practically, 
the Delta4 was found to have the lowest concordance coefficient based on measurements relative 
to the other systems for the same passing criteria, indicating lower agreement with the predicted 
gamma index as shown in Figure 6.1b and Figure 6.2b, and Table 6.1. As shown in Figure 6.3 and in 
Figure 6.4, it is possible to modify the passing criteria to get better agreement with the other 
systems, e.g. choosing 4%/3mm for the Delta4 was in better agreement with 3%/3mm in the other 
systems. However it should be noted that the lower agreement may indicate the possibility of 
potential false failures. Lower passing rates indicate that a system has greater measurement 
response to delivery deviations compared to the other systems and is therefore more likely to cause 
an investigation of failures in clinical practice.  It is interesting to note that despite the high 
resolution of EPID and Gafchromic film being closest to the virtual measurements; their concordance 
correlation coefficients indicate weak correlation with the predicted γ. For the film, this is most likely 
due to intrinsic film heterogeneity causing noise artefacts combined with variability in scanning  
procedures, which can be enough to disrupt the gamma index analysis passing rate [91,124]. The 
decreasing concordance coefficient with tightening criteria supports the effect of noise in the film. 
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The EPID is also susceptible to small anomalies as reported by Gordon et al [131] . For EPID, the 
concordance coefficient appears to be stable across the different passing criteria suggesting the 
effects are systematic which may be correctable in future releases of the software and therefore 
improve the agreement [131]. Out of all the systems, the ArcCHECK measurements exhibited the 
closest statistical agreement with the predicted gamma index where for passing criteria of 3%/3mm 
and 3%/2mm ρc was >0.95.  The deliberately inserted modifications were designed to test the QA 
systems, however, the likelihood of this type of error occurring in clinical practice should be 
considered. An MLC motor is affected due to wear-and-tear, leading to a leaf travelling slower than 
expected and therefore the leaf lag behind the other leaves, in a way that would be similar to the 
deviations simulated in this study. The tolerance on the MLC control software (commonly 2mm on a 
Varian linac), means that there are generally two possible feedback scenarios: if possible, all the 
other leaves are slowed down and the dose rate is decreased to compensate for the slower leaf; or 
an interlock may be activated. Software errors may also lead to a mis-translation of the MLC 
positions. This study has demonstrated that in the event of subtle changes, as shown in Figure 6.5, 
Figure 6.6 and Figure 6.7, the detector array systems are able to detect some of these deviations if 
suitable passing criteria, such as 2%/2mm, are used. However, even lower passing criteria may be 
required for film, EPID, and ArcCHECK. Heilemann et al also concluded that 2%/2mm is necessary to 
detect positional deviations in MLCs for RapidArc deliveries [76]. 
 
This study has focussed on whether the measured gamma index calculation in various systems 
correlates with the predicted gamma index calculation. However, all systems have strengths and 
weaknesses and other aspects of these systems including usability, time taken to perform QA, ease 
of use and transportability, and so forth, were outside the scope of the present work. It should also 
be considered that all the systems were used according to manufacturer’s recommendations, and 
that in practice one may refine the methodology for using each to achieve optimal use of the 
system.  
 
It is important to understand the sensitivity and limitations of the gamma index analysis combined 
with the equipment in use. For the same passing criteria, different devices and software 
combinations exhibit varying levels of agreement with the predicted analysis. When looking at the 
literature, it is important to note the type of equipment used and gamma index criteria. As shown in 
this study, passing criteria of 3%/3mm may not give the same results for measurements by different 
QA systems. 
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7 THE IMPACT OF THE GAMMA INDEX 
CALCULATION IN 2D AND 3D ON DETECTOR 
ARRAY RESOLUTION  
7.1 INTRODUCTION 
As previously discussed, detector arrays have been limited by their spatial resolution with most 
commercial systems limited to no better than 0.5cm centre-to-centre spacing.  In chapters 4 and 6 
the detector array systems have been relatively compared against Gafchromic film. Recently, a high 
resolution commercial system has been made available which has a centre-to-centre spacing of 
0.25cm. This system is the PTW OCTAVIUS 1000SRS detector array.  
 
Furthermore, traditionally the γ index has been used to compare a 2D measured plane against a 3D 
dose distribution.  There is a growing trend in using 3D back-projected EPID based in-vivo systems 
and independent calculations using Monte Carlo [132] to perform 3D versus 3D gamma index 
comparison. DVH-based analysis techniques have been proposed, however the gamma index 
continues to be prevalent. There have been quasi-3D commercial systems available such as the 
ArcCHECK and Delta4; however these have not constructed a true 3-dimensional dose distribution. 
Recently, software algorithm and hardware improvements have led to the possibility of using 
measured 2D data from commercial detector arrays to reconstruct a 3D-dose distribution and 
perform a volumetric comparison against the TPS. A limitation is that detector arrays have so far 
been limited by their spatial resolution which may affect the accuracy of the reconstructed 3D 
volume and subsequently the γ calculation due to under-sampling [126]. One commercial system 
that can use 2D measured data to reconstruct a 3D dose cube is the PTW OCTAVIUS® 4D [64,65]. At 
the time of writing, this can be used either with the OCTAVIUS® Detector 729 or with the high 
resolution OCTAVIUS® Detector 1000SRS.  
 
The purpose of this study was to extend the work from chapter 5 by comparing the PTW 2D-Array 
729 directly against the OCTAVIUS 1000SRS to check the impact of the gamma index passing rate on 
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two detector array systems with significant difference in resolution. An additional aim was to assess 
whether the gamma index passing rate in a 2D plane measurement was a suitable surrogate for a 3D 
volumetric gamma index.  
 
7.2 METHOD 
7.2.1 Equipment 
Due to its design, it was not possible to use the OCTAVIUS 1000SRS detector array within the 
octagonal OCTAVIUS II phantom to measure a composite 2D plane to directly compare against 
previous measurements using the 2D-ARRAY 729. Instead, the 1000SRS array required the use of the 
PTW OCTAVIUS 4D phantom. Measurements were also performed using the 729 array within the 
OCTAVIUS 4D. 
7.2.1.1 Cross-calibration procedure 
At the time of measurements on the linac, the detector arrays were cross-calibrated in the 
OCTAVIUS 4D phantom; in this procedure, a known dose was delivered and the response of the 
central detector was used to calculate a cross-calibration factor. This factor was applied to the entire 
matrix of detectors [94]. 
 
7.3 DELIBERATE PLAN MODIFICATION TESTS 
The deliberate change tests for the prostate IMRT and RapidArc plans used in Chapter 4 and 6 were 
used. Following the same methodology used previously (Chapter 6), the plans were measured with 
the OCTAVIUS4D with the SRS1000 array and 729 array in situ. The 2D coronal plane measurements 
that were previously performed using the 2D-ARRAY 729 within the OCTAVIUS II phantom were 
used. 
 
The 1000SRS array is limited to measuring over an active area on 11cm x 11cm. Therefore the 3D dose 
cylinder is limited to 11cm length and 5.5cm radius. In order to maintain a consistent analysis, the 
3D dose reconstruction was performed in a cylinder of 11cm length and 5.5cm radius for the 2D-
ARRAY 729 and SRS1000. It was possible to manually specify the dimension of the reconstructed 
dose distribution within the Verisoft software, as shown in Figure 7.1. For the 2D coronal plane 
measurements using the 2D-ARRAY 729 in the OCTAVIUS II phantom, the region of interest for the 
analysis was set to 11cm x 11cm.  
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The expected 2D and 3D γ pass rates were simulated by exporting the normal plan and perturbed 
plan predicted dose distributions in DICOM format. The predicted γ was calculated, using the 
bespoke Matlab software, for a 2D coronal-plane as well as in 3D. Perturbed plan measurements (2D 
coronal-plane and 3D-reconstructed-dose) were evaluated against the normal dose distribution. The 
same cylinder and plane dimensions, above, were applied to the simulated 3D and 2D dose 
distributions respectively. 
 
For evaluations, the global γ was used with passing criteria of 3%/2mm, and a 20% threshold. The γ 
results based on measurements were compared against the 3D volume predicted analysis. The 
concordance correlation coefficient, ρc, was used to assess agreement between the analyses. 
 
 
 
 
Figure 7.1 The parameter specification window for 3D dose reconstruction in Verisoft V6.0. 
 
7.4 RESULTS 
A summary of mean percentage of points passing with γ<1 is given in Table 7.1. There was good 
agreement between the predicted γ for the 2D coronal plane and 3D volume analysis (ρc>0.90). The 
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measured 2D and 3D data had a lower agreement with the predicted and had consistently lower 
pass-rates, see Figure 7.2. However, there was statistically strong agreement between the 3D 
1000SRS measured pass-rate and 3D predicted pass-rate (ρc=0.93). The OCTAVIUS 729 used in the 
OCTAVIUS 4D phantom to reconstruct a 3D dose distribution had the worst agreement of ρc = 0.28. 
 
Table 7.1 Summary of mean and minimum gamma index passing criteria for each system for 
the range of changes introduced. The concordance correlation coefficient, ρc, is also 
given assessing agreement with the predicted 3D volume gamma index pass-rate. 
 
 % detectors/pixels passing with γ<1 and ρc 
Mean min ρc Pearson ρ  
Predicted 
3D volume 98.8 92.4 N/A N/A 
2D coronal plane 98.6 91.8 0.98 0.99 
Measured 
OCTAVIUS729 2D 
coronal 
97.8 86.9 0.81 0.99 
OCTAVIUS 1000 SRS 
3D volume 
98.1 91.5 0.93 0.98 
OCTAVIUS729 3D 
volume 
97.2 94.6 0.34 0.47 
 
 
Figure 7.3 shows a comparison of 2D dose profiles (plotted as discrete points) for the RapidArc 
prostate normal plan measurement from the 3D reconstructed dose distributions using the 729 and 
1000SRS array. The profile from the TPS predicted dose distribution is plotted for comparison.  
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Figure 7.2 Global gamma index passing rates for 3%/2mm for the different equipment and 
simulated analysis. 
 
 
Figure 7.3 2D dose profile for the 3D reconstructed measured dose from the 729 and 1000SRS 
arrays compared against the TPS dose profile. 
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Figure 7.4 2D coronal planes. Top row: TPS, SRS1000 in OCTAVIUS 4D, OCTAVIUS 729 in 
OCTAVIUS 4D, and 2D-ARRAY 729 in OCTAVIUS II dose distribution for the plan with 
5mm MLC positional modification.  Bottom row: 3%/3mm γ distribution for the plan 
with 5mm MLC positional modification in Matlab predicted, OCTAVIUS-1000SRS, 
OCTAVIUS 729, and coronal 2D-ARRAY.  
 
7.5 DISCUSSION 
This study has shown that the impact of the 2D and 3D gamma index can be significant depending on 
the spacing of detectors within an array and the way that it is used. In the case of a planar 
measurement using the sparsely arranged 2D-ARRAY 729 (as originally intended for this piece of 
equipment) the gamma index passing rate was in reasonable agreement with the predicted 3D 
volumetric passing rate. However when the 2D-ARRAY 729 was used in the OCTAVIUS 4D phantom 
to reconstruct a 3D dose distribution it gave the worst overall agreement at ρc = 0.28. The gamma 
index distribution in Figure 7.4 indicates that this is likely due to artificial bands of failed points. The 
reason for these is given in Figure 7.3 where it is clear that there has been incorrect interpolation at 
the profile edges due to the low resolution which can result in the interpolated dose points in those 
regions appearing to have an artificially lower dose than the TPS dose. This problem is shown to 
disappear when using the higher resolution 1000SRS detector array where the dose reconstruction is 
more accurate, leading to a statistically stronger agreement.  
 
Interestingly the agreement for the passing rate using the 2D-ARRAY 729 within the OCTAVIUS4D 
phantom improves to ρc = 0.80 when comparing the measured analysis using 3%/3mm against the 
(a) (b) (d) 
729-4D 729-coronal SRS-4D 
SRS-4D 729-4D Matlab Predicted 729 Coronal 
TPS 
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predicted 3D analysis using 3%/2mm. This is similar to the trend found with the Delta4 in Chapter 5, 
where the Delta4 appeared to have greater sensitivity to measurements, but with the lowest 
agreement with the predicted gamma index. Therefore similar interpolation issues, as found in this 
study, may be apparent in the Delta4’s proprietary gamma index calculation. However the ‘black 
box’ natures of the Delta4 calculation, means it is not possible to investigate further. 
 
The development of the 1000SRS is a promising step in the detector array technology. With a spacing 
of 2.5mm in the central 5.5cm x 5.5cm area, this is similar to the typical grid spacing in treatment 
planning systems providing better accuracy in the dose reconstruction as demonstrated in this study. 
The major limitation is the size of the array which would be limited to small treatment regions. This 
study shows that sparse detector arrays may increase measurement uncertainty when used to 
reconstruct 3D dose distributions, however further studies with a number of different plans with 
different geometries are required for confirmation. 
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8 DEVELOPMENT OF A METHODOLOGY FOR 
USING A DETECTOR ARRAY IN A NATIONAL 
ROTATIONAL IMRT DOSIMETRY AUDIT 
8.1 BACKGROUND AND RATIONALE 
Radiotherapy dosimetry audits allow for the testing of procedures and the identification of errors 
[31–33]. Dosimetry audits range in complexity from measuring machine output under reference 
conditions [31,32,34–38] to complex radiotherapy such as intensity modulated radiotherapy (IMRT) 
measurements [39–43]. As the complexity of treatment technology continues to increase so do the 
potential uncertainties and inaccurate dose delivery can have clinical implications [29,30]. 
Furthermore, there is an important role of dosimetry audits within clinical trials where there is some 
evidence that poor dosimetry may affect clinical outcomes [133–135]. Dosimetry audits can be 
classified into three levels as described by [136]; these are: 
 
 Level I:   independent measurement of linear accelerator output under reference 
conditions in a regular phantom (for example solid water blocks) 
 
 Level II:   independent dose measurement with variations in the irradiation 
configuration (e.g. IMRT) and position of measurement in a regular phantom 
 
 Level III: independent measurement of dose in an anthropomorphic phantom that is 
planned and treated as similar to a patient as possible. 
 
These can be further broken down into two categories: 
1. Site visit: taking equipment to a neighbouring centre or a range of centres and performing 
an independent measurement. 
2. Postal audit: a centrally organised audit using dosimeters such as TLDs or alanine, for 
example the IAEA/WHO system [36] 
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In the UK, Level I category 1 dosimetry audits are organised by the Institute of Physics and 
Engineering in Medicine (IPEM) through 8 regional audit subgroups, and the National Physical 
Laboratory (NPL). National dosimetry audits for Mega-voltage (MV) beams and electrons have 
previously been performed [31,32] and set the benchmark for Level 1 audits in the UK.  
 
Postal audits are usually favoured for international audits such as those organised by the 
International Atomic Energy Agency [IAEA] [36] and the European Society for Therapeutic Radiation 
Oncology (ESTRO) [35]. 
 
Since the introduction of commercial volumetric modulated arc radiotherapy (VMAT) in 2008 [9,26] 
there has been a fast uptake of this complex technology, as well as an increase in the number of 
centres with Helical Tomotherapy. A survey of United Kingdom (UK) cancer centres in July 2010 
indicated that around 30% were treating with some form of rotational radiotherapy (Varian 
RapidArc [Varian Medical Systems Inc., Palo Alto, CA], Elekta VMAT [Elekta AB, Stockholm, Sweden] 
or Helical Tomotherapy [Accuray-Tomotherapy, Madison,WI]), and that this would increase to 50% 
by the end of 2011 [137]. Conventional methods such as individual ionization chamber point dose 
measurements and film dosimetry are time consuming. Therefore, a novel methodology was 
required in order to perform a large-scale dosimetry audit of this emerging technology.  
 
In this study, development of a methodology for using a commercial detector array in a dosimetry 
audit of complex rotational radiotherapy has been undertaken. This work was carried out in 
collaboration with the National Physical Laboratory (NPL), NCRI Radiotherapy Trials QA group and 
the Institute of Physics and Engineering in Medicine. The methodology has been developed by 
evaluating the approach in ten cancer centres treating with some form of rotational radiotherapy. 
Comparison was made between measurements using the detector array and those performed using 
0.125 cm3 ionization chambers, alanine and EBT2 Gafchromic film (International Specialty Products, 
Wayne NJ).  
 
8.2 METHODS AND MATERIALS 
Ten UK cancer centres that had already begun treating with a form of rotational radiotherapy 
(Varian RapidArc, Elekta VMAT or Helical Tomotherapy) were visited in the period between 
June 2011 and November 2011. Of those centres, five used Varian RapidArc, two centres used 
Pinnacle SmartArc (Philips Healthcare, Eindhoven, Netherlands) delivered on Elekta and three had 
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Helical Tomotherapy. One centre also chose to use Pinnacle SmartArc, in addition to RapidArc, 
delivered on a Varian linear accelerator. A full summary is given in Table 8.1.  
 
Table 8.1 Summary of equipment and delivery techniques in the ten centres visited. 
Centre Machine Modality Delivery type TPS and version 
1 Varian Clinac 2100C/D RapidArc 2-Arc Varian Eclipse v8.6.15 
2 Varian Clinac 2100C/D RapidArc 2-Arc Varian Eclipse v8.6.17 
3 Elekta Synergy SmartArc (VMAT) 
2-Arc 
Philips Pinnacle3 v9.0 
Single-Arc 
4 Varian Clinac 2300iX 
RapidArc 2-Arc Varian Eclipse v10.0.34 
SmartArc (VMAT) 2-Arc Philips Pinnacle3 v9.0 
5 Varian Clinac 2300iX RapidArc 2-Arc Varian Eclipse v10.0.34 
6 Elekta Synergy SmartArc (VMAT) Single-Arc Philips Pinnacle3 v9.0 
7 Tomotherapy HiArt Tomotherapy Helical HiArt v4.0 
8 Tomotherapy HiArt Tomotherapy Helical HiArt v3.0 
9 Varian Clinac 2300iX RapidArc 2-Arc Varian Eclipse v8.9.15 
10 Tomotherapy HiArt Tomotherapy Helical HiArt v4.0 
 
8.2.1 The RTTQA 3DTPS Test for RapidArc, VMAT and Tomotherapy 
All centres taking part were asked to plan a three-dimensional (3D) treatment planning system (TPS) 
test, that had been designed by the UK National Cancer Research Institute (NCRI) Radiotherapy Trials 
Quality Assurance (RTTQA) group specifically for the rotational radiotherapy delivery techniques, 
henceforth referred to as the 3DTPS Test [138]. This test is based on the multi-target benchmarking 
test reported in AAPM report 119 [139] and the RTTQA clinical trial credentialing programme first 
described by Clark et al [41,140]. Development of this test and its application has previously been 
described [138]. In summary, this test checks multi-leaf collimator (MLC) positioning, transmission 
and relative dose levels in transverse, coronal and sagittal planes. The 3DTPS Test, shown in Figure 
8.1, is comprised of a virtual 20 cm diameter cylindrical homogeneous water phantom and a set of 
clinically relevant volumes. These volumes include five planning target volumes (PTVs) and a single 
organ at risk (OAR). PTV2 is the primary target volume and is prescribed a dose of 25 Gy in 10 
fractions. PTV1 and PTV4 are prescribed 15 Gy, and PTV3 and PTV5 prescribed 20 Gy. The OAR was 
required to be kept below 10 Gy [138].  
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Centres were asked to use their common clinical parameters to plan the 3DTPS Test. Each plan was 
required to be optimised following the guidelines in the International Commission on Radiation Units 
and Measurements (ICRU) report 83 [112] to achieve the dose constraints for each of the PTVs 
whilst minimising dose to the OAR and remaining volume as far as possible [138] and were assessed 
by the RTTQA group. 
 
Figure 8.1 Transverse slice image of the 3DTPS test (left). The dashed lines indicate the planes 
measured. The black dots indicate dose points, note that two points were taken in 
PTV2 (one in the coronal and one in the sagittal plane). The image on the right shows 
a 3D reconstruction of the test with all PTVs and OAR labelled. 
 
Table 8.2 3DTPS treatment planning objectives. 
VOLUME Mean Dose Min Dose Max Dose 
OAR N/A N/A DMax<10Gy 
PTV1 15Gy (+0.5Gy) D99%>13.5Gy D10%<16.5Gy 
PTV2 (Primary PTV) 25Gy (+0.5Gy) D99%>22.5Gy D1%<26.75Gy 
PTV3 20Gy (+0.5Gy) D99%>18Gy D10%<22Gy 
PTV4 15Gy (+1Gy) D99%>13.5Gy D10%<18Gy 
PTV5 20Gy (+0.5Gy) D99%>18Gy D10%<22Gy 
DMax= Maximum dose, D99% = Dose received by 99% of the volume, D10% = Dose received by 10% of the volume, D1%   = Dose 
received by 1% of the volume 
 
8.2.2 Choice of detector array and phantom combination 
The choice of the detector array system for this study depended on the following criteria: 
 
PTV1 PTV2 
PTV3 
OAR 
PTV1 
PTV2 
PTV4 
PTV5 
OAR PTV3 
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1. Designed to be able to measure rotational radiotherapy 
2. Be robust and transportable 
3. Allow direct comparison with ionization chambers, film and alanine 
The PTW OCTAVIUS II phantom and 2D-Array seven29 combination fulfilled all of the criteria 
identified above and was also a system that members of the audit team were already familiar with in 
their respective clinical institutions [94]. Figure 8.2  shows the versatility of the OCTAVIUS II system. 
Two inserts from the manufacturer were available, one of which was designed to allow a PTW 
semiflex 0.125 cm3 ionization chamber to be used in nine different positions. The design was such 
that the measurement depth was the same as that of the detectors within the 2D-Array and ensured 
that the position of the collecting volume of the semiflex chambers corresponded with the nine 
central detectors in the central row of the 2D-Array. Another insert held 20 cm x 25.4 cm Gafchromic 
film sheets at the same measuring plane as the 2D-Array. An in-house insert was made for the 
alanine pellets and was designed to provide identical measuring positions as available for the 
semiflex chamber insert. 
 
Figure 8.2  The OCTAVIUS II system with (a) 2D-ARRAY 729, (b) Gafchromic EBT2 film insert, (c) 
PTW semiflex 0.125cc ion chamber insert, and (d) alanine insert. Note that for the 
2D-ARRAY 729, the base of the OCTAVIUS phantom has a compensation gap to 
correct for the inherent under-response of the array; this is indicated by the black 
(a) (b) 
(c) (d) 
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smile on the outside. For the other dosimetry systems, a solid base is used (indicated 
by the red smile). 
 
8.2.3 Semiflex ionization chambers 
Two PTW Semiflex 0.125 cm3 ionization chambers were taken on each audit visit. The ionization 
chambers were calibrated in terms of absolute dose to water traceable to the primary standard held 
at the National Physical Laboratory (NPL, Teddington, UK) for a range of quality indices (QI; 
TPR20/10). The host centres provided information regarding the QI prior to each visit. Absorbed 
dose to water calibration factors for the given QI were extracted from the NPL calibration curves. 
Temperature and pressure were corrected using a calibrated thermometer and barometer from the 
NPL.  
 
8.2.4 Gafchromic EBT2 film 
Gafchromic EBT2 20 cm x 25.4 cm film sheets were used. The orientation of the film was always 
consistent for all measurements; each film had a mark at manufacture to allow consistency in setup. 
All Gafchromic films were processed and analysed by another member of the audit team (Yat Tsang) 
at Mount Vernon Hospital at least 24 hours after exposure. Films were scanned using the Epson 
Espression 10000 XL flatbed (Seiko Epson Corp., Nagano, Japan) colour scanner at a resolution of 
75 dpi, using the red channel [91]. The films were all scanned in the same orientation and a jig was 
used to place the films in the same part of the scanner to minimize any displacement effects and to 
use the optimum part of the scanner which was determined through the commissioning process. A 
uniformity correction was applied by scanning a blank film from each batch. A calibration curve for 
each Gafchromic film batch was determined for a range of doses between 0 and 600 cGy at Mount 
Vernon Hospital.  
 
8.3 ALANINE PELLETS 
Alanine pellets were provided by the NPL. These were chosen for three reasons: 
1. Absolute dosimetry, direct traceability to the primary graphite calorimeter held at NPL 
2. Energy independence 
3. To allow the possibility of a postal audit if necessary 
 
Each pellet was 2.4 mm in thickness and 4.5 mm in diameter. The alanine batch had calibration 
factors determined at the NPL. The pellets used required a dose of around 1000 cGy to reduce the 
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uncertainty associated with the measurement. At this dose level the uncertainty in the 
measurement was 0.85% (coverage factor, k=1). The pellet-to-pellet reproducibility was 0.5% (k=1) 
[43,141]. In all measurement cases, three alanine pellets were stacked together within each location 
in the jig. All pellets were processed by the NPL using electron paramagnetic resonance 
spectrometry (EPR) [141,142].  
 
8.3.1 Miscellaneous equipment 
Barometers and thermometers, calibrated at the NPL, were taken on each audit visit. 
  
8.4 SEMIFLEX IONIZATION CHAMBER OUTPUT CALIBRATION 
On conventional linear accelerators, standard output measurements were carried out following the 
UK Institute of Physics and Engineering in Medicine (IPEM) code of practice [143] by setting up the 
ionization chamber in solid water and delivering 200 MU to 5 cm depth at 95 cm or 100 cm focus-to-
surface-distance (FSD),according to the host centre protocol, for a 10x10 cm field size.  
 
The Tomotherapy centres used a helical plan for their absolute dose calibration, which delivered a 
homogeneous dose of 200 cGy to a 6 cm diameter by 6 cm length cylindrical PTV in the 
Tomotherapy Virtual Water™ phantom (commonly referred to as the ‘cheese’ phantom) [144]. To 
perform an independent output, users were asked to generate a delivery QA (DQA) plan in the 
OCTAVIUS scan using the cheese phantom helical output plan. The expected dose to the central 
semiflex ionization chamber position was determined. The output difference was thus determined 
by comparing the measured semiflex with the expected dose. 
 
In all cases, the average of at least 5 measurements was calculated. The output was measured at the 
start and end of each audit, and all ionization chamber measurements were subsequently corrected 
for the average output. The output was also determined by each host centre using their own 
ionization chamber and phantom to cross-reference with the output measured by the audit team. 
The difference between the outputs was expected to be within ±1%. 
 
8.5 2D-ARRAY CROSS-CALIBRATION 
The 2D-Array was cross-calibrated in the OCTAVIUS phantom. The water equivalent depth to the 
centre of the chambers in the array was 16 cm. An isocentric setup was used. On the conventional 
linear accelerators a 10x10 cm single static field was used. The host centre was asked to provide the 
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monitor units required to deliver 200 cGy to the chambers in this setup condition. For Tomotherapy, 
this was done by delivering a helical output plan in the same way as the ionization chamber 
measurement. Prior to cross calibrating the 2D-Array, the semiflex ionization chamber and alanine 
pellets were inserted into the OCTAVIUS phantom to independently measure the expected dose in 
this condition and minimise uncertainty in the array measurement.  
 
8.6 VERIFICATION PLAN CREATION 
Each centre was provided with four sets of computed tomography (CT) scans of the OCTAVIUS 
phantom. These were as follows: 
1. OCTAVIUS phantom with 2D-Array inserted, with the detector plane setup in the coronal 
(horizontal) orientation  
2. OCTAVIUS phantom with 2D-Array inserted, with detector plane setup in the sagittal 
(vertical) orientation 
3. OCTAVIUS phantom with homogeneous insert for ionization chamber, film, and alanine 
dosimetry, with the detector plane setup in the coronal (horizontal) orientation 
4. OCTAVIUS phantom with homogeneous insert for ionization chamber, film, and alanine 
dosimetry, with the detector plane setup in the sagittal (vertical) orientation 
Centres were provided with CT number to relative electron density and mass density calibration 
curves and were instructed to import the appropriate curve into their TPS where appropriate. This 
was not a mandatory step as the uncertainty was estimated to be within 0.5%. Each centre was 
instructed to apply their normal procedure for correcting for the couch; e.g. inserting a couch 
structure in the planning system. The collecting volumes of the ionization chambers (0.125 cm3) in 
the nine different possible positions within the insert were contoured onto the coronal and sagittal 
CT scans with the homogeneous insert to enable calculation of the predicted dose for the semiflex 
chamber and alanine. 
 
Centres were given detailed instructions to ensure that the position of the 3DTPS Test dose 
distribution relative to the phantom was consistently reproduced, and thus the dose planes were 
measured in the same part of the plan from centre-to-centre.  The dose planes that were measured 
to sample the regions of interest using all dosimetric methods are shown in Figure 8.3. There were 
two coronal (horizontal) planes and a sagittal (vertical) plane. The first coronal plane directly 
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intersected PTV1, PTV2, PTV4 and PTV5. The second coronal plane was 4 cm posterior with respect 
to the first, and intersected the OAR, PTV1 and PTV3. The sagittal plane intersected PTV2, PTV4, 
PTV5 and the OAR.  
 
Six separate point dose locations were chosen, to sample different dose levels in the 3DTPS test. In 
the first coronal plane, these were a central point in PTV2 and a point within PTV1. In the sagittal 
orientation, a point was recorded in PTV2 and in the OAR. Centres were instructed to use the dose-
volume-histogram (DVH) in their TPS to record the absolute mean dose and standard deviation for 
one fraction for each chamber. For the alanine measurements, at least 9 fraction deliveries were 
required to deliver at least 1000 cGy to the pellets. The average dose recorded by the pellets was 
therefore rescaled to a single fraction delivery to allow a direct comparison with the semiflex and 
2D-Array. 
 
All verification plans were returned for independent evaluation using the Visualization and 
Organization of Data for Cancer Analysis (VODCA) independent evaluation software version 4.3.3 
[145]. DICOM dose cubes were exported from each plan to be used for analysis. Predicted doses for 
the ionization chamber and alanine were calculated using the TPS and independently verified using 
VODCA. 
 
8.6.1 Measurement planes 
Each separate OCTAVIUS scan had the 3DTPS volumes registered on to it relative to the 3DTPS 
phantom. This allowed for consistency in setting up the isocentre position so that the dose 
distribution is reconstructed in the same position on the OCTAVIUS phantom across different 
centres. The dose planes that were measured to sample the regions of interest using all dosimetric 
methods are shown in Figure 8.3. There were two coronal planes. The first coronal plane directly 
intersected PTV1, PTV2, PTV4 and PTV5. The second coronal plane was 4cm posterior with respect 
to the first, and intersected the OAR, PTV1 and PTV3. There was a sagittal plane which intersected 
PTV2, PTV4, PTV5 and the OAR.  
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Figure 8.3 Dose planes measured for the 3DTPS test. 
 
Centres were given detailed instructions regarding the generation of verification plans to ensure that 
the dose distribution relative to the 3DTPS volumes on the OCTAVIUS phantom was consistent from 
centre-to-centre. In total six separate verification plans were generated for the 3DTPS test, Figure 
8.4 shows how the dose distributions should look for the main planes to be measured. In total six 
separate verification plans were generated for the 3DTPS test: 
 
1. Coronal plan with 2D Array inserted 
2. Coronal plan with 2D Array inserted, isocentre 4cm ANT 
3. Sagittal plan with 2D Array inserted 
4. Coronal plan with homogeneous insert 
5. Coronal plan with homogeneous insert, isocentre 4cm ANT 
6. Sagittal plan with homogeneous insert 
 
1st Coronal Plane, 
through the 
array centre 
2ndCoronal Plane, 
4cm POST 
Sagittal Plane, through 
middle of OAR 
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Figure 8.4 Measuring plane dose distribution. 1st Coronal plane (a), 2nd coronal plane (b), 
sagittal plane (c). 
 
8.6.2 Individual dose point measurement 
For the predicted dose for semiflex ionization chamber and alanine, the CT scans with the 
homogeneous insert had contoured on them the collecting volume of the PTW Semiflex ionization 
chambers. In both the sagittal and coronal CT scans, the chamber positions were contoured and 
labelled ‘Chamber 1 – 9’. Centres were instructed to use the DVH in their TPS to record the absolute 
mean dose and standard deviation for 1 fraction for each relevant chamber for the coronal and 
sagittal plans.  
 
A total of 6 separate semiflex ionization chamber points were chosen, each in a different position to 
sample different dose levels in the 3DTPS test. In the 1st coronal plane, two points were recorded, a 
central point in the main PTV (PTV2) and a point within PTV1. In the 2nd coronal plane, a point was 
recorded in PTV1 and PTV3. In the sagittal orientation, a point was recorded in the main PTV and in 
the OAR. All are shown visually in Figure 8.5. Alanine measurements were also carried out in the 
same points. In addition, the individual chambers in the 2D-ARRAY 729 corresponding to the same 
(a) (b) 
(c) 
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position as the semiflex ionization chambers were recorded to perform a direct comparison with the 
ionization chambers and alanine. 
 
 
Figure 8.5 Point dose measurements in (a) coronal 1, (b) coronal 2, and (c) sagittal plane. 
Alanine measurements were carried out in (a) and (c). 
 
8.7 ANALYSIS OF DATA 
To evaluate the 2D-Array against the other systems of dosimetry, data analysis was carried out as 
described below.  
 
8.7.1 Comparison of the 2D-Array against semiflex ion chamber and 
alanine  
As there was a consistent approach for creating the 3DTPS verification plans, it was possible to make 
a direct comparison between the semiflex ionization chamber and alanine measured dose with the 
dose recorded by the corresponding individual detectors within the 2D-Array. The statistical 
agreement between the measurements by the three systems was tested by calculating the 
concordance correlation coefficient, ρc [123], and generating Bland-Altman plots [146]. The Bland-
Altman plot is achieved by plotting the absolute dose difference between two systems as a function 
of the mean dose measurement of the two systems. The 95% levels of agreement (i.e. the mean 
difference ± 1.96 s.d.) are also plotted. The R statistical software package was used [147] (R Core 
Team, University of Auckland, NZ). Furthermore, the measured dose points for the alanine were 
compared against the corresponding predicted dose from the TPS to provide a further comparison 
between the different systems. 
 
8.7.2 Comparison between 2D-Array and Gafchromic film planes 
To compare 2D-Array and Gafchromic film plane measurements, the global gamma index (γ) method 
of evaluation [45,48] was used with a 20% threshold relative to a point selected in a high dose, low 
 
(a) (b) (c) 
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gradient region. The gamma index evaluation was performed taking into account the 3D dose 
distribution; i.e. the complete TPS dose cube, not only the dose distribution of the measured plane. 
Various criteria for γ were analysed, including the commonly used 3% dose difference (DD) and 3mm 
distance-to-agreement (DTA) criteria. For the 2D-Array, analysis was performed using the PTW 
Verisoft software version 4.1. Absolute γ analysis was performed for the 2D-Array; the dose point for 
the dose difference criteria was chosen in a high dose, low gradient region. In the absolute analysis 
neither the dose cube nor the 2D-Array were normalized. For Gafchromic film, the analysis was 
performed using the Scanditronix Wellhöfer OmniPro™ I’mRT software version 1.7 (IBA Dosimetry 
GmbH, Schwarzenbruch, Germany). Both the film and plan data were normalized to a point in a 
high-dose low-gradient region, to perform a relative comparison, as is currently used for dosimetry 
audit using film in the UK [41,43]. This procedure is commonly used for film analysis due to the 
known difficulty in performing an absolute dose calibration for film [68].  
 
8.7.3 Reporting of data to host centres 
For each audit visit, a report of the results was compiled. This included all output measurements, 
semiflex ionization chamber and alanine point dose results along with results from the 
corresponding ionization chamber within the 2D-ARRAY 729, and gamma index analysis for both the 
2D-ARRAY 729 and Gafchromic film. Results for criteria of 4%/4mm, 3%/3mm and 2%/2mm were 
included, as well as gamma index distribution maps. 
 
8.8 TIMING STUDY 
During each visit, start and end times of events were recorded. Events recorded were categorised 
into: initial equipment setup, standard output measurements by audit team and host centre, output 
in OCTAVIUS phantom using semiflex chamber and alanine, 2D-ARRAY 729 cross-calibration, 2D-
ARRAY 729 plan measurements (including online analysis), plan measurements using ionization 
chamber, Gafchromic film and alanine measurements for the 3DTPS test, output measurements at 
the end of the day. Miscellaneous events such as: set up between coronal and sagittal OCTAVIUS 
phantom orientation and time taken to swap the base of the OCTAVIUS after the 2D-ARRAY 729 
measurements. 
 
8.9 RESULTS 
In total 36 2D-Array and Gafchromic film planes were measured, as well as 72 ionization chamber 
points and 40 sets of alanine measurements. After processing the film, it was discovered that 9 out 
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of the 36 (25%) appeared to have significant artefacts that were traced back to a single batch. These 
films were subsequently discounted from further analysis. The difference between the standard ion 
chamber output measured by the audit team and host centre was within ±1% in all cases.  
 
8.9.1 Comparison of individual 2D-Array chambers against semiflex ion 
chamber and alanine  
The mean percentage dose difference between the 2D-Array and semiflex ionization chamber and 
alanine points was -1.6% ± 1.8% (mean ± one standard deviation) and -1.5% ± 1.8% respectively. It 
should be noted that this data includes points measured in a low dose high gradient region. 
However, removing the low dose high dose gradient data resulted in a mean difference of -1.1% ± 
1.1% and -0.8% ± 1.1%, respectively for the 2D-Array against semiflex and alanine. The difference 
between the semiflex dose points and alanine was found to be narrower at 0.5% ± 0.7%. Figure 8.6 
has scatter plots showing the trend between the 2D-Array doses against the semiflex ionization 
chambers and alanine doses, respectively, and between the semiflex and alanine doses. The 
corresponding Bland-Altman plots showing, along with 95% levels of agreement are also plotted. For 
the 2D-Array versus semiflex data, it can be seen that 95% of 2D-Array points measured were within 
-6.0 cGy and 2.4 cGy absolute dose differences. For the 2D-Array vs alanine, these were within -5.6 
cGy and 2.3 cGy, and for ion chamber vs alanine this was narrower at -1.1 cGy and 2.3 cGy. There 
was a statistically significant concordance correlation coefficient for all the comparisons (ρc>0.998, 
p<0.001 in all cases). 
 
A histogram for the percentage difference between the measured dose and the predicted dose for 
each of the 2D-Array, semiflex ionization chamber, and alanine data is shown in Figure 8.7. It was 
found that the mean difference for the 2D-Array was +0.4% ± 3.0%, for the semiflex ionization 
chambers it was +0.2% ± 2.9%, and  for alanine it was -0.4% ± 3.6%. In the high dose PTV region only 
(i.e. PTV2 in the 3DTPS test), this was -0.1% ± 1.7% for 2D-Array, -0.2% ± 1.8% for semiflex, and -0.6% 
± 1.6% for alanine. It should be noted that since this data was normally distributed with random 
variations as seen in Figure 8.7 that it wasn’t possible to conduct a meaningful correlation analysis.  
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Figure 8.6 Scatter plots and Bland-Altman agreement plots for (a & b) individual 2D-ARRAY 729 
detector dose against semiflex ion chamber measurements, (c & d) individual 2D-
ARRAY 729 detector dose against alanine measurements, and (e & f) semiflex ion 
(a) (b) 
(c) (d) 
(e) (f) 
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chamber measurements against alanine measurements. On each scatter plot, 
perfect agreement is indicate by the dashed line. On each Bland-Altman plot, upper 
and lower 95% Limits of agreement are shown using dotted lines and mean 
difference using bold line. 
 
8.9.2 Comparison between 2D-Array and Gafchromic film  
A summary of the mean percentage of detectors/pixels with gamma index <1 for  passing criteria for 
the 2D-Array and Gafchromic film planes for passing criteria 4%/4mm, 3%/3mm, and 2%/2mm is 
given in Table 8.3. The percentage of 2D-Array and Gafchromic film planes achieving ≥95% of 
detectors or pixels with a γ<1, P95%, is also given.  
 
Table 8.3 Range of detectors/pixels passing with γ<1 for the 2D-Array and Gafchromic film 
planes for passing criteria 4%/4mm, 3%/3mm, and 2%/2mm. The percentage of 2D-
Array and Gafchromic film planes achieving ≥95% of detectors or pixels with a γ<1, 
P95%, is also given. 
Device 
4%/4mm 3%/3mm 2%/2mm 
Range P95% Range P95% Range P95% 
2D-Array 95.3 – 100 100 86.3 – 100 83.3 55.3 – 100 55.6 
Gafchromic film 97.7 – 100 100 93.8 – 100 88.9 86.2 – 100 40.7 
 
 
Figure 8.7 shows the histogram of the 2D-Array and Gafchromic film results for the commonly used 
passing criteria of 3%/3mm. When using the passing criteria of 3%/3mm, the P95% is 83.3% for 2D-
Array and 88.9% for Gafchromic film. For this passing criteria, the plane that had the lowest detector 
pass-rate for the 2D-Array had 72.6% of the detectors with γ< 1, and the film plane with the lowest 
pixel pass-rate for Gafchromic film had 94.0% pixels with γ<1. The 2D-Array gave an absolute gamma 
index comparison whereas Gafchromic relied on a relative one, therefore the passing rate in the 
latter would be expected to be higher as dose differences are normalised out. Figure 8.8 shows an 
example of where there were 2D-Array failures for passing criteria of 3%/3mm due to a >3% dose 
deviation in the PTV region. The Gafchromic film passes as this dose deviation has been cancelled 
out in the relative gamma analysis. 
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Figure 8.7  Relative frequency histograms showing (a) percentage difference between measured 
dose and predicted dose for the 2D-Array, semiflex and alanine, and (b) 2D-ARRAY 
729 versus Gafchromic film gamma index analysis calculated at 3%/3mm. 
 
 
(a) 
(b) 
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Figure 8.8 Comparison of the gamma index distribution between the 2D-ARRAY 729 and 
Gafchromic film in a case where the absolute point dose difference was <1% and a 
case where the dose difference was 4%. In the former case it can be seen the there 
is good agreement between the 2D-ARRAY 729 and film. In the latter case, the 
difference between the absolute and relative gamma index is evident. 
 
8.9.3 Timing study 
The minimum time taken to perform an audit ranged from a minimum of 6.5 hours to a maximum of 
10.9 hours, with a median time of 8.0 hours. Figure 8.9 shows a typical timescale for an audit visit 
assuming a 9:00 am start time; the median time for each event is plotted. The time taken to perform 
individual 2D-ARRAY 729 plan measurements had a median of 13 minutes (range 7 – 30 minutes), 
whereas semiflex ionization chamber and film minutes took a median of 10 minutes (5 – 25 
minutes). The additional median time for the 2D-ARRAY 729 are attributed to time taken to perform 
an online gamma index analysis. The alanine plan measurements accounted for the most amount of 
time per event, with a median time of 45 minutes (35 – 90 minutes). Other events such as the initial 
setup, output measurements, 2D-ARRAY 729 cross-calibrations, and setups between measurements 
had a combined median time of 2.3 hours (1.3 – 4.3 hours).  
 
Using this data it is possible to estimate the likely time taken if only the 2D-ARRAY 729 was used for 
plan measurements as intended. It is estimated that the median time will be 3.5 hours per audit visit 
Predicted dose 2D array Gafchromic film 
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(2.2 – 6.7 hours). As such it is anticipated that most audit visits within the national audit would be 
possible to be completed in half a working day. 
 
 
Figure 8.9 Median timescale for audit visits, assuming a 9:00 am start time. 
 
8.10 DISCUSSION 
This study demonstrates that, in a direct comparison, the 2D-Array agrees and correlates well with 
both ion chambers and alanine for dose point measurements. This is shown by the strong 
concordance correlation coefficients being >0.998 in all cases and this strong trend can be seen in 
the scatter plots in Figure 8.6. However, the corresponding Bland-Altman plots in Figure 8.6 indicate 
that there was a systematic tendency for the 2D-Array to slightly under-respond relative to ion 
chambers and alanine, and that this was independent of the dose level; i.e. the difference was 
consistent for low to high dose points. However, the average negative difference between the 2D-
Array and semiflex ionization chambers and alanine, of approximately -1%, can be mainly attributed 
to influence from the inhomogeneities caused by the air-filled ion chambers within the array and 
also to the requirement to use the different OCTAVIUS phantom bases, since the semi-cricoid 
correction air gap, designed to compensate for the inherent under-response of the 2D-Array 
posteriorly does not provide a perfect or uniform compensation. This difference is low and within 
measurement uncertainty [62]. The direct comparison between ion chamber and alanine dose point 
measurements showed much smaller differences. This agreement is due to the use of the same solid 
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OCTAVIUS base as described previously and because the calibration of both systems is traceable to 
the same primary standard.  
 
Of interest is that when the measured dose points are compared with the predicted dose from the 
TPS it can be seen in the histogram (Figure 8.7a) that the trend is similar for each of the 2D-Array, 
semiflex ionization chamber and alanine data. When looking at the mean difference between the 
measured dose and the predicted dose, it was found that the results from the 2D-Array analysis 
were within 0.5% of those from the semiflex and alanine analysis for measurements in the high dose 
low gradient region (PTV2 in the 3DTPS test). This shows that the difference between the 2D-Array 
measurement and the predicted dose calculated in the OCTAVIUS phantom, with the 2D-Array 
scanned in situ, is similar to the difference found between the semiflex ionization chamber/alanine 
measurement and the predicted dose calculated in the homogeneous OCTAVIUS phantom scan. This 
suggests that it is valid to use the 2D-Array data to report individual dose point results in regions of 
interest to the audited centres, in addition to planar comparisons using the gamma index. 
 
For the gamma index analysis comparison between the 2D-Array and Gafchromic film it was found 
that the relative comparison of the film in OmniPro masked some of the absolute dose differences 
due to the normalization procedure described in the methods section; as shown in Figure 8.8. For 
the 2D-Array measurements it was possible to perform an absolute gamma index analysis against 
the TPS predicted dose in the Verisoft software. It can be seen in the histograms in Figure 8.7b that 
more 2D-Array planes analysed using absolute γ would fail compared to film if a passing criteria of 
≥95% detector or pixels should pass with a γ<1 for the commonly used passing criteria of 3%/3mm. 
In general, where there were 2D-Array failures for passing criteria of 3%/3mm, it was found that the 
absolute dose difference in the point chosen for the gamma index normalisation was close to, or 
outside, ±3%; however there wasn’t sufficient data to test statistical significant. Practically, the 
ability of the 2D-Array to give an immediate absolute result was beneficial and allowed for a direct 
investigation of any unexpected results as they arose during the visits. 
 
Various studies have compared and evaluated detector arrays for routine IMRT and VMAT 
verification [62,63,66,70,74,75,92,110,113,148,149]. However, at the time of writing, use of these 
detectors for radiotherapy dosimetry audits has not been reported in the literature and the only 
report available for a dosimetry audit for rotational radiotherapy was in a Swiss IMRT audit [42] 
which included RapidArc in the comparison. Dosimetry audits can be effectively performed by using 
only the 2D-Array only for plan measurements. During each visit, a simple timing study was 
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performed where the time to perform specific events such as plan measurements was recorded. It 
was estimated that the time taken if only the 2D-Array was used for a rotational radiotherapy 
dosimetry audit, the total time per visit would be a median of 3.5 hours (2.2 – 6.7 hours). This 
streamlined time would allow these audits to be practically performed in an afternoon or evening 
which will be more favourable for busy radiotherapy centres. Palmer et al. [37] recommend that in 
order to ensure good compliance rates, audit time should be kept to within four hours of machine 
time.  
 
Using the methodology developed in this study, a national dosimetry audit of rotational 
radiotherapy using the 2D-Array and OCTAVIUS phantom only for plan measurements was 
performed in the United Kingdom [150]. There was a requirement that the audited centre must have 
started, or be ready to start, clinical treatments with rotational radiotherapy. The audit used the 
3DTPS as a baseline test and furthermore offered clinical trial credentialing measurements. As part 
of the audit, the other systems of dosimetry were taken as back up. The semiflex ionization 
chambers and alanine continued to be used for standard output measurements. 
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9 A METHODOLOGY FOR DERIVING OPTIMAL 
GAMMA INDEX ACCEPTANCE CRITERIA FOR 
DETECTOR ARRAY MEASUREMENTS 
9.1 INTRODUCTION 
As discussed previously in this thesis, the gamma index (γ) method is one of the most common 
techniques for comparing measured and predicted dose distributions [45]. The number of points 
passing with γ<1 for criteria of 3%/3mm, is the most frequently reported parameter in the literature, 
with a typical tolerance for the passing rate being 95%. However, the use of the γ passing rate has 
been shown to have a weak correlation against clinically relevant metrics and the result has also 
been shown to vary depending on the QA system and software used. 
 
Furthermore the passing rate may not give enough meaningful information, particularly when 
performing dose delivery benchmarking studies or trend analysis, where subtle differences are of 
interest. As an example of the passing rate limitation, it is possible to have a systematic dose 
difference of 2% but the passing rate would still be 100% if 3% acceptance criteria were used for the 
dose difference. Other metrics that could be extracted from the gamma index map are possible but 
have not been extensively evaluated, and there are no significant reports in the literature about 
typical acceptance values. 
 
The purpose of this study was to investigate whether the use of the mean, median, maximum, or 
near-maximum gamma index (i.e. the maximum gamma index in 1% of points; γ1%) could be suitable 
alternatives to the passing rate and what acceptance criteria could be used. 
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9.2 METHODOLOGY 
9.2.1 Deliberate plan delivery deviation simulations 
To evaluate and benchmark different metrics for the gamma index, the 3DTPS test was used with 
deliberate changes introduced. The expected γ calculations were simulated, in a similar 
methodology as described in Chapter 4, by exporting the normal plan and perturbed plan predicted 
dose distributions in DICOM format. The predicted γ was calculated, using in house Matlab-based 
independent gamma index calculation software, for a 2D coronal & 2D sagittal plane through the 
geometric centre of the virtual phantom; see Figure 8.3. The 2D perturbed plan planes were 
compared against a 3D volume for the gamma index calculation. Additionally, a full 3D volume 
gamma index calculation was performed by comparing the 3D deliberately changes plan DICOM 
cube against the 3D normal plan DICOM cube. The γ index matrices were interrogated to give 
passing rates as well as mean, median, max and near-max γ (γ1%) metrics. A global gamma index 
passing criterion of 3%/2mm with 20% threshold was used for these investigations as a starting 
point. 
9.2.1.1 Dose deviations 
Systematic dose deviations will be mainly attributed to inaccurate TPS modelling parameters related 
to the modelling of the dynamic MLC motion. To simulate this, purposeful dose modifications were 
introduced ranging from -5% to +5% in 1% increments. These were performed by offsetting the 
normalization value of the plans within the Eclipse TPS. This subsequently resulted in a MU offset by 
the modified amount. It should be noted that the increase in MU also affects the entire MLC leaf 
bank motion. 
9.2.1.2 Spatial deviations 
Spatial deviations were simulated with deliberate changes of 1, 2, 3, 4, 5mm throughout all control 
points for one 5mm MLC. Alignment errors were not simulated. The justification for excluding these 
is illustrated in Figure 9.1, where it can be seen that these types of errors cause significant failures 
and in a real-scenario the measurement setup would be checked and a diagnosis of incorrect setup 
would be rectified by repeating the measurement. As such, the final result that would be recorded 
would be one after a repeat measurement was taken. For the above dose and spatial deviations, a 
similar scenario would occur whereby the setup would be checked, calibrations would be repeated, 
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and measurements repeated as necessary, but there is a higher likelihood that they would be found 
to be consistent and therefore be recorded in the final results. 
9.2.1.3 Combined dose and spatial deviations 
The dose deviations and the spatial deviations described above were combined to represent a more 
realistic scenario. For each MLC deliberate change plan, a dosimetric deviation of +3% and -3% dose 
was introduced. 
 
 
Figure 9.1 Example gamma index distribution for a 3mm Left-right alignment deviation. 
Calculated using global gamma 3%/2mm. 
 
9.2.2 Retrospective analysis of measured data from the UK national audit 
of VMAT and Tomotherapy 
Following on from the simulation study, the data from the completed UK national audit of VMAT and 
Tomotherapy [150] was used to investigate whether similar trends could be observed. The audit was 
based on the methodology described in Chapter 7. The Matlab-based software was used to 
retrospectively re-analyse 80 dose planes measured for the 3DTPS virtual phantom test in the 
coronal 1 and sagittal plane. The software was set up to automatically calculate global γ calculations 
for 3%/2mm for a 20% threshold and in line with the simulation study, the γ passing rate, γmean, 
γmedian, γmax, and γ1% were calculated.  
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9.2.3 Correlation of gamma index metrics against treatment plan DVH 
metrics 
To assess the suitability of the different gamma index metrics; the correlation against treatment plan 
DVH metrics was assessed. Previous studies have attempted to correlate the γ passing rates against 
DVH metrics and have reported weak correlations [86,151,152]. At the time of writing, no reports in 
the literature could be found which have investigated whether it is possible to correlate other 
metrics such as the mean or median calculated γ against DVH metrics. 
9.2.3.1 Correlation based on simulation data 
As a feasibility study these values were calculated for the 3DTPS test for a 2D coronal & sagittal 
plane similar to Figure 8.3 and for a 3D volume gamma calculation. The primary PTV (PTV2) mean 
dose and the OAR max dose for the 3DTPS test were calculated for the normal plan as well as the 
perturbed plans. The percentage difference between the perturbed plan DVH metrics and the 
normal plan were calculated to use in the correlation analysis; which made use of the Pearson 
correlation coefficient. Due to the absolute nature of the gamma index calculation it would not be 
possible to correlate against DVH metrics that had a range of positive and negative values. Therefore 
the DVH metric percentage differences were calculated as absolute % dose difference: 
 
    |(
                    
          
)      |   [9.1] 
 
9.2.4 Correlation based on measured data 
Since the 3DTPS plan measurements at all centres taking part in the audit followed the same 
procedure, it was possible to define regions of interest within the 2D measured planes that 
corresponded to the different structures of the 3DTPS test. In the coronal plane and the sagittal 
plane it was possible to define a 2D ROI for PTV2, and in the sagittal plane it was possible to define a 
2D ROI for the OAR. As such this made it possible to calculate the mean absolute percentage dose 
difference within the PTV2 ROI and the maximum absolute percentage dose difference within the 
OAR ROI as defined using equations 9.2 and 9.3 respectively: 
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9.2.5 Methods for Estimating Gamma Index Acceptance Criteria 
After evaluating whether the gamma index metrics could be correlated against DVH metrics, the 
next step was to assess whether it is possible to estimate acceptance criteria for the different 
metrics. This was performed using the two methods as discussed below in sections 9.2.5.1 and 
9.2.5.2. 
9.2.5.1 Receiver Operator Characteristic (ROC) Analysis  
One method that has been used to estimate optimal QA acceptance criteria is the Receiver Operator 
Characteristic (ROC) [153–155]. Using the ROC method, one can evaluate the sensitivity and 
specificity of a range of acceptance criteria to estimate the most appropriate criterion. This analysis 
was performed on the simulation study data initially. To be able to perform a ROC analysis, a cut-off 
value for a true positive should be defined. In this particular case the test is whether the gamma 
index analysis is able to detect an out-of-tolerance ∆D%. Therefore the analysis has been performed 
comparing the γ index metrics against the PTV2 mean ∆D% and OAR maximum ∆D%. The threshold 
value for an out-of-tolerance     has been set at ±3% [28]. This analysis was performed using the 
simulation study and repeated using the measured data. In order to calculate the ROC curves for 
each γ metric, the sensitivity and specificity were calculated using the following equations: 
 
             
  
     
     (9.4) 
            
  
     
     (9.55) 
 
Where TP, FN, FP and TN are defined as follows: 
 True-positive (TP): instance where the γ metric is out of tolerance and where ∆D% is also 
out of tolerance. 
 False-positive (FP): instance where the γ metric is in tolerance, whereas ∆D% is out of 
tolerance. 
 True-positive (TP): instance where the γ metric is in tolerance and where ∆D% is also in 
tolerance. 
 False-negative (FN): instance where the γ metric is out of tolerance, whereas ∆D% is in 
tolerance. 
 
An ideal metric would have 100% sensitivity (i.e. no false positive results) and 100% specificity (i.e. 
no false negative results). In practice, however, the optimal acceptance criterion is the one with the 
best trade-off between sensitivity and specificity.  For example, consider two possible criteria on a 
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ROC curve. The first criterion is calculated with 75% sensitivity and 100% specificity, whereas the 
second criterion has an associated sensitivity of 100% and specificity of 70%. In the first example, the 
criterion would mean that potentially 25% of cases that should have failed may be falsely passed. 
The only advantage is that there is minimum risk that plans that should pass would be recorded as 
failed by the criterion; meaning fewer resources would be used investigating failed results. This 
criterion would only be valid if one knows the potential clinical impact of a result that should have 
failed, but passed based on the criterion. The second criterion would reduce the risk of false 
positives; however it would consequently mean that a higher proportion of cases may be failed 
when they should have passed. In a benchmarking setting, subtle differences are critical and 
therefore an acceptance criterion with 100% sensitivity will be optimal. Therefore acceptance 
criteria in this study were estimated assuming 100% sensitivity required. 
 
To avoid recommending a gamma index metric that is not statistically reliable, the area under the 
ROC curve (AUC) was calculated for each γ metric. The number varies from 0.5 – 1. For all of the ROC 
calculations above, the AUC was also calculated. The following guide has been used to interpret the 
results [156]: 
 1 = Perfect test 
 0.9 < AUC < 1 = highly accurate 
 0.7 < AUC ≤ 0.9  = moderately accurate 
 0.5 < AUC ≤ 0.7 = less accurate 
 0.5 = non-informative 
The acceptance criterion for each γ metric was estimated assuming 100% sensitivity required, with 
the associated specificity recorded. The AUC was used to estimate whether that metric is a reliable 
test.  
9.2.5.2 Estimating Acceptance Criteria Based on AAPM TG119 Recommendations  
Another method is to use measured data to retrospectively estimate acceptance criteria based on 
statistical confidence limit (CL) calculations. This was originally proposed by Venselaar et al who use 
the following equation to calculate acceptance criteria for dose difference, δΔD [157]: 
 
    | {  }|          (9.7) 
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where σ is standard deviation.  
The AAPM TG119 report made use of confidence interval calculations to specify acceptance criteria 
for the percentage dose difference between calculated and planned doses and for the gamma index 
passing rate for 3%/3mm [139]. The report calculated the 95% confidence interval by substituting 
the 1.5 multiplier in equation (9.7) by 1.96. Additionally, the following equation was proposed to 
calculate acceptance criteria for gamma index passing rate, δΓ [139]: 
 
       ( { }       )   (9.8) 
 
where   is the gamma index passing rate.  
 
The choice of multiplication factor will determine how strict the calculated acceptance criteria. In a 
similar analogy to the choice of sensitivity and specificity target values when performing ROC 
analysis, as described in section 9.2.5.1., the choice of formalism for calculating the CL is open to 
interpretation depending on requirements. Equation (9.7) was used to calculate acceptance criteria 
for the γmean, γmedian, γmax, and γ1% and equation (9.8) was used to calculate acceptance criterion for 
passing rate to compare against those calculated by ROC analysis. In this study, calculations were 
performed with multiplication factors of 1.5 and 1.96 for comparison. 
 
This method for estimating acceptance criteria is reliant on the data available having a Gaussian 
distribution and on the data having no significant outliers which would skew the CI calculation and 
thus result in more lenient acceptance criteria. For these reasons it was not possible to use this 
calculation on the simulated deliberate modification plans. 
 
9.2.6 Comparison of different passing criteria  
All previous evaluations above have been made for passing criteria of 3%/2mm. It is important to 
understand whether this methodology would be transferrable to other systems. As has been shown 
in Chapter 6, different systems could report different results for the same passing criteria. However 
it was also shown that passing criteria from one system could be modified to give agreeable results 
with the results from another system using different passing criteria. For example 4%/3mm on the 
Delta4 phantom gave results which agreed with 3%/3mm on the PTW 2D-ARRAY 729. Varying the 
passing criteria in this study and correlating against 3%/2mm could be used as a surrogate to test the 
robustness of this methodology. For the simulation study and the retrospective analysis, the gamma 
index was re-calculated for passing criteria of 3%/3mm and 2%/2mm for a threshold of 20%. These 
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were performed to check the consistency of the trend of the gamma index results against 3%/2mm 
and therefore to understand whether the passing thresholds could be scaled for different passing 
criteria. Comparisons were carried out for the γ passing rate and γmean.  
 
 
9.2.7 Evaluation of different lower thresholds for the gamma index 
It is common to limit the gamma index calculation to all points that are ≥10-20% of the maximum 
dose value within the dose distribution [49]. This is to eliminate dose in the out-of-field region where 
a large relative dose difference can be calculated and skew the gamma index result (whereas the 
absolute dose difference is small relative to the prescription point). However, it was interesting to 
evaluate different threshold values other than 20% to check whether this value is appropriate, or 
whether a lower/higher value should be used. Therefore the analysis of the NRRA data was repeated 
by varying the lower threshold from 0% up to 90%. Calculations were made for global and local 
gamma. For each threshold the mean gamma index and passing rate was calculated. 
 
9.3 RESULTS 
9.3.1 Correlation of gamma index metrics against DVH metrics 
9.3.1.1 Simulation Study 
The γmean, γmedian and γ1% metrics had very strong statistically significant correlations against the PTV2 
mean DVH metric for 3D volumetric γ calculation as well as 2D planar γ (ρ>0.95, p<0.01); this can be 
seen in the data in Table 9.1. Figure 9.2 shows the trend of γ metrics against the absolute PTV2 mean 
dose deviation, and Figure 9.3 shows the correlation against the absolute OAR maximum dose 
deviation. The γ passing rate had a comparatively weaker linear correlation against the PTV2 DVH 
metrics; however a non-linear trend was apparent. The maximum γ had poor correlation against the 
PTV2 metrics. The opposite trend was found with the correlation of γ metrics against the OAR DVH 
metric (ρ>0.95, p<0.01). The maximum γ had a strong correlation, whereas the remaining metrics 
suffered from poor correlation. 
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Figure 9.2  3%/2mm global 3D volume (a) gamma index pass-rate, (b) mean gamma, (c) median 
gamma, (d) max gamma, (e) near-max gamma against the PTV2 mean absolute dose 
deviation. 
 
 
 
 
 
 
 
 
(a) (b) 
(c) (d) 
(e) 
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Figure 9.3  3%/2mm global 3D volume (a)pass-rate, (b) mean gamma, (c) median gamma, (d) 
max gamma, (e) near-max gamma against OAR maximum dose deviation. 
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Table 9.1  Summary of mean, coefficient of variance (cv) and Pearson correlation coefficient (ρ) for each γ 
parameter for 3%/3mm, 3%/2mm, 2%/2mm using a 20% threshold.  All ρ have p<0.01. 
 
γ metric 
DVH metric 
PTV2 mean OAR 
ρ p-value ρ p-value 
3D volume gamma     
Passing rate -0.76 <0.01 -0.07 0.75 
γmean 0.97 <0.01 0.02 0.91 
γmedian 0.95 <0.01 -0.03 0.91 
γmax 0.19 0.36 0.93 <0.01 
γ1% 0.96 <0.01 0.22 0.30 
2D Coronal Plane     
Passing rate -0.81 <0.01 -0.15 0.47 
γmean 0.97 <0.01 0.04 0.85 
γmedian 0.95 <0.01 -0.03 0.89 
γmax 0.49 0.01 0.82 <0.01 
γ1% 0.88 <0.01 0.44 0.03 
2D Sagittal Plane     
Passing rate -0.77 <0.01 -0.05 0.81 
γmean 0.96 <0.01 0.01 0.96 
γmedian 0.94 <0.01 -0.03 0.90 
γmax 0.17 0.41 0.92 <0.01 
γ1% 0.90 <0.01 0.44 0.03 
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Figure 9.4 shows the correlation between a 3D volumetric gamma index analysis vs. analysis made in 
the 2D coronal and sagittal planes for 3%/2mm and 20% lower dose threshold. It was found that the 
2D analysis had statistically strong Pearson correlations of >0.99 (p<0.01) against 3D for the mean 
gamma index metric.  The passing rate had correlation >0.95 (p<0.01). The coronal plane had closer 
agreement with the 3D gamma index. 
 
 
Figure 9.4  Simulated 3D volumetric gamma index vs 2D coronal and sagittal planes for (left) 
mean gamma index and (right) passing rate for 3%/2mm, 20% threshold.  
9.3.1.2 Measured data 
The correlation between the γ metrics and estimated PTV2 absolute mean dose deviation and OAR 
absolute maximum dose deviation are shown in Table 9.2 and in Figure 9.5. Lower correlations were 
found compared to the simulation study but were statistically strong at ρ > 0.7 (p-value < 0.05 in all 
cases). 
 
Table 9.2  Summary of mean, coefficient of variance (cv) and Pearson correlation coefficient (ρ) for each γ 
parameter for 3%/3mm, 3%/2mm, 2%/2mm using a 20% threshold.  All ρ have p<0.01. 
γ metric  
DVH metric 
PTV2 mean OAR 
ρ p-value ρ p-value 
Passing rate -0.78 <0.01 -0.64 <0.01 
γmean 0.74 <0.01 0.58 <0.01 
γmedian 0.69 <0.01 0.51 <0.01 
γmax 0.75 <0.01 0.65 <0.01 
γ1% 0.78 <0.01 0.69 <0.01 
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Figure 9.5 3%/2mm, 20% threshold global gamma index passing rate (points passing with γ<1) 
given as a percentage (plotted on the left y-axis), median, mean and near-max 
gamma index (plotted on the right y-axis) plotted against (a) the mean absolute dose 
difference in the 2D ROI corresponding to PTV2 mean and (b) the absolute maximum 
dose difference in the 2D ROI corresponding to OAR. The trend line for the γmax is not 
displayed. 
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9.3.2 Acceptance criteria based on ROC analysis 
9.3.2.1 Derivation from simulation study 
The ROC curves for the gamma index metrics accuracy in detecting outside of ±3% dose deviation in 
the PTV2 mean and OAR maximum dose DVH metrics are shown in Figure 9.6a and Figure 9.6b, and 
for the measured data shown in Figure 9.6c and Figure 9.6d.  The diagonal line indicates a random 
guess and also equates to AUC=0.5. The estimated acceptance criteria, along with the specificity and 
AUC are given in Table 9.3. The AUC values are given with their corresponding p-value where 
statistical significance is taken as p<0.05.  
 
In the simulation study, the gamma index metrics, except for the γmax, had an AUC indicating high 
accuracy in detecting dose deviations in PTV2. The γmax metric was close to the diagonal line on the 
ROC curve and therefore is statistically not reliable. A similar trend was seen in the measured data, 
except that the γmax had a better AUC. 
 
The γ metrics were moderately accurate against the OAR max DVH metric according to the AUC 
values; however, in order to achieve 100% for these metrics, the acceptance criteria for the passing 
rate would be required to be 100% and to reduce significantly to <0.2 for the other metrics; with a 
corresponding low specificity. The γmax metric had the best performance with a statistically highly 
accurate result of 0.94 (p<0.01) for the AUC. 
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Figure 9.6  Simulation study ROC analysis of the sensitivity and specificity of gamma metrics to 
predict a 3% deviation in (top) PTV2 mean dose deviation and (bottom) OAR 
maximum dose deviation. Gamma analysis performed using 3%/2mm with 20% 
threshold. 
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Table 9.3 Acceptance criteria for the gamma index metrics to predict a ±3% dose deviation in 
the PTV2 mean dose and OAR maximum dose based on the simulation and 
measured data. In all cases, sensitivity was 100%. 
γ metric  
DVH metric 
PTV2 mean OAR max 
Acceptance 
criterion 
AUC 
Specificity 
Optimal criterion 
AUC 
Specificity 
Simulation data      
Passing rate ≥99.9% 
0.95 (p<0.01) 
73.3% 
100% 
0.84 (p<0.01) 
62.5% 
γmean <0.38 
0.96 (p<0.01) 
80% 
<0.02 
0.71 (p<0.04) 
12.5% 
γmedian <0.35 
0.97 (p<0.01) 
80% 
0.00 
0.72 (p=0.03) 
12.5% 
γmax <0.90 
0.64 (p=0.22) 
33.3 
<1.05 
0.94 (p<0.01) 
75% 
γ1% <0.85 
0.96 (p<0.01) 
80% 
<0.19 
0.75 (p=0.01) 
12.5%  
Measured data     
Passing rate ≥91.1% 
0.95 (p<0.01) 
86.0% 
100% 
0.89 (p<0.01) 
63.6% 
γmean <0.46 
0.93 (p<0.01) 
74.0% 
<0.22 
0.87 (p<0.01) 
18.2% 
γmedian <0.37 
0.92 (p<0.01) 
63.1% 
<0.14 
0.83 (p<0.01) 
9.1% 
γmax  <1.65 
0.94 (p<0.01) 
84.6% 
<0.99 
0.92 (p<0.01) 
63.6% 
γ1%  <1.22 
0.95 (p<0.01) 
83.0% 
<0.75 
0.90 (p<0.01) 
40.9% 
 
9.3.3 Acceptance Criteria Based on Confidence Limits 
The estimated acceptance criteria based on calculating confidence intervals for the different global 
gamma index metrics are given in Table 9.4 for passing criteria of 3%/2mm and a lower dose 
threshold of 20%. 
 
Table 9.4 Acceptance criteria based on confidence interval calculations for the measured audit 
data for Global 3%/2mm, 20% threshold. 
 Metric 
C.L. Formalism Pass-rate γmean γmedian  γmax γ1% 
AAPM TG119 [139] ≥ 92.3% <0.55 <0.54 <1.73 <1.28 
Venselaar et al 
[157] 
≥ 93.7%  <0.50 <0.49 <1.58 <1.18 
 
9.3.4 Correlation of different gamma index passing criteria 
The correlation of passing criteria 3%/3mm, 2%/2mm, and 2%/3mm with 3%/2mm for the mean 
gamma index metric and passing rate is given in Figure 9.7a and b for the simulation study and in 
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Figure 9.7c and d for the measured audit data. The mean gamma correlations were all >0.99 
(p<0.01) in both cases. The passing rate had a lower correlation but statistically strong at >0.95 
(p<0.01).    
 
 
 
Figure 9.7  Simulated (a) and measured (b) mean gamma index values for passing criteria 
3%/3mm and 2%/2mm against 3%/2mm. The dashed line indicates a 1:1 agreement. 
 
 
9.3.5 The effect of varying the lower dose threshold for γ analysis 
The impact of varying the lower dose threshold on the gamma index analysis is shown in Figure 9.8 
for the global mean gamma index metric and passing rate. The results show a non-linear trend which 
is similar between local and global gamma index. It is seen that there is a steep variation in the 
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gamma index result from a lower dose threshold of 0% up 10% for global gamma and up to 5% for 
local gamma. After this point the trend becomes more stable. 
 
Figure 9.8 Average (a) γmean (b) gamma index passing rate for the measured data as a function 
of lower dose threshold. The error bars represent standard error of the mean. The 
line linking the individual points is for visualization only. 
 
9.4 DISCUSSION 
It has been shown that useful information may be extracted from gamma index calculations that 
have not been extensively studied in the literature. Figure 9.2 and Figure 9.3 demonstrate the 
limitations of using the passing rate in correlations against DVH metrics. As the passing rate only 
evaluates whether points are above or below γ=1, there becomes a threshold below which points 
will always be γ<1. For example it is possible when using 3%/2mm passing criteria, that a systematic 
dose difference of ±2% the measurement would still pass as the pass-rate would be 100%. As shown 
in Figure 9.2 and Figure 9.3, the trend line represents the best fit using the least squares method, 
however it would be possible, depending on the algorithm used, to fit a range of different linear 
trends, and therefore this should only be taken as a guide. Hence the passing rate has weak 
statistical robustness in predicting the impact on DVH metrics. The other gamma index metrics could 
be more robustly correlated as they have no upper limit on their value. In the simulated and the 
measured data, the γmean, γmedian and γ1% demonstrated statistically strong correlations with the PTV2 
mean dose DVH metric. However, they suffered from poor correlation against the OAR DVH metric. 
Interestingly, this weak correlation was not as apparent in the measurement data as the simulated 
data, possibly due to the resolution of the detector array smoothing out the maximum point 
difference. The γmax correlated well with the OAR metric but had a poor correlation against PTV2 in 
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the simulation study. Hence is important to note that no single γ metric will give all the required 
information for both PTVs and OARs. 
 
The acceptance criteria for the different γ metrics based on the ROC analysis varied between the 
simulation study and the measured data and also between the prediction of an outside ±3% 
deviation in the PTV2 mean dose DVH metric and OAR maximum dose DVH metric. The γmean and 
γmedian metrics showed the best consistency for predicting a PTV2 mean dose deviation for 3%/2mm 
and a lower dose threshold of 20% across the simulated and measured data. Using the methods for 
calculating acceptance criteria based on the confidence limits gave larger numbers than those 
derived based on ROC analysis but there was overall closer agreement between the values for γmean. 
The main disadvantage of the confidence interval approach is that it is not directly related to a given 
dose deviation and also relies on having good quality measured data to avoid skewing the criteria 
estimate. For this reason, using ROC analysis is statistically more robust for deriving acceptance 
criteria. Using the calculations from the different methods, it appears that an acceptance value of 
0.45 for the γmean would be appropriate for 3%/2mm. 
 
By varying the dose deviation variable in the ROC analysis between 1% – 5% it was possible to 
estimate guideline criterion for different dose deviations. For each dose deviation variable, the 
optimal acceptance criterion was estimated assuming 100% sensitivity. Table 9.5 shows guideline 
criterion for γmean for this study. This can be supplemented by also evaluating the maximum gamma 
index value with particularly the simulation study analysis indicating that points with γ>1.1 may be 
associated with a >3% increase in the OAR maximum dose.   
 
Table 9.5 Acceptance criterion based on ROC analysis for the measured audit data for Global 
3%/2mm, 20% threshold for PTV dose deviation. 
Mean γ criterion  Indicative dose deviation AUC 
0.15 ±1% 0.75 
0.30 ±2% 0.83 
0.45 ±3% 0.93 
0.60 ±4% 0.97 
0.90 ±5% 1.00 
 
As a proof-of-concept, 30 Head & Neck cases that were also measured during the national audit 
were analysed using ROC. The endpoint of ±3% primary PTV dose deviation was tested for the global 
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mean gamma criterion (for 3%/2mm, 20% threshold). The optimal acceptance criterion was found to 
be 0.43 (sensitivity 100%, specificity 62%, AUC=0.750, p=0.04) in good agreement with the value 
derived from the 3DTPS test for predicting a primary PTV dose deviation. This indicates that the 
values derived in this study are valid for the PTW 2D-ARRAY 729 and OCTAVIUS combination rather 
than being plan-specific. 
 
The simulation acceptance criteria were derived based on a 3D volumetric gamma index calculation. 
There was a strong correlation between the 3D γ volume metrics and the 2D coronal plane and 
sagittal plane γ calculations. The coronal plane γ had a closer agreement to the 3D volume γ, with a 
bigger difference seen in the sagittal plane. This highlights that the configuration of the 
measurement plane should be characterized to check whether different criterion would be needed.  
To date, this has also only been tested on PTW planar 2D-Array measured data. As in Chapter 6, 
different software and hardware combinations could give different gamma index results, and it 
would therefore be necessary to perform this evaluation on the other commercial systems to be 
able to propose universal (or manufacturer specific) tolerances. However, the aim of this study was 
to develop a framework for investigating different metrics and outlining a methodology for arriving 
at optimal acceptance values. This can be supported by Figure 9.7a and Figure 9.7b, where there is 
evidence that the γmean varies linearly with changing passing criteria and so, theoretically, a similar 
linear correlation would be expected if the data were measured using a different system and 
compared with results in this study. There is a strong correlation (ρ>0.99, p<0.01) between mean 
gamma calculated for 3%/2mm against other passing criteria, which also shows statistical robustness 
of the γmean. As shown in Figure 9.7c and Figure 9.7d, the passing criteria shows more dispersion of 
the data although the correlation is still strong at ρ>0.95. 
 
The impact of varying the lower dose threshold for the gamma index calculation has been 
investigated. It can be seen in Figure 9.8a and Figure 9.8b respectively, that γmean and passing-rate 
vary non-linearly with changing the lower dose threshold. For global γmean calculations, there was 
trend towards a very steep increase from 0 – 10% threshold, which changes to a lower gradient 
linear increase between 10 – 40% threshold, and then gradually reducing in gradient >40% until 
plateauing above 80%. A similar inverse trend is seen in the passing rate, except that the non-
linearity became more pronounced at >20% rather than 40%. This indicates that the choice of an 
acceptance tolerance value must always be specified with a fixed lower threshold value used. 
Additionally the choice of the lower threshold should be chosen in a region of the trend where there 
is low gradient to ensure the tolerance value is robust to slight variations in measurement 
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uncertainty. In particular the acceptance criteria should not be specified for a threshold <10%. A 
value of 20% is therefore considered suitably robust. 
 
This methodology can be further extended by measuring the deliberately changed plans using 2D 
and 3D detector array/phantom measurements to test the criteria estimated by the simulation 
study. In a benchmark setting, this methodology could be used prospectively by introducing the 
same types of deliberate changes into the test plan(s) to be used and measuring those plans using 
the equipment that will be used to determine suitable acceptance criteria. 
 
In conclusion, the γ passing rate may lack statistical robustness to be suitable for benchmarking of 
dose delivery. It is more suited to routine clinical measurements, once there is confidence in the 
accuracy of the TPS and linac hardware commissioning. Van Esch et al [158] give a pragmatic 
approach for sensible usage of the passing rate in this scenario. The γmean metric has better potential 
to be used as a parameter to predict PTV dose deviation as the value is not bound by an upper limit 
and can give a more useful guide regarding potential deviations in dose difference. However this 
needs to be complemented by the use of the γmax for OAR dose deviations. Future work should be to 
assess whether the γmean or γmedian metrics could be used to correlate against machine-specific 
parameters such as the MU or against metrics that score the complexity of a particular plan 
[159,160].   
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10 DISCUSSION AND CONCLUSIONS 
10.1 DISCUSSION 
This thesis has focussed on evaluating the performance of detector arrays for the verification of 
advanced IMRT and VMAT treatment plans. Commercial detector arrays with different geometrical 
configurations to one another in attempting to find an optimal, yet practical, solution to verification 
of intensity modulated radiotherapy. Through development of characterisation tests, it has been 
possible to assess the response of various commercial detector array systems and their combined 
gamma index analysis software. Deliberately inserted changes were designed to test the QA 
systems, however, the likelihood of this type of deviation occurring in clinical practice should be 
considered. An MLC motor is affected due to wear-and-tear, leading to a leaf travelling slower than 
expected and therefore the leaf lags behind the other leaves, in a way that would be similar to the 
modifications simulated in this thesis. The tolerance on the Linac MLC control software (commonly 
2mm on a Varian linac), means that there are generally two possible feedback scenarios: if possible, 
all the other leaves are slowed down and the dose rate is decreased to compensate for the slower 
leaf; or an interlock may be activated. Software errors may also lead to a mis-translation of the MLC 
positions. This study has demonstrated that in the event of subtle plan deviations the detector array 
systems evaluated are able to detect some of these if suitable gamma index passing criteria, such as 
2%/2mm, are used. However, even lower passing criteria may be required for film, EPID, and 
ArcCHECK. Heilemann et al also concluded that 2%/2mm is necessary to detect positional deviations 
in MLCs for RapidArc deliveries [76]. This work agrees well with various other studies that have been 
performed on the impact of errors in different detector array systems [75,85,92,110,113,149].  
 
The common factor in all commercial array systems is the reliance on the gamma index method to 
provide the quantitative evaluation of the measured dose distribution against the TPS calculated 
dose distribution. The mathematical definition of the gamma index is straightforward; however it 
has presented challenges from the computing sense in terms of the speed of the calculation of the 
metric. The different computational approaches that are possible can produce variability in the 
calculation of the gamma index between different software. This has been demonstrated in Chapter 
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5 where a bespoke Matlab software was designed with the flexibility to vary different parameters. 
Two of these parameters were (a) whether or not to interpolate the evaluated dose distribution 
such that the pixel spacing is sufficiently less than the distance criterion to avoid uncertainties in the 
gamma calculation, and (b) whether to search the entire evaluated distribution or limit the search. It 
has been shown that for two commercial software (OmniPro ImRT 7.0 and Verisoft 5.1) that one 
performed such an interpolation whilst the other did not. The results in this thesis indicate that it is 
important to understand the response and limitations of the gamma index analysis combined with 
the hardware/software equipment in use. For the same passing criteria, different devices and 
software combinations exhibit varying levels of agreement with the Matlab predicted gamma index 
analysis. As shown in this study, passing criteria of say 3%/3mm may not give the same results for 
measurements by different QA systems. 
 
It has been shown that the impact of the 2D and 3D gamma index can be significant depending on 
the spacing of detectors within an array and the way that it is used. In the case of a planar 
measurement using the sparsely arranged 2D-ARRAY 729 (as originally intended for this piece of 
equipment) the gamma index passing rate was in reasonable agreement with the predicted 3D 
volumetric passing rate. However when the 2D-ARRAY 729 was used in the OCTAVIUS 4D phantom 
to reconstruct a 3D dose distribution, it gave the worst overall agreement at ρc = 0.28.  
 
The suitability of the gamma index evaluation method in detecting clinically significant deviations 
has previously been questioned [86] and alternatives have been suggested [86,161–163]. However, 
the gamma index has been widely accepted and is implemented into most commercial software. The 
gamma index provides the means for an efficient analysis which is particularly important within a 
busy clinical environment [164]. It has also been used effectively within dosimetry audits of complex 
radiotherapy [41,43,106,150]. If one is performing a retrospective analysis of patient-specific QA in 
order to streamline the process, the gamma index provides a suitable means to explore trends over 
a period of time [165,166]. 
 
This work has found that it is suitable to use a detector array in a dosimetry audit of rotational 
radiotherapy in place of standard systems of dosimetry such as ion chambers, alanine and film. In a 
direct comparison, the 2D-Array agrees and correlates well with both ion chambers and alanine for 
dose point measurements. This was shown by the strong concordance correlation coefficients being 
>0.998 in all cases. For the gamma index analysis comparison between the 2D-Array and Gafchromic 
film it was found that the relative comparison of the film in OmniPro masked some of the absolute 
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dose differences due to the normalization procedure described in the methods section. For the 2D-
Array measurements it was possible to perform an absolute gamma index analysis against the TPS 
predicted dose in the Verisoft software. Practically, the ability of the 2D-Array to give an immediate 
absolute result was beneficial and allowed for a direct investigation of any unexpected results as 
they arose during the visits. The methodology developed in Chapter 8 has been successfully used in 
a UK audit of 34 cancer centres with 43 treatment delivery systems [150].  
 
A follow-up analysis of the library of measured data during the audit found that additional metrics 
such as the mean gamma index or dose differences over regions of interest can be gleaned from the 
measured dose distributions as demonstrated in Chapter 9. A methodology for being able to 
prospectively ascertain appropriate gamma index acceptance criteria for the detector array system 
in use, via simulation of deliberate plan changes and ROC analysis, has been developed. It has been 
shown that setting appropriate tolerances can be achieved and should be performed as the 
methodology takes into account the configuration of the commercial system as well as the software 
implementation of the gamma index.  
 
10.2 CONCLUSIONS 
This thesis has found that there are variable factors affecting the performance of detector arrays in 
the accurate verification of IMRT and VMAT treatment plans. These range from the configuration of 
the detector array to the software that is used along with its implementation of the gamma index 
analysis. In measuring treatment plans with deliberately introduced modifications, it was found that 
the different commercial systems (which had different resolution and configuration) were able to 
detect clinically relevant deviations as long as the correct gamma index passing criteria is used. Using 
a bespoke Matlab software has demonstrated differences in commercial software implementations. 
As such, it is important to understand the response and limitations of the gamma index analysis 
combined with the equipment in use. It was found for the same pass-rate criteria, different devices 
and software combinations exhibit varying levels of agreement with each other. Therefore it is not 
possible to recommend universal passing criteria for detector arrays or an optimal device 
configuration; however this thesis has shown that a methodology incorporating Receiver Operator 
Characteristic (ROC) analysis, in conjunction with a range of test plans with deliberately introduced 
changes, could be used to derive optimal passing criteria in order to detect clinically relevant 
deviations.  Using a commercial detector array for a dosimetry audit of rotational radiotherapy is 
suitable in place of standard systems of dosimetry. 
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11 FUTURE WORK 
11.1 INTRODUCTION 
This thesis has highlighted that detector arrays are suitable for verification of advanced IMRT given 
careful implementation. There are additional research topics that have arisen from this work that 
merit further investigations which could be performed. The following headings give descriptions for 
further work that should be investigated.  
 
11.2 INVESTIGATION OF THE CHAPTER 9 METHODOLOGY IN VARIOUS 
COMMERCIAL DETECTOR ARRAY SYSTEMS   
Extension of the methodology in Chapter 9 to other commercial detector array systems would 
ascertain if similar results could be achieved, independent of the measurement system. Additionally 
it would be of interest to compare other gamma index metrics such as the mean gamma in the 
different systems. The deliberately modified plans could be measured in the OCTAVIUS II and 
OCTAVIUS4D phantom to give 2D and 3D measurements which would give a direct comparison 
against the simulation results. This work would allow for more global recommendations on various 
devices and the appropriate acceptance criteria that could be considered, and may allow for the 
harmonisation of analysis techniques. This could be of benefit in dosimetriy audits, particularly those 
that rely on individual centres to perform their own measurements of a standard treatment plan 
using local equipment [167].  
 
11.3 FURTHER EVALUATION OF DETECTOR ARRAYS FOR 3D DOSE GUIDED 
RECONSTRUCTION IN PATIENT ANATOMY 
The development of the SRS-1000 is a promising step in the detector array technology. With a 
spacing of 2.5mm in the central 5.5cm x 5.5cm area, this is similar to the typical voxel spacing in 
treatment planning systems providing better accuracy in the dose reconstruction as demonstrated in 
this study. The major limitation is the size of the array which would be limited to small treatment 
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regions. This thesis showed that sparse detector arrays may increase measurement uncertainty 
when used to reconstruct 3D dose distributions, however further studies with a number of different 
plans with different geometries are required for confirmation. 
 
Additionally, algorithms have been developed to use the 3D measured data to back-project a dose 
distribution within patient anatomy. The accuracy of these algorithms and their comparison against 
gamma analysis has become a topic of interest. The measurements made in this thesis using the 
OCTAVIUS 4D phantom would be suitable for such a future comparison. 
 
11.4 CORRELATION OF GAMMA INDEX AGAINST MACHINE SPECIFIC METRICS 
At the time of writing, a separate collaboration with Belfast Cancer Centre was underway to 
investigate the use and analysis of machine Dynalog file acquisition in an audit setting. Dynalog files 
are text files (on the Varian Clinac series) or binary files (on Varian TrueBeam models) which record 
the machine state every 20ms. Within these files is information about where the MLCs are 
positioned during those intervals, and the number of MUs recorded. The information is recorded 
against the corresponding expected values from the treatment plan. The information in the Dynalogs 
can then be interrogated to evaluate the accuracy of the delivery. This work has been linked to the 
national rotational radiotherapy audit and limited to Varian linear accelerators. As part of this, a 
standard 3DTPS RapidArc plan generated by the author at Royal Surrey County Hospital was 
delivered at different centres with Varian linac technology. During the audits, as well as 
measurements using the 2D-ARRAY 729, dynalog acquisition was switched on. The aim of this is to 
investigate the ability of different Varian linacs to deliver the same MLC leaf pattern. Work is being 
carried out to correlate the results from the 2D-ARRAY 729 with the dynalog analysis. The analysis of 
the dynalogs files is being led by Belfast and correlations will be attempted with the metrics 
investigated in Chapter 9.  
 
11.5 CORRELATION OF GAMMA INDEX AGAINST TREATMENT PLAN SPECIFIC 
METRICS 
Further work should also be carried out to assess whether the different gamma index metrics could 
be used to correlate against treatment plan specific parameters such as the number of MU or 
against metrics that score the complexity of a particular plan [159,160]. If there are statistically 
significant correlations between these parameters then it may be possible to develop a formalism 
where treatment plan specific metrics could be used to predict whether a certain plan is likely to fail 
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an in-phantom verification measurement. This could be used to adjust the treatment plans 
appropriately and therefore allows for further streamlining in IMRT/VMAT QA by not having to 
perform a patient-specific measurement on every treatment plan. 
 
11.6 CAN DETECTOR ARRAY DATA GIVE MEANINGFUL INFORMATION ABOUT 
THE ACCURACY OF LOW DOSE MODELLING? 
Whilst setting a lower threshold for the gamma index calculation has been shown in Chapter 9 to be 
justified to avoid skewing the result, the disadvantage is that it may hide errors in the accuracy with 
which the low dose TPS modelling has been configured; particularly the leakage component of the 
MLC modelling. This part of the beam model will have a lower impact on a high dose PTV but is 
nonetheless a potentially unavoidable source of uncertainty. There may be more impact for OARs. 
Further work could be carried out using the database of measurements from the national 
Tomotherapy and VMAT audit and focussing on the accuracy of the predicted TPS dose in the low 
dose regions against the measured dose. 
 
11.7 WHAT THRESHOLD VALUE SHOULD BE USED FOR ROC ANALYSIS TO 
DERIVE GAMMA INDEX ACCEPTANCE CRITERIA? 
As shown in Chapter 8, it is possible to use ROC analysis to prospectively derive appropriate gamma 
index acceptance criteria through a simulation study. A key parameter in the ROC analysis was the 
setting of the threshold value for an out-of-tolerance      In this work, this has been set at ±3% 
[28].  Work is needed to ascertain what level of dose difference is clinically acceptable for IMRT and 
VMAT treatments. This is a complex study that would require retrospective analysis of dosimetry 
data alongside patient related outcome data. A threshold value could then be used more accurately 
in a ROC analysis. 
 
11.8 EMERGING APPROACHES IN ADVANCED IMRT VERIFICATION 
There is currently growing interest in new approaches for IMRT verification, notably in vivo 
dosimetry using the EPID [168–171]. This technique involves measuring a transit dose by positioning 
the EPID device behind the patient on-treatment. The measured transit fluences are then back-
projected onto an image of the patient anatomy using novel reconstruction algorithms to estimate 
the actual dose distribution within the patient. These techniques require evaluation and one method 
that would be interesting to investigate would be to use a detector array for the verification of the in 
vivo system. The deliberately modified plans developed in Chapter 4 could be used. An in vivo 
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measurement could be performed with a detector array / phantom combination, with the array 
simultaneously performing a measurement. The transit dose is reconstructed onto the phantom and 
this could potentially allow a direct comparison against the measured dose by the array. This would 
provide a novel methodology for verifying the accuracy of the in vivo system. Potential pitfalls will 
need to be carefully considered such as the inhomogeneities in the detector array system when 
measuring a transit dose. It must be remembered that the detector array system has been designed 
to measure dose in water and the calibration procedures are designed to cancel out the 
inhomogeneity effects. In this regard, 3D polymer gel dosimetry would be a solution as a true 3D 
dose distribution could be measured. As the whole dosimeter is tissue-equivalent there would be no 
issues with back-projecting the transit dose onto it for a like-for-like comparison against the 
measured distribution. 
 
11.9 INVESTIGATION OF OTHER EVALUATION METRICS 
Other metrics have been briefly discussed in Chapter 2, e.g. chi index, kappa index etc. There should 
be ongoing work to update the bespoke gamma index code appropriately to keep up with 
developments in the field; for example Sumida et al have recently proposed a novel radiobiological 
gamma index [172]. It would be interesting to use the measured data from Chapter 9 to perform a 
comparison between different metrics and whether the methodology described could be applied to 
them.  
 
11.10 EVALUATION OF THE OCTAVIUS1500 DETECTOR ARRAY FOR 3D 
DOSE RECONSTRUCTION 
The work carried out in Chapter 7 on 3D measurement guided dose reconstruction using the 
OCTAVIUS4D phantom, could be expanded to include the recently released (October 2014) 
OCTAVIUS1500 detector array. This work made use of the SRS1000 array which has a detector-to-
detector spacing of 2.5mm and the 2D-ARRAY 729 which has a 10mm spacing. It was found that the 
2D-ARRAY 729 caused artefacts in the 3D dose reconstruction due to the wide spacing. The 
OCTAVIUS1500 detector array has a spacing of 7mm and therefore it would be of interest to 
investigate whether it provides a reasonable 3D dose reconstruction, particularly as it covers a larger 
measurement area of 27cm x 27cm which could potentially offset the limited size of the SRS1000 
array. 
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11.11 CAN THE BESPOKE MATLAB SOFTWARE BE USED TO DETERMINE 
OPTIMUM DETECTOR ARRAY CONFIGURATION? 
The bespoke Matlab gamma index software described in Chapter 5 is configurable to the user’s 
needs with multiple options for changing different parameters. So far it is able to handle planar and 
3D DICOM dose cube data. One interesting approach could be utilising the code in determining an 
optimum detector array configuration. The software would need to be altered so that it can 
effectively handle any type of detector array that should be possible to set by the user. Variables 
that would need to be included would be shape, size and detector spacing. The proposed 
methodology should be that gamma index calculations be first performed in an idealised situation 
using different plans with deliberate changes (as described in this thesis). Then calculations should 
be performed using practical configuration to determine a theoretical optimal design. 
Considerations would then need to be made on the practicalities and limitations of creating such a 
device, including cost, type of detector required, physical constraints and so forth. As such the scope 
of this type of work would be suitable for PhD thesis and could potentially be supported by an 
interested manufacturer. 
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 Basic Detector Array Appendix A
Commissioning Tests 
 
A.1 Introduction 
 
Basic commissioning tests of the detector arrays used throughout this thesis were performed on a Varian 
Clinac iX (Varian Medical Systems, Palo Alto, CI). The Clinac incorporates the Millennium 120 leaf MLCs, 
with the central 80 MLCs covering a 20x20cm each having a 0.5cm width at the isocentre; the remaining 
MLCs have 1cm width. All measurements were for 6 MV beam energy. The methodology was in keeping 
with previously published reports [60,66,74,88–94]. All systems were used according to individual 
manufacturer recommendations. For this section the methodology is described and results given for the 
2D-ARRAY 729; this was the most heavily used detector array in this thesis and the configuration of it and 
the associated OCTAVIUS II phantom required the most stringent tests. Measurements for the other 
detector array systems agreed well with the published literature reports [60,66,74,88–94]. 
 
A.1.1 Effective point of measurement 
 
The  effective point of measurement (EPOM) was determined following the methodology of Poppe et al 
[89] and Van Esch et al [62]. For the 2D-ARRAY 729 The EPOM is specified in the manual as being 0.75cm 
from the surface. This places the point centrally between the parallel plate electrodes. Some groups in the 
literature report that the EPOM is 0.5cm from the surface, i.e. that it is at the top electrode [89]. In order to 
validate the EPOM for the 2D-ARRAY, an independent measurement was carried out. This was performed 
by placing various thicknesses of solid water on top of the 2D-ARRAY. There is a slab of 5mm PMMA on the 
top electrode. Assuming that the relative electron density of PMMA is 1.18, a water equivalent depth of 
5.9cm was used. The settings used were 6MV, 100cm FSD, 10x10 cm field size, and 100 MU. Measurements 
were recorded for the central chamber. The readings were then normalised to the depth of dose maximum. 
A percentage depth dose (PDD) curve was then plotted using the effective water depth. The PDD measured 
by a diode in water was then plotted on the same graph. The shift in the two profiles was then calculated. 
 
A.1.2 Dosimetric linearity 
 
Dose linearity was determined between 5 – 2500 cGy. Dose rate linearity was checked for dose rates 
ranging from 100 – 600 MU/min. Output versus field size was checked for 2x2 – 25x25 field sizes. For field 
sizes of 5x5cm, 10x10, and 25x25cm, profiles in the 2D-ARRAY were compared with diode data measured in 
Appendix A: Basic commissioning of detector arrays 
 
159 
 
a Scanditronix Wellhöfer water tank at the same depth. For all the tests, except EPOM, the setup was such 
that the effective depth of the 2D-ARRAY was at 5cm. The beam energy used throughout was 6MV (quality 
index, QI=0.670), focus-to-surface-distance (FSD) was 100cm, and 100 MU was used in all cases except the 
dose linearity check. For the linearity measurements, a 10x10cm field size was used.  
 
The linearity of the 2D-ARRAY 729 with varying dose per pulse was also assessed. The dose per pulse was 
varied by changing the focus-to-surface distance (FSD). At each FSD, the field size at the surface was kept at 
a constant 10x10 in order to maintain the same scattering conditions. The inverse square law was used to 
set the collimators on the machine. The dose-per-pluse was previously measured using a Farmer chamber 
in solid water at 2cm depth, for a 10x10cm field size and 100cm FSD. The 2D-ARRAY 729 was setup in this 
condition for the measurements. At 6MV it was measured to be 0.033 cGy per pulse. Correction for 
different collection efficiency was calculated but was negligible. Table A.1 shows the FSD, field sizes that 
were used. 
 
Table A.1. FSD and field size used for dose per pulse linearity assessment. 
FSD (cm) Dose per pulse (cGy/pulse) Machine field size setting 
90 0.041 11.1 x 11.1 
100 0.033 10.0 x 10.0 
110 0.027 9.1 x 9.1 
120 0.023 8.3 x 8.3 
130 0.020 7.7 x 7.7 
 
Measurements were performed using both the Farmer chamber at 5cm depth and 2D-ARRAY 729 at 5cm 
depth. Readings were normalised to the 100cm FSD measurement. 
 
Furthermore, the detectors within the array have a relative calibration against the central detector and this 
was confirmed by setting an isocentric field with a 27x27cm field size to cover all the detectors within the 
array and assessing uniformity by looking at a profile through each line of detectors. 
 
A.1.3 Field size comparisons 
 
The 2D-ARRAY was compared with the RFA Linear Diode Array (LDA). The LDA is an array of 25 photon 
diodes, spaced 1cm centre-to-centre, providing similar measuring conditions to the 2D-ARRAY. Using the 
LDA and RFA water tank, profiles were taken for an open 20x20 cm 6MV field, a 20x20 cm field with 15˚ 
enhanced dynamic wedge (EDW), and a 20x20 cm field with  60˚ EDW. Measurements were performed 
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with 100 cm FSD and with the LDA at 5cm depth. A similar measuring scenario was recreated with the 2D-
ARRAY and solid water. LDA and 2D-ARRAY 729 profiles were compared with the single diode full profile. 
 
A.1.4 Comparisons of using the OCTAVIUS scan with 2D-ARRAY 729 in situ vs 
homogeneous scan. 
 
Calculating on the scan of the OCTAVIUS with the 2D-ARRAY 729 in situ with an advanced calculation 
algorithm may result in perturbation of the predicted dose by the air filled ionization chambers, which may 
add to uncertainties, particularly when using the gamma index analysis [45]. Therefore, a dosimetric 
comparison was performed between using the OCTAVIUS scan with the 2D-ARRAY 729 in situ and a 
homogeneous insert.  
 
Firstly, the directional response of the OCTAVIUS phantom was assessed by delivering a 10x10cm field in 
15° gantry angle increments at 6MV with the phantom setup isocentrically. The dose to the central 
detector was recorded. To avoid irradiating through the couch, the sectors comprising the first 180° were 
measured with the OCTAVIUS phantom in the normal setup, and the remaining sectors were measured by 
inverting the phantom. The expected dose at the central detector was calculated in the Varian Eclipse™ 
v8.9 treatment planning system (Varian Medical Systems, Palo Alto, California) using the Analytical 
Anisotropic Algorithm (AAA) v8.9 algorithm [108] for both scans. 
 
A 100 MU, 10x10 cm field was delivered isocentrically to the 2D-ARRAY 729 in the OCTAVIUS phantom from 
24 gantry angles. These were delivered every 15°. Expected doses in the central ionization chamber of the 
2D-ARRAY 729 were obtained from Eclipse. The plan was calculated on a CT scan of the OCTAVIUS phantom 
with the 2D-Array in situ in the coronal orientation. A comparison between expected central chamber dose 
and measured central chamber dose was performed. Calculations were performed using both the Pencil 
Beam Convolution (PBC) algorithm and the Analytical Anisotropic Algorithm (AAA). Irradiations were 
carried out with the 2D-ARRAY 729 setup in the OCTAVIUS phantom. For the posterior response, the 2D-
Array and OCTAVIUS were turned upside-down and irradiated with anterior gantry angles to avoid 
measuring through the couch. The OCTAVIUS phantom has also been scanned with the homogeneous 
ionization chamber insert. Predicted doses were also calculated using this CT scan using the PBC and AAA. 
 
Each gantry angle measurement was assessed separately. The total delivered dose was also compared with 
the total expected dose from all gantry angles. 
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A.2 Results and Discussion 
 
A.2.1 Basic commissioning 
 
A.2.2 Effective point of measurement  
 
The percentage depth dose (PDD) measured by the 2D Array is shown plotted against the water tank beam 
data in Figure A.1. The The difference between the 2D Array and the beam data was deduced to be a 
2.5mm forward shift from the front electrode, i.e. an EPOM of 7.5mm from the surface of the 2D-ARRAY 
729. Therefore the EPOM has been validated to be at the centre of the ionization chambers and is also in 
agreement with the published literature [62]. 
 
Figure A.1. Comparison of the PDD for the 2D-ARRAY 729 and from the beam data 
 
 
A.2.3 Linearity of the 2D-ARRAY 729 with dose, dose-rate and dose-per-pulse 
 
Dose linearity between 5 to 2500 cGy was excellent, as seen in in Figure A.2., and had a Pearson correlation 
coefficient, r, of 1.0. Dose rate linearity was found to be within ±0.2% between 100 – 600 MU/minute.  
Responses were normalised to 400 MU/min. Figure A.3. shows that there is no response relationship with 
varying dose rate. Figure A.4. shows the response as a function of dose per pulse for the 2D-ARRAY 729 and 
Farmer chamber. 
 
2.5mm 
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Figure A.2. Linearity of the 2D-ARRAY 729 with monitor units 
 
 
Figure A.3. Linearity of the 2D-ARRAY 729 with dose rate 
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Figure A.4. Linearity of the 2D-ARRAY 729 with dose per pulse compared to Farmer chamber 
 
 
A.2.4 Directional response in the OCTAVIUS scan with 2D-Array in situ vs 
homogeneous scan 
 
The result of the directional response evaluation can be seen in Figure A.5. The graph shows the difference 
between the measured and expected dose in the central detector within the 2D-Array as a function of 
gantry angle. Table A.2. shows comparison of the total measured dose with predicted doses. The difference 
between the total dose given to the central detector and expected was 0.3% when the 2D-Array was 
scanned in the OCTAVIUS phantom and was -1.3% when a homogeneous insert was used. It can be seen 
that using a homogeneous scan results in a significant under-response when the beam incidence is lateral 
or entering the array through an oblique direction. This is due to the lack of modelling of the 
inhomogeneities caused by the vented ion chambers within the 2D-Array. When the scan of the 2D-Array 
was used, this improved the response. It is worth noting that this comparison is reported for the AAA 
algorithm. Calculating on the 2D-Array scan using the pencil beam convolution algorithm with 
heterogeneity correction yielded, as expected, a similar result to that seen with the homogeneous insert 
calculated using AAA. 
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Figure A.5. Angular response of the 2D-Array; comparison using predicted doses using PBC and AAA in 
the 2D-ARRAY 729 scan, and PBC and AAA calculations in the homogeneous scan.    
 
 
Table A.2. Comparison of total dose at the centre chamber from all 10x10 100 MU beams delivered 
isocentrically from 24 gantry angles. 
 2D Array 
measured 
Predicted 
2D Array scan 
PBC 
2D Array scan 
AAA 
Homogeneous 
PBC 
Homogeneous 
AAA 
Dose at 
centre (cGy) 
 
1478.3 1481.9 1467.3 1497.0 1500.6 
%  diff 
(measured – 
predicted) 
- -0.2 +0.7 -1.2 -1.5 
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A.2.5 Output vs field size response of the 2D-Array 
 
The output versus field size response of the 2D array was output factors measured using the RK-chamber in 
a water tank. Both setups were to 5cm depth and 100cm FSD. Field sizes were delivered between 3 – 10 
cm2 in 1 cm2 increments and then 12, 14, 17, 20, and 25 cm2. Figure A.6. shows the output factors for the 
2D Array and Farmer chamber. Comparisons were also made with the output factors in the beam data 
charts. Excellent agreement can be seen between the 2D Array and chart data. The results show good 
agreement. 
 
 
Figure A.6. Output vs field size comparison between the 2D-ARRAY 729 and beam data at 5cm depth in 
water, 100cm FSD. 
 
A.2.6 Comparison of the 2D-ARRAY 729 with diode profiles taken in the RFA Water 
tank 
 
Profiles of field sizes 5 x 5cm, 10x10xm and 20 x 20 cm measured with the 2D-ARRAY 729 compared 
excellently with profiles measured using a diode in a water tank (the concordance correlation coefficient, 
ρc, was > 0.999 for all). Results for the 5x5cm field are shown in Figure A.7. The 10x10cm results are shown 
in Figure A.8. Results for the 20x20cm are shown in Figure A.9. 
 
 
 
Appendix A: Basic commissioning of detector arrays 
 
166 
 
 
Figure A.7. (a) Comparison of 5cm field size measured by the 2D-ARRAY 729 and RFA water tank diode 
at 5 cm water-equivalent depth, 100 cm FSD. 
 
 
Figure A.8. Comparison of 10cm field size measured by the 2D-ARRAY 729 and RFA water tank diode at 
5 cm water-equivalent depth, 100 cm FSD. 
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Figure A.9. Comparison of 20cm field size measured by the 2D-ARRAY 729 and RFA water tank diode at 
5 cm water-equivalent depth, 100 cm FSD. 
 
A.2.7 Comparison of the 2D-ARRAY 729 with Linear Diode Array (LDA) profiles taken 
in the RFA plotting tank 
 
The 2D Array was compared with a Linear Diode Array (LDA) in a water tank. The LDA is an array of 25 
photon diodes, spaced 1cm centre-to-centre, providing similar measuring conditions to the 2D Array. Using 
the LDA and water tank, profiles were taken for an open 20x20 cm 6MV field, a 20x20 cm field with 15˚ 
enhanced dynamic wedge (EDW), and a 20x20 cm field with 60˚ EDW. Measurements were performed with 
100 cm FSD and with the LDA at 5cm depth. A similar measuring scenario was recreated with the 2D Array 
and solid water. LDA and 2D Array profiles were compared with the single diode full profile as shown in 
Figures A.10 and A.11. 
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Figure A.10. Comparison between 2D-ARRAY 729, LDA, and single diode profile, 6 MV at dmax 
 
 
Figure A.11. Comparison between 2D-ARRAY 729, LDA, and single diode profile, Wedge 15˚ Y1 direction, 
6 MV at dmax. Comparison between 2D-ARRAY 729, LDA, and single diode profile, Wedge 
60˚ Y1 direction, 6 MV at dmax. 
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Abstract 
 
Purpose: To develop a methodology for the use of a commercial detector array in dosimetry audits of 
rotational radiotherapy. 
 
Materials and methods: The methodology was developed as part of the development of a national audit of 
rotational radiotherapy. Ten cancer centres were asked to create a rotational radiotherapy treatment plan 
for a three-dimensional treatment-planning-system (3DTPS) test and audited. Phantom measurements 
using a commercial 2D ionization chamber (IC) array were compared with measurements using 0.125cm3 
IC, Gafchromic film and alanine pellets in the same plane. Relative and absolute gamma index (γ) 
comparisons were made for Gafchromic film and 2D-Array planes respectively. 
 
Results: Comparisons between individual detectors within the 2D-Array against the corresponding IC and 
alanine measurement showed a statistically significant concordance correlation coefficient (both ρc>0.998, 
p<0.001) with mean difference of -1.1%±1.1% and -0.8%±1.1%, respectively, in a high dose PTV. In the γ 
comparison between the 2D-Array and film it was that the 2D-Array was more likely to fail planes where 
there was a dose discrepancy due to the absolute analysis performed. 
 
Conclusions: It has been found that using a commercial detector array for a dosimetry audit of rotational 
radiotherapy is suitable in place of standard systems of dosimetry.  
 
 
A critical evaluation of the PTW 2D-Array seven29 and Octavius II phantom for IMRT and VMAT 
verification. 
 
J. Clin. Appl. Med. Phys. 2013;14(6):4460. 
 
Mohammad Hussein,1,2a Elizabeth J. Adams,1 Thomas J. Jordan,1 Catharine H. Clark,1,3 and Andrew Nisbet1,2 
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Department of Medical Physics,1 Royal Surrey County Hospital NHS Foundation Trust, Guildford, Surrey, UK; 
Department of Physics,2 University of Surrey, Guildford, Surrey, UK; National Physical Laboratory,3 
Teddington, UK 
 
ABSTRACT 
Quality assurance (QA) for intensity- and volumetric-modulated radiotherapy (IMRT and VMAT) has 
evolved substantially. In recent years, various commercial 2D and 3D ionization chamber or diode detector 
arrays have become available, allowing for absolute verification with near real time results, allowing for 
streamlined QA. However, detector arrays are limited by their resolution, giving rise to concerns about 
their sensitivity to errors. Understanding the limitations of these devices is therefore critical. In this study, 
the sensitivity and resolution of the PTW 2D-ARRAY seven29 and OCTAVIUS II phantom combination was 
comprehensively characterized for use in dynamic sliding window IMRT and RapidArc verification. 
Measurement comparisons were made between single acquisition and a multiple merged acquisition 
techniques to improve the effective resolution of the 2D-ARRAY, as well as comparisons against 
GAFCHROMIC EBT2 film and electronic portal imaging dosimetry (EPID). The sensitivity and resolution of 
the 2D-ARRAY was tested using two gantry angle 0° modulated test fields. Deliberate multileaf collimator 
(MLC) errors of 1, 2, and 5 mm and collimator rotation errors were inserted into IMRT and RapidArc plans 
for pelvis and head & neck sites, to test sensitivity to errors. The radiobiological impact of these errors was 
assessed to determine the gamma index passing criteria to be used with the 2D-ARRAY to detect clinically 
relevant errors. For gamma index distributions, it was found that the 2D-ARRAY in single acquisition mode 
was comparable to multiple acquisition modes, as well as film and EPID. It was found that the commonly 
used gamma index criteria of 3% dose difference or 3 mm distance to agreement may potentially mask 
clinically relevant errors. Gamma index criteria of 3%/2 mm with a passing threshold of 98%, or 2%/2 mm 
with a passing threshold of 95%, were found to be more sensitive. We suggest that the gamma index 
passing thresholds may be used for guidance, but also should be combined with a visual inspection of the 
gamma index distribution and calculation of the dose difference to assess whether there may be a clinical 
impact in failed regions.  
 
PACS numbers: 87.55.Qr, 87.56.Fc 
Key words: IMRT, VMAT, QA, detector arrays 
 
A comparison of the gamma index analysis in various commercial IMRT/VMAT QA systems 
 
Radiother. Oncol. 2013;109:370-376. 
 
Mohammad Hussein1,2, Pejman Rowshanfarzad3, Martin A Ebert3,4, Andrew Nisbet1,2, Catharine H Clark1,5 
 
1 Department of Medical Physics, Royal Surrey County Hospital, Guildford, UK, 2 Centre for Nuclear and 
Radiation Physics, University of Surrey, UK, 3 School of Physics, University of Western Australia, Crawley, 
Western Australia, Australia, 4 Department of Radiation Oncology, Sir Charles Gairdner Hospital, Nedlands, 
Western Australia, Australia, 5 National Physical Laboratory, London, UK 
 
Abstract 
 
Purpose 
 
The purpose of this study was to investigate the variability of the global gamma index (γ) analysis in various 
commercial IMRT/VMAT QA systems and to assess the impact of measurement with low resolution 
detector arrays on γ. 
 
Materials 
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Five commercial QA systems (PTW 2D-Array, Scandidos Delta4, SunNuclear ArcCHECK, Varian EPID, and 
Gafchromic EBT2 film) were investigated. The response of γ analysis to deliberately introduced errors in 
pelvis and head & neck IMRT and RapidArc™ plans was evaluated in each system. A theoretical γ was 
calculated in each commercial QA system software (PTW 2D-Array, Scandidos Delta4, SunNuclear 
ArcCHECK, Varian EPID, and Gafchromic EBT2 film), using treatment planning system resolution virtual 
measurements and compared to an independent calculation. Error-induced plans were measured on a 
linear accelerator and were evaluated against the error-free dose distribution calculated using Varian 
Eclipse™ in the relevant phantom CT scan. In all cases, global γ was used with a 20% threshold relative to a 
point selected in a high dose and low gradient region. The γ based on measurement was compared against 
the theoretical to evaluate the response of each system.  
 
Results 
 
There was statistically good agreement between the predicted γ based on the virtual measurements from 
each software (concordance correlation coefficient, ρc>0.92) relative to the independent prediction in all 
cases. For the actual measured data, the agreement with the predicted γ reduces with tightening passing 
criteria and the variability between the different systems increases. This indicates that the detector array 
configuration and resolution have greater impact on the experimental calculation of γ due to under-
sampling of the dose distribution, blurring effects, noise, or a combination.  
 
Conclusions 
 
It is important to understand the response and limitations of the gamma index analysis combined with the 
equipment in use. For the same pass-rate criteria, different devices and software combinations exhibit 
varying levels of agreement with the predicted γ analysis.  
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% --- Routine to import data set1 (similar code for data set 2). 
% 
% --- Select Data set 1 
function select_file_Callback(hObject, eventdata, handles) 
 
clc; 
 
file2=handles.file2; 
 
if file2~=0 
     
    [direct,file]=uigetfile({'*.dcm','DICOM files (*.dcm)';'*.xls',... 
        'Microsoft Excel 97-2003 (*.xls)';'*.mcc','PTW 2D-Array measurement 
(*.mcc)';... 
        '*.*','All files (*.*)'},'Select a file to load into dataset 1', file2); 
     
else 
     
    [direct,file]=uigetfile({'*.dcm','DICOM files (*.dcm)';'*.xls',... 
        'Microsoft Excel 97-2003 (*.xls)';'*.mcc','PTW 2D-Array measurement 
(*.mcc)';... 
        '*.*','All files (*.*)'},'Select a file to load into dataset 1'); 
     
end 
 
path1=strcat(file,direct); 
 
[~, ~, ext1] = fileparts(path1); 
 
handles.ext1=ext1; 
handles.direct1=direct; 
handles.file1=file; 
 
if strcmp(ext1,'.dcm')==1, 
     
    dicom_file=dicomread(path1); 
    info1=dicominfo(path1); 
    handles.info1=info1; 
     
    handles.spacing_1=info1.PixelSpacing(1); 
     
    if strcmp(info1.Manufacturer, 'Math Resolutions, LLC')==1, 
         
        interpfactor=1; 
         
    else 
         
        interpfactor=0; 
         
    end 
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    %check if dicom is 2D plane or 3D cube 
    % num_dims: 2(=2D), 4(=3D) 
    num_dims1=ndims(dicom_file); 
     
    handles.num_dims1=num_dims1; 
     
    % if dicom_file is a cube 
     
    if num_dims1==4, 
         
        info2=handles.info2; 
        cube=squeeze(dicom_file); 
        cube=double(cube); 
        cube=cube*info1.DoseGridScaling; 
        cube=interp3(cube, interpfactor); 
         
        check_info1=exist('info1.Manufacturer'); 
         
        if check_info1==1 
             
            if strcmp(info2.Manufacturer, 'Math Resolutions, LLC')==1, 
                 
                cube2=handles.cube2; 
                [x, y, z]=size(cube2); 
                cube_expand=zeros(x, y, z); 
                cube_expand(3:end-1,2:end-1,2:end-1)=cube; 
                cube=cube_expand; 
                 
            else 
                 
            end 
             
        else 
             
        end 
         
        handles.file=file; 
        handles.cube=cube; 
        handles.cube_plot=cube; 
        handles.data1_orientation_val=1; 
         
        max_dose=max(cube(:)); 
         
        set(handles.data1_orientation,'enable','on'); 
        set(handles.slider1,'enable','on'); 
         
        sizeImg = size(cube); 
        minSlice = 1; 
        maxSlice = sizeImg(3); 
        startSlice = round((maxSlice-minSlice)/2); 
         
        handles.slice = startSlice; 
         
        sliderStep = [1, 1] / (maxSlice - minSlice); 
         
        set(handles.slider1,'value',startSlice); % 
        set(handles.slider1,'max',maxSlice); % 
        set(handles.slider1,'min',minSlice); 
        set(handles.slider1, 'SliderStep', sliderStep); 
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        set(handles.slicedepth_max,'value',maxSlice); % 
        set(handles.slicedepth_min,'value',minSlice); % 
         
        plane=cube(:,:,startSlice); 
        handles.plane=plane; 
         
    else 
         
        plane=double(dicom_file); 
        plane=plane*info1.DoseGridScaling/10; 
        max_dose=max(plane(:)); 
        handles.plane=plane; 
         
    end 
     
    axes(handles.axes1); 
    imagesc(plane); 
    colormap(jet) 
    caxis([0 max_dose]) 
    freezeColors 
    axis equal 
    axis tight 
     
    [sizex,sizey]=size(plane); 
    sizeplane = size(plane); 
    minplane = 1; 
    maxplane = sizeplane(1); 
    startplane = round((maxplane-minplane)/2); 
    planeStep = [1, 1] / (maxplane - minplane); 
     
    set(handles.profile_scroll,'value',startplane); % 
    set(handles.profile_scroll,'max',maxplane); % 
    set(handles.profile_scroll,'min',minplane); 
    set(handles.profile_scroll, 'SliderStep', planeStep); 
     
    axes(handles.profile_axes) 
    plot(plane(round(sizex/2),:)) 
    hold 
     
    message=strcat(direct,' loaded.'); 
    set(handles.Directory,'String',message); 
    clc 
     
elseif strcmp(ext1,'.xls')==1 
     
    %% 
    % Import the data 
    handles.num_dims1=2; 
    if strcmp(direct,'Matlab OCTAVIUS 729 coronal.xls')==1 
         
        [~, ~, raw] = xlsread(path1,'Normal','B1:CZ105'); 
         
    elseif strcmp(direct,'Matlab OCTAVIUS SRS1000 coronal.xls')==1 
         
        [~, ~, raw] = xlsread(path1,'TPS','B1:AR41'); 
         
    else 
         
        [~, ~, raw] = xlsread(path1,'TPS','B1:AB27'); 
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    end 
     
    % Create output variable 
    xls_data = cell2mat(raw); 
    % Clear temporary variables 
    clearvars raw; 
     
    xls_data=flipud(xls_data); 
    %xls_data=interp2(xls_data,3,'spline'); 
     
    max_dose=max(xls_data(:)); 
     
    handles.xls_data=xls_data; 
     
    plane=xls_data; 
    handles.plane=plane; 
    [sizex,~]=size(plane); 
     
    sizeplane = size(plane); 
    minplane = 1; 
    maxplane = sizeplane(1); 
    startplane = round((maxplane-minplane)/2); 
    planeStep = [1, 1] / (maxplane - minplane); 
     
    set(handles.profile_scroll,'value',startplane); % 
    set(handles.profile_scroll,'max',maxplane); % 
    set(handles.profile_scroll,'min',minplane); 
    set(handles.profile_scroll, 'SliderStep', planeStep); 
     
    axes(handles.profile_axes) 
    plot(plane(round(sizex/2),:)) 
    hold 
     
    clc 
     
    axes(handles.axes1); 
    imagesc(xls_data); 
    colormap(jet) 
    caxis([0 max_dose]) 
    freezeColors 
     
    axis equal 
    axis tight 
     
    message=strcat(direct,' loaded.'); 
    set(handles.Directory,'String',message); 
     
end 
 
guidata(hObject, handles); 
 
% --- Executes on selection change in data1_orientation. 
% 
% Pop-up menu to select axial, coronal or sagittal plane 
% 
function data1_orientation_Callback(hObject, eventdata, handles) 
 
ext1=handles.ext1; 
ext2=handles.ext2; 
 
if strcmp(ext1,'.dcm')==1, 
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    data1_orientation_val=get(hObject,'Value'); 
    handles.data1_orientation_val=data1_orientation_val; 
     
    set(handles.data2_orientation, 'Value', data1_orientation_val); 
    data2_orientation_Callback(handles.data2_orientation, eventdata, handles) 
    
    cube=handles.cube; 
     
    if data1_orientation_val ==1 
        cube_plot=cube; 
    elseif data1_orientation_val == 2 
        cube_plot=permute(cube,[3 2 1]); 
    elseif data1_orientation_val == 3 
        cube_plot=permute(cube,[3 1 2]); 
    end 
     
    max_dose=max(cube(:)); 
     
    handles.cube_plot=cube_plot; 
     
    sizeImg = size(cube_plot); 
    minSlice = 1; 
    maxSlice = sizeImg(3); 
    startSlice = round((maxSlice-minSlice)/2); 
     
    handles.slice=startSlice; 
     
    sliderStep = [1, 1] / (maxSlice - minSlice); 
     
    set(handles.slider1,'value',startSlice); % 
    set(handles.slider1,'max',maxSlice); % 
    set(handles.slider1,'min',minSlice); 
    set(handles.slider1, 'SliderStep', sliderStep); 
     
    set(handles.slicedepth_max,'string',maxSlice); % 
    set(handles.slicedepth_min,'string',minSlice); % 
    set(handles.slicedepth_current,'string',startSlice); % 
     
    if data1_orientation_val==1 
         
        axes(handles.axes1) 
        imagesc(cube_plot(:,:,startSlice)); 
        colormap(jet) 
        caxis([0 max_dose]) 
        freezeColors 
        axis equal 
        axis tight 
         
    else 
         
        axes(handles.axes1) 
        imagesc(cube_plot(:,:,startSlice)); 
        colormap(jet) 
        caxis([0 max_dose]) 
        freezeColors 
        axis equal 
        axis tight 
         
    end 
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    plane=cube_plot(:,:,startSlice); 
    handles.plane=plane; 
     
    [sizex,sizey]=size(plane); 
     
    sizeplane = size(plane); 
    minplane = 1; 
    maxplane = sizeplane(1); 
    startplane = round((maxplane-minplane)/2); 
    planeStep = [1, 1] / (maxplane - minplane); 
     
    set(handles.profile_scroll,'value',startplane); % 
    set(handles.profile_scroll,'max',maxplane); % 
    set(handles.profile_scroll,'min',minplane); 
    set(handles.profile_scroll, 'SliderStep', planeStep); 
     
    axes(handles.profile_axes) 
     
    if strcmp(ext2,'.dcm')==1, 
         
        hold 
        plot(plane(round(sizex/2),:)) 
        hold 
         
        clc 
         
    else 
        plot(plane(round(sizex/2),:)) 
        hold 
         
        clc 
         
    end 
     
elseif strcmp(ext1,'.xls')==1 
     
    % 
    % enter code here 
    % 
end 
 
guidata(hObject, handles); 
 
 
% --- Executes during object creation, after setting all properties. 
function data1_orientation_CreateFcn(hObject, eventdata, handles) 
 
% 2D Gamma index calculation routine 
 
% --- Executes on button press in calc_gamma. 
function calc_gamma_Callback(hObject, eventdata, handles) 
 
tic; 
 
local_global=get(handles.gamma_type,'Value'); 
interp_type=get(handles.interpolation_type, 'Value'); 
calc_2D_3D=get(handles.calc_2D_3D, 'Value'); 
search_dist=get(handles.search_dist,'String'); 
data1_orientation_val=get(handles.data1_orientation,'Value'); 
data2_orientation_val=get(handles.data2_orientation,'Value'); 
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h=waitbar(0, 'Calculating....'); 
 
ext1=handles.ext1; 
ext2=handles.ext2; 
 
set(handles.display_map_result,'enable','on'); 
 
doseCriterion=get(handles.dose_diff,'String'); 
doseCriterion=str2double(doseCriterion)/100; 
 
distanceCriterion=get(handles.DTA,'String'); 
distanceCriterion=str2double(distanceCriterion); 
 
normDose=get(handles.normalisation,'String'); 
normDose=str2double(normDose); 
 
% interpolation factor used for map 1 
interpfactor=get(handles.interpfactor,'String'); 
interpfactor=str2double(interpfactor); 
 
% interpolation factor used for map 2 
 
interpfactor2=get(handles.interpfactor2,'String'); 
interpfactor2=str2double(interpfactor2); 
 
%Interpolate maps 
 
if interp_type==1, 
     
    interp_text = 'spline'; 
     
elseif interp_type==2, 
     
    interp_text = 'linear'; 
     
elseif interp_type==3, 
     
    interp_text = 'cubic'; 
     
elseif interp_type==4, 
     
    interp_text = 'nearest'; 
     
end 
 
search_dist=search_dist*2^interpfactor; 
 
if strcmp(ext1,'.dcm')==1, 
     
    info1=handles.info1; 
    num_dims1=handles.num_dims1; 
     
    spacing_x_1=info1.PixelSpacing(1)/2^interpfactor; 
    spacing_y_1=info1.PixelSpacing(2)/2^interpfactor; 
     
    % check if file is cubic or 2D plane 
    if num_dims1==4, 
         
        slice=handles.slice; 
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        cube1=handles.cube; 
         
        [sizex_orig, sizey_orig, sizez_orig]=size(cube1); 
         
        if data1_orientation_val ==1 % Axial 
             
            spacing_x_1=info1.PixelSpacing(1)/2^interpfactor; 
            spacing_y_1=info1.PixelSpacing(2)/2^interpfactor; 
            slice_thickness=info1.GridFrameOffsetVector(2)-
info1.GridFrameOffsetVector(1)/2^interpfactor; 
             
        elseif data1_orientation_val == 2 % Coronal 
            cube1=permute(cube1,[3 2 1]); 
             
            spacing_y_1=info1.PixelSpacing(2)/2^interpfactor; 
            slice_thickness=info1.PixelSpacing(1)/2^interpfactor; 
            spacing_x_1=(info1.GridFrameOffsetVector(2)-
info1.GridFrameOffsetVector(1))/2^interpfactor; 
             
        elseif data1_orientation_val == 3 
             
            cube1=permute(cube1,[3 1 2]); % Sagittal 
             
            slice_thickness=info1.PixelSpacing(2)/2^interpfactor; 
            spacing_y_1=info1.PixelSpacing(1)/2^interpfactor; 
            spacing_x_1=(info1.GridFrameOffsetVector(2)-
info1.GridFrameOffsetVector(1))/2^interpfactor; 
             
        end 
         
        plane_orig=cube1(:,:,slice); 
         
        cube1=interp3(cube1, interpfactor, interp_text); 
 
        [sizex, sizey, sizez]=size(cube1); 
         
        handles.sizex=sizex; 
        handles.sizey=sizey; 
        handles.sizez=sizez; 
                 
        slice_interp=slice*2^interpfactor-(2^interpfactor-1); 
        plane=cube1(:,:,slice_interp); 
                 
    else 
         
        plane=handles.plane; 
        plane_orig=plane; 
        plane=interp2(plane, interpfactor , interp_text); 
        [sizex, sizey]=size(plane); 
         
    end 
     
     
elseif strcmp(ext1,'.xls')==1 
     
    direct=handles.direct1; 
     
    plane=handles.xls_data; 
    num_dims1=2; 
    plane_orig=plane; 
    plane=interp2(plane,interpfactor,interp_text); 
Appendix C: Gamma index software matlab code extract 
181 
 
    [sizex , sizey]=size(plane); 
     
    if strcmp(direct,'Matlab OCTAVIUS 729 coronal.xls')==1 || 
strcmp(direct,'Matlab OCTAVIUS SRS1000 coronal.xls')==1, 
         
        spacing_x_1=2.5/2^interpfactor; 
        spacing_y_1=2.5/2^interpfactor; 
         
    else 
         
        spacing_x_1=10/2^interpfactor; 
        spacing_y_1=10/2^interpfactor; 
         
    end 
     
end 
 
 
if strcmp(ext2,'.mcc')==1 
     
    plane2=handles.array_plot; 
    plane2_orig=plane2; 
     
    plane2=interp2(plane2,interpfactor2,interp_text); 
     
    [sizex_2,sizey_2]=size(plane2); 
     
    spacing_x_2=10/2^interpfactor2; 
    spacing_y_2=10/2^interpfactor2; 
     
    cube_coronal=permute(cube1,[3 2 1]); 
    waitbar(0,h,'Done processing....'); 
     
    [sizex, sizey, sizez]=size(cube_coronal); 
    eval_slice=round(sizez/2-2^interpfactor); 
    plane=cube_coronal(:,:,eval_slice); 
     
    spacing_x_1=(info1.GridFrameOffsetVector(2)-
info1.GridFrameOffsetVector(1))/2^interpfactor; 
    spacing_y_1=info1.PixelSpacing(2) / 2^interpfactor; 
    slice_thickness=info1.PixelSpacing(1) / 2^interpfactor; 
     
    num_dims2=2; 
     
    search_dist_z = round(distanceCriterion * 2 * 2^interpfactor); 
     
    %diff_threshold=NaN(sizex_2, sizey_2); 
    %lowercut=0.95; 
    %uppercut=1; 
    %diff_threshold(plane2>=lowercut*max(plane2(:))& 
plane2<=uppercut*max(plane2(:)))=1; 
    %plane2_threshold=plane2.*diff_threshold; 
    %normDose=nanmean(plane2_threshold(:)); 
     
    search_dist_x=round((sqrt(sizex_2^2+sizey_2^2)*2^interpfactor)); 
    search_dist_y=round((sqrt(sizex_2^2+sizey_2^2)*2^interpfactor)); 
     
    offset_x=(sizex_2*(abs(spacing_x_2/spacing_x_1)))-
((spacing_x_2/spacing_x_1)-1)-sizex; 
    offset_y=(sizey_2*(abs(spacing_y_2/spacing_y_1)))-
((spacing_y_2/spacing_y_1)-1)-sizey; 
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elseif strcmp(ext2,'.dcm')==1 
     
    info2=handles.info2; 
     
    num_dims2=handles.num_dims2; 
     
    if num_dims2==4, 
         
        cube2=handles.cube2; 
        [sizex_2, sizey_2, sizez_2]=size(cube2); 
        spacing_x_2=info2.PixelSpacing(1)/2^interpfactor2; 
        spacing_y_2=info2.PixelSpacing(2)/2^interpfactor2; 
        offset_x=sizex_2-sizex_orig; 
        offset_y=sizey_2-sizey_orig; 
         
        if offset_x > 0 || offset_y > 0 
             
            cube2=cube2(1+offset_x/2^interpfactor:sizex_2, 
1+offset_y/2^interpfactor:sizey_2, 1:sizez_2); 
             
        elseif offset_x < 0 && offset_y < 0 
             
            cube2_expand=zeros(sizex_orig, sizey_orig, sizez_orig); 
            cube2_expand(1:sizex_2, 1:sizey_2, :)=cube2; 
            cube2=cube2_expand; 
 
        else 
                         
        end 
         
        cube2=interp3(cube2, interpfactor2, interp_text); 
         
        if data2_orientation_val ==1 % Axial 
             
            spacing_x_2=info2.PixelSpacing(1)/2^interpfactor2; 
            spacing_y_2=info2.PixelSpacing(2)/2^interpfactor2; 
             
             
        elseif data2_orientation_val == 2 % Coronal 
            cube2=permute(cube2,[3 2 1]); 
             
            spacing_y_2=info2.PixelSpacing(2)/2^interpfactor2; 
            spacing_x_2=(info2.GridFrameOffsetVector(2)-
info2.GridFrameOffsetVector(1))/2^interpfactor2; 
             
        elseif data2_orientation_val == 3 
             
            cube2=permute(cube2,[3 1 2]); % Sagittal 
             
            spacing_y_2=info2.PixelSpacing(1)/2^interpfactor2; 
            spacing_x_2=(info2.GridFrameOffsetVector(2)-
info2.GridFrameOffsetVector(1))/2^interpfactor2; 
             
        end 
 
        slice=handles.slice; 
        [sizex_2, sizey_2, sizez_2]=size(cube2); 
        plane2=cube2(:,:,slice); 
        handles.current_slice2=slice; 
    else 
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        plane2=handles.plane2; 
        plane2_orig=plane2; 
        plane2=interp2(plane2,interpfactor2,interp_text); 
        [sizex_2, sizey_2]=size(plane2); 
         
    end 
     
    search_dist_z = round(distanceCriterion * 2 * 2^interpfactor); 
    search_dist_x=round((sqrt(sizex_2^2+sizey_2^2)*2^interpfactor)); 
    search_dist_y=round((sqrt(sizex_2^2+sizey_2^2)*2^interpfactor)); 
         
elseif strcmp(ext2,'.xls')==1 
     
    direct=handles.direct1; 
    num_dims2=2; 
    plane2=handles.xls_data2; 
    plane2_orig=plane2; 
    plane2=interp2(plane2,interpfactor2,interp_text); 
    [sizex_2,sizey_2]=size(plane2); 
     
    if strcmp(direct,'Matlab OCTAVIUS 729 coronal.xls')==1 || 
strcmp(direct,'Matlab OCTAVIUS SRS1000 coronal.xls')==1, 
         
        spacing_x_2=2.5/2^interpfactor2; 
        spacing_y_2=2.5/2^interpfactor2; 
         
    else 
         
        spacing_x_2=10/2^interpfactor2; 
        spacing_y_2=10/2^interpfactor2; 
         
    end 
     
    offset_x=(sizex_2*(abs(spacing_x_2/spacing_x_1)))-
((spacing_x_2/spacing_x_1)-1)-sizex; 
    offset_y=(sizey_2*(abs(spacing_y_2/spacing_y_1)))-
((spacing_y_2/spacing_y_1)-1)-sizey; 
     
end 
 
% Insert calculation code here -------------------------------------------- 
 
if num_dims1==4 && num_dims2==4 && calc_2D_3D==1, 
               
    eval_plane1 = zeros(sizex + search_dist_x * 2, sizey + search_dist_y * 2); 
    eval_plane1(:,:) = -10^8; 
    eval_plane1(search_dist_x + 1:search_dist_x + sizex,search_dist_y + 
1:search_dist_y + sizey) = plane; 
     
    gValue=zeros(search_dist_x * 2 + 1, search_dist_y * 2 + 1); 
    gValue(:,:)=100; 
    gamma=zeros(sizex_2, sizey_2); 
    distdiff=zeros(search_dist_x * 2 + 1, search_dist_y * 2 + 1); 
    dose_diff=zeros(sizex_2, sizey_2); 
     
    for i=1:search_dist_x * 2 + 1 
         
        for j=1:search_dist_y * 2 + 1 
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            distdiff(i,j)=sqrt(sqrt((((i-search_dist_x-1)*spacing_x_1))^2+(((j-
search_dist_y-1)*spacing_y_1))^2)^2); 
             
        end 
         
    end 
     
     
    for x=1:sizex_2 
         
        waitbar(x/sizex_2,h); 
         
        if getappdata(h,'canceling') 
            break 
        end 
         
        for y=1:sizey_2 
             
            testdose=eval_plane1(1+(x-1)*spacing_x_2/spacing_x_1:(x-
1)*spacing_x_2/spacing_x_1+search_dist_x*2+1,... 
                1+(y-1)*spacing_y_2/spacing_y_1:(y-
1)*spacing_y_2/spacing_y_1+search_dist_y*2+1); 
             
            if local_global==1, 
                 
                test_dosediff=(plane2(x,y)-testdose)/normDose; 
                 
            else 
                 
                test_dosediff=(plane2(x,y)-testdose)./testdose; 
                 
            end 
             
            gValue=sqrt((test_dosediff./doseCriterion).^2 + (distdiff ./ 
(distanceCriterion)).^2); 
             
            gamma(x,y)=min(gValue(:)); 
             
        end 
         
    end 
     
     
elseif num_dims1==4 && num_dims2==4 && calc_2D_3D==2, 
     
    search_dist_z = 2; 
    %search_dist_x=round((sqrt(sizex_2^2+sizey_2^2)*2^interpfactor)); 
    %search_dist_y=round((sqrt(sizex_2^2+sizey_2^2)*2^interpfactor)); 
    search_dist_x=6; 
    % 
    search_dist_y=6; 
    
    eval_cube1=zeros(sizex + search_dist_x*2, sizey + search_dist_y*2, 
search_dist_z*2+1); 
     
    eval_cube1(:,:,:)=-10^8; 
     
    eval_cube1(search_dist_x + 1 : search_dist_x + sizex,... 
        search_dist_y + 1 : search_dist_y + sizey,:) = ... 
        cube1(:,:,slice_interp - search_dist_z : search_dist_z + slice_interp); 
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    gValue=zeros(search_dist_x * 2 + 1, search_dist_y * 2 + 1, search_dist_z * 2 
+ 1); 
    gValue(:,:,:)=100; 
    distdiff=zeros(search_dist_x * 2 + 1, search_dist_y * 2 + 1, search_dist_z * 
2 + 1); 
    gamma=zeros(sizex_2, sizey_2); 
     
for k=1:search_dist_z * 2 + 1 
     
    for i=1:search_dist_x * 2 + 1 
         
        for j=1:search_dist_y * 2 + 1 
             
            distdiff(i,j,k)=sqrt(sqrt((((i-search_dist_x-
1)*spacing_x_1))^2+(((j-search_dist_y-1)*spacing_y_1))^2)^2+((k-search_dist_z-
1)*slice_thickness)^2); 
             
        end 
         
    end 
     
end 
 
     
    for x=1:sizex_2 
         
        waitbar(x/sizex_2,h); 
         
        if getappdata(h,'canceling') 
            break 
        end 
         
        for y=1:sizey_2 
             
             
            testdose=eval_cube1(1+(x-1)*spacing_x_2/spacing_x_1:(x-
1)*spacing_x_2/spacing_x_1+search_dist_x*2+1,... 
                1+(y-1)*spacing_y_2/spacing_y_1:(y-
1)*spacing_y_2/spacing_y_1+search_dist_y*2+1,:); 
             
            if local_global==1, 
                 
                 
                test_dosediff=(cube2(x,y,slice)-testdose)/normDose; 
                 
            else 
                 
                test_dosediff=(cube2(x,y,slice)-testdose)./testdose; 
                 
            end 
             
            gValue=sqrt((test_dosediff./doseCriterion).^2 + 
(distdiff./(distanceCriterion)).^2); 
             
            gamma(x,y)=min(gValue(:)); 
             
        end 
         
    end 
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elseif num_dims1==4 && num_dims2==2 && calc_2D_3D==2, 
     
    gValue=zeros(search_dist_x * 2 + 1, search_dist_y * 2 + 1, search_dist_z * 2 
+ 1); 
    gValue(:,:,:)=100; 
    distdiff=zeros(search_dist_x * 2 + 1, search_dist_y * 2 + 1, search_dist_z * 
2 + 1); 
    gamma=zeros(sizex_2, sizey_2); 
    dose_diff=zeros(sizex_2, sizey_2); 
     
    if strcmp(ext2,'.mcc')==1, % perform 3D gamma analysis on 2D array data 
(provided a Dose Cube is imported) 
         
        for k=1:search_dist_z * 2 + 1 
             
            for i=1:search_dist_x * 2 + 1 
                 
                for j=1:search_dist_y * 2 + 1 
                     
                    distdiff(i,j,k)=sqrt(sqrt((((i-search_dist_x-
1)*spacing_x_1))^2+(((j-search_dist_y-1)*spacing_y_1))^2)^2+... 
                        ((k-search_dist_z-1)*slice_thickness)^2); 
                     
                end 
                 
            end 
             
        end 
         
         
        for x=1:sizex_2 
             
            waitbar(x/sizex_2,h); 
             
            if getappdata(h,'canceling') 
                break 
            end 
             
            for y=1:sizey_2 
                 
                testdose = 
cube_coronal(5*(2^interpfactor)*x+(10*2^interpfactor)-(2^interpfactor-1)-
search_dist:5*(2^interpfactor)*x+(10*2^interpfactor)-(2^interpfactor-
1)+search_dist,... 
                    4*(2^interpfactor)*y+(9*2^interpfactor)-search_dist: 
4*(2^interpfactor)*y+(9*2^interpfactor)+search_dist,... 
                    eval_slice-search_dist_z: eval_slice+search_dist_z); 
                 
                test_dosediff=(plane2(x,y)-testdose)/normDose; 
                 
                gValue=sqrt((test_dosediff./doseCriterion).^2 + (distdiff ./ 
(distanceCriterion)).^2); 
                 
                gamma(x,y)=min(gValue(:)); 
                 
                % calculate TPS dose over the chamber area of 5mm x 5mm 
                TPS_chamber=testdose(round(search_dist+1-
spacing_x_2/spacing_x_1/4) : round(search_dist+1+spacing_x_2/spacing_x_1/4),... 
                    round(search_dist+1-spacing_y_2/spacing_y_1/4) : 
round(search_dist+1+spacing_y_2/spacing_y_1/4),... 
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                    round(search_dist_z+1-spacing_x_2/slice_thickness/4) : 
round(search_dist_z+1+spacing_x_2/slice_thickness/4)); 
                 
                dose_diff(x,y)=((plane2(x,y)-
mean(TPS_chamber(:)))/mean(TPS_chamber(:)))*100; 
                 
            end 
             
        end 
         
        gammamap(gamma) 
        diff_threshold=NaN(sizex_2, sizey_2); 
        lowercut=0.95; 
        uppercut=1; 
        diff_threshold(plane2>=lowercut*max(plane2(:))& 
plane2<=uppercut*max(plane2(:)))=1; 
         
        plane2_threshold=plane2.*diff_threshold; 
         
        dose_diff_threshold=dose_diff.*diff_threshold; 
        ICRU_mean=nanmean(dose_diff_threshold(:)); 
        ICRU_median=nanmedian(dose_diff_threshold(:)); 
        ICRU_SD=nanstd(dose_diff_threshold(:)); 
        ICRU_count=nansum(dose_diff_threshold(:)>=-1000); 
         
    else 
         
        1; 
         
    end 
         
    %######################## 2D vs 2D gamma analysis ######################### 
     
elseif num_dims1==2 && num_dims2==2, 
     
    calc_type=2; 
     
    eval_plane1 = zeros(sizex + search_dist * 2, sizey + search_dist * 2); 
    eval_plane1(:,:) = -10^8; 
    eval_plane1(search_dist + 1:search_dist + sizex,search_dist + 1:search_dist 
+ sizey) = plane; 
     
    gValue=zeros(search_dist * 2 + 1, search_dist * 2 + 1); 
    gValue(:,:)=100; 
    gamma=zeros(sizex_2, sizey_2); 
    distdiff=zeros(search_dist * 2 + 1, search_dist * 2 + 1); 
    dose_diff=zeros(sizex_2, sizey_2); 
     
    DTA_map = zeros(sizex_2, sizey_2); 
    DTA_map(:,:) = 2 * distanceCriterion; 
    dose_diff_map = zeros(sizex_2, sizey_2); 
    CI_map = zeros(sizex_2, sizey_2); 
    kappa_map=zeros(sizex_2, sizey_2); 
     
    if strcmp(ext2,'.dcm')==1 || strcmp(ext2,'.xls')==1, 
         
        if calc_type==1, 
             
            % perform calculation using search of whole evaluated distribution 
             
            for x=1:sizex_2 
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                waitbar(x/sizex_2,h); 
                 
                if getappdata(h,'canceling') 
                    break 
                end 
                 
                for y=1:sizey_2 
                     
                     
                    for i=1:sizex 
                         
                        for j=1:sizey 
                             
                            test_dosediff=(plane2(x,y)-plane)/normDose; 
                            distdiff=sqrt((((x-1)*spacing_x_2)-((i-
1)*spacing_x_1))^2+(((y-1)*spacing_y_2)-((j-1)*spacing_y_1))^2); 
                            
gValue(i,j)=sqrt((test_dosediff(i,j)./doseCriterion).^2 + (distdiff ./ 
(distanceCriterion)).^2); 
                             
                        end 
                         
                    end 
                     
                    gamma(x,y)=min(gValue(:)); 
                     
                end 
                 
            end 
             
             
        elseif calc_type==2, 
             
            % perform calculation using limited search distance specified in mm 
             
            for i=1:search_dist * 2 + 1 
                 
                for j=1:search_dist * 2 + 1 
                     
                    distdiff(i,j)=sqrt(sqrt((((i-search_dist-
1)*spacing_x_1))^2+(((j-search_dist-1)*spacing_y_1))^2)^2); 
                     
                end 
                 
            end 
             
             
            for x=1:sizex_2 
                 
                waitbar(x/sizex_2,h); 
                 
                if getappdata(h,'canceling') 
                    break 
                end 
                 
                for y=1:sizey_2 
                     
                    testdose=eval_plane1(1+(x-1)*spacing_x_2/spacing_x_1:(x-
1)*spacing_x_2/spacing_x_1+search_dist*2+1,... 
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                        1+(y-1)*spacing_y_2/spacing_y_1:(y-
1)*spacing_y_2/spacing_y_1+search_dist*2+1); 
                     
                    if local_global==1, 
                         
                        test_dosediff=(plane2(x,y)-testdose)/normDose; 
                         
                    else 
                         
                        test_dosediff=(plane2(x,y)-testdose)./testdose; 
                         
                    end 
                     
                    gValue=sqrt((test_dosediff./doseCriterion).^2 + (distdiff ./ 
(distanceCriterion)).^2); 
                     
                    gamma(x,y)=min(gValue(:)); 
                     
                end 
                 
            end 
             
        end 
         
    end 
     
end 
 
%-------------------------------------------------------------------------- 
time_taken=num2str(toc,'%.2f'); 
 
diff_threshold=NaN(sizex_2, sizey_2); 
diff_threshold_plot=zeros(sizex_2, sizey_2); 
 
lowercut=get(handles.lower_cut,'String'); 
lowercut=str2double(lowercut)/100; 
 
uppercut=get(handles.upper_cut,'String'); 
uppercut=str2double(uppercut)/100; 
 
diff_threshold(plane2>=lowercut*max(plane2(:))& 
plane2<=uppercut*max(plane2(:)))=1; 
diff_threshold_plot(plane2>=lowercut*max(plane2(:))& 
plane2<=uppercut*max(plane2(:)))=1; 
 
plane2_threshold=plane2.*diff_threshold; 
 
if interpfactor2==0, 
     
plane_threshold=plane_orig.*diff_threshold; 
 
elseif interpfactor2==interpfactor, 
     
plane_threshold=plane.*diff_threshold;     
 
end 
 
gamma_thresh=gamma.*diff_threshold; 
 
handles.gamma=gamma; 
handles.gamma_plane=gamma; 
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handles.gamma_thresh=gamma_thresh; 
 
%Compute cumulative histogram 
 
gammavert=gamma_thresh(:); 
 
k=0; 
if max(gammavert) > 5, 
     
    for j=0:0.05:5 
         
        k=k+1; 
        cumul(k)=sum(gammavert>=j)/sum(gammavert>=0)*100; %#ok<AGROW> 
        gammaval(k)=j; %#ok<AGROW> 
         
    end 
     
else 
     
    for j=0:0.05:max(gammavert) 
         
        k=k+1; 
        cumul(k)=sum(gammavert>=j)/sum(gammavert>=0)*100; %#ok<AGROW> 
        gammaval(k)=j; %#ok<AGROW> 
         
    end 
     
end 
gamma_cumul=cumul'; 
gammavalt=gammaval'; 
 
sort_gamma_cumul=sort(gamma_cumul); 
[x_cumul, ~]=size(sort_gamma_cumul); 
 
GPH=get(handles.GPH,'String'); 
GPH=str2double(GPH); 
 
gamma_cumul_find=find(sort_gamma_cumul<1,1,'last'); 
gammaval_1=(gammavalt(x_cumul-gamma_cumul_find)+gammavalt(x_cumul-
gamma_cumul_find+1))/2; 
gammaval_1=num2str(gammaval_1,'%.2f'); 
 
gamma_cumul_find=find(sort_gamma_cumul<5,1,'last'); 
gammaval_5=(gammavalt(x_cumul-gamma_cumul_find)+gammavalt(x_cumul-
gamma_cumul_find+1))/2; 
gammaval_5=num2str(gammaval_5,'%.2f'); 
 
gamma_cumul_find=find(sort_gamma_cumul<GPH,1,'last'); 
gammaval_GPH=(gammavalt(x_cumul-gamma_cumul_find)+gammavalt(x_cumul-
gamma_cumul_find+1))/2; 
gammaval_GPH=num2str(gammaval_GPH,'%.2f'); 
 
% Calculate % points with gamma>1 
a=sum(gamma_thresh(:)>1); 
a=double(a); 
b=nansum(diff_threshold(:)); 
 
pass_rate=100-(a/b*100); 
 
if pass_rate >= 95; 
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    set(handles.gamma_pass,'BackgroundColor',[0 1 0]); 
     
else 
     
    set(handles.gamma_pass,'BackgroundColor',[1 1 1]); 
     
end 
 
pass_rate=num2str(pass_rate,'%.1f'); 
 
%Calculate mean and max gamma 
mean_g=nanmean(gamma_thresh(:)); 
mean_g=num2str(mean_g,'%.2f'); 
 
median_g=nanmedian(gamma_thresh(:)); 
median_g=num2str(median_g,'%.2f'); 
 
max_g=max(max(gamma_thresh(:))); 
max_g=num2str(max_g,'%.2f'); 
 
%Display pass rate, mean gamma, and max gamma in GUI 
set(handles.gamma_pass,'String',pass_rate); 
set(handles.gamma_mean,'String',mean_g); 
set(handles.gamma_median,'String',median_g); 
set(handles.gamma_max,'String',max_g); 
set(handles.gamma_1,'String',gammaval_1); 
set(handles.gamma_5,'String',gammaval_5); 
set(handles.gamma_GPH,'String',gammaval_GPH); 
 
%-------------------------------------------------------------------------------
- 
% calculate dose difference using lower and upper cut values 
% to be moved from here eventually 
 
dosediffplot_perc=((plane2_threshold-plane_threshold)./plane_threshold)*100; 
dosediffplot_abs=(plane2_threshold-plane_threshold)./plane_threshold; 
 
mean_diff_perc=num2str(nanmean(dosediffplot_perc(:)),'%.2f'); 
median_diff_perc=num2str(nanmedian(dosediffplot_perc(:)),'%.2f'); 
std_diff_perc=num2str(nanstd(dosediffplot_perc(:)),'%.2f'); 
 
handles.gamma_cumul=gamma_cumul; 
handles.gammavalt=gammavalt; 
 
handles.dosediffplot_perc=dosediffplot_perc; 
handles.dosediffplot_abs=dosediffplot_abs; 
 
set(handles.mean_diff,'string',mean_diff_perc); 
set(handles.median_diff,'string',median_diff_perc); 
set(handles.sd_diff,'string',std_diff_perc); 
 
%-------------------------------------------------------------------------------
-- 
% display profile after calculation ends 
 
val4=handles.val4; 
 
%set handle to the lower right axis in the GUI to display profile 
axes(handles.gamma_axes); 
box on 
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% display according to the current selection in the popmenu in the analysis 
% area 
 
if val4==1 %Gamma Map 
    imagesc(gamma); 
    caxis([0 1.6]) 
    freezeColors 
     
    axis equal 
    axis tight 
    hold; 
    contour(diff_threshold_plot,1,'y'); 
    hold; 
     
elseif val4==2 %Std Histogram 
     
    hist(gamma_thresh(:)) 
     
elseif val4==3 %Cumul histogram 
     
    plot(gammavalt, gamma_cumul) 
    axis([0 1.5 0 100]) 
     
elseif val4==4 %Difference map(%) 
     
    contourf(dosediffplot_perc) 
    colormap(jet) 
    freezeColors 
     
    axis equal 
    axis tight 
     
elseif val4==5 %Difference map (Gy) 
     
    contourf(dosediffplot_abs) 
    colormap(jet) 
    freezeColors 
     
    axis equal 
    axis tight 
     
elseif val4==6 %DTA map 
     
end 
 
close(h) 
 
%--------------------------------------------------------------------------- 
% display time taken to perform calculation 
message=strcat('Calculation time taken: ',time_taken,' s'); 
set(handles.time, 'String', message); 
 
handles.gamma_plane=1; 
handles.gamma_vol=0; 
 
clc 
 
guidata(hObject, handles); 
 
ext2=handles.ext2; 
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if strcmp(ext2,'.dcm')==1, 
     
    data2_orientation_val=get(hObject,'Value') 
    %handles.data2_orientation_val=data2_orientation_val; 
     
    cube2=handles.cube2; 
     
    if data2_orientation_val ==1 
        cube_plot2=cube2; 
    elseif data2_orientation_val == 2 
        cube_plot2=permute(cube2,[3 2 1]); 
    elseif data2_orientation_val == 3 
        cube_plot2=permute(cube2,[3 1 2]); 
    end 
     
    max_dose=max(cube2(:)); 
    handles.cube_plot2=cube_plot2; 
     
    sizeImg = size(cube_plot2); 
    minSlice = 1; 
    maxSlice = sizeImg(3); 
    startSlice = round((maxSlice-minSlice)/2); 
     
    handles.slice = startSlice; 
     
    sliderStep = [1, 1] / (maxSlice - minSlice); 
     
    set(handles.slider3,'value',startSlice); % 
    set(handles.slider3,'max',maxSlice); % 
    set(handles.slider3,'min',minSlice); 
    set(handles.slider3, 'SliderStep', sliderStep); 
     
    if data2_orientation_val==1 
         
        axes(handles.axes2) 
        imagesc(cube_plot2(:,:,startSlice)); 
        colormap(jet) 
        caxis([0 max_dose]) 
        freezeColors 
        axis equal 
        axis tight 
         
    else 
         
        axes(handles.axes2) 
        imagesc(cube_plot2(:,:,startSlice)); 
        colormap(jet) 
        caxis([0 max_dose]) 
        freezeColors 
        axis equal 
        axis tight 
         
    end 
     
    plane2=cube_plot2(:,:,startSlice); 
    handles.plane2=plane2; 
     
    [sizex,sizey]=size(plane2); 
     
    sizeplane = size(plane2); 
    minplane = 1; 
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    maxplane = sizeplane(1); 
    startplane = round((maxplane-minplane)/2); 
    planeStep = [1, 1] / (maxplane - minplane); 
     
    set(handles.profile_scroll,'value',startplane); % 
    set(handles.profile_scroll,'max',maxplane); % 
    set(handles.profile_scroll,'min',minplane); 
    set(handles.profile_scroll, 'SliderStep', planeStep); 
     
    axes(handles.profile_axes) 
     
    plot(plane2(round(sizex/2),:)) 
     
elseif strcmp(ext2,'.xls')==1 
     
    % 
    % enter code here 
    % 
end 
 
guidata(hObject, handles); 
 
info1=handles.info1; 
cube1=handles.cube; 
cube1_orig=cube1; 
cube1=interp3(cube1, interpfactor, interp_text); 
 
if data1_orientation_val ==1 % Axial 
 
    spacing_x_1=info1.PixelSpacing(1)/2^interpfactor; 
    spacing_y_1=info1.PixelSpacing(2)/2^interpfactor; 
    slice_thickness=info1.GridFrameOffsetVector(2)-
info1.GridFrameOffsetVector(1)/2^interpfactor; 
     
elseif data1_orientation_val == 2 % Coronal 
    cube1=permute(cube1,[3 2 1]); 
     
    spacing_y_1=info1.PixelSpacing(2)/2^interpfactor; 
    slice_thickness=info1.PixelSpacing(1)/2^interpfactor; 
    spacing_x_1=(info1.GridFrameOffsetVector(2)-
info1.GridFrameOffsetVector(1))/2^interpfactor; 
     
elseif data1_orientation_val == 3 
     
    cube1=permute(cube1,[3 1 2]); % Sagittal 
     
    slice_thickness=info1.PixelSpacing(2)/2^interpfactor; 
    spacing_y_1=info1.PixelSpacing(1)/2^interpfactor; 
    spacing_x_1=(info1.GridFrameOffsetVector(2)-
info1.GridFrameOffsetVector(1))/2^interpfactor; 
     
end 
 
[sizex, sizey, sizez]=size(cube1); 
 
info2=handles.info2; 
 
cube2=handles.cube2; 
cube2=interp3(cube2, interpfactor2, interp_text); 
 
if data2_orientation_val ==1 % Axial 
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    spacing_x_2=info2.PixelSpacing(1)/2^interpfactor2; 
    spacing_y_2=info2.PixelSpacing(2)/2^interpfactor2; 
     
     
elseif data2_orientation_val == 2 % Coronal 
    cube2=permute(cube2,[3 2 1]); 
     
    spacing_y_2=info2.PixelSpacing(2)/2^interpfactor2; 
    spacing_x_2=(info2.GridFrameOffsetVector(2)-
info2.GridFrameOffsetVector(1))/2^interpfactor2; 
     
elseif data2_orientation_val == 3 
     
    cube2=permute(cube2,[3 1 2]); % Sagittal 
     
    spacing_y_2=info2.PixelSpacing(1)/2^interpfactor2; 
    spacing_x_2=(info2.GridFrameOffsetVector(2)-
info2.GridFrameOffsetVector(1))/2^interpfactor2; 
     
end 
 
[sizex_2, sizey_2, sizez_2]=size(cube2); 
 
search_dist_z = round(distanceCriterion * 4 / (slice_thickness * 
2^interpfactor)); 
%search_dist=round(distanceCriterion*2*2^interp_1); 
search_dist_x=6; 
search_dist_y=6; 
 
offset_x=(sizex_2*(abs(spacing_x_2/spacing_x_1)))-((spacing_x_2/spacing_x_1)-1)-
sizex; 
offset_y=(sizey_2*(abs(spacing_y_2/spacing_y_1)))-((spacing_y_2/spacing_y_1)-1)-
sizey; 
 
if offset_x > 0 
     
    cube2=cube2(1+offset_x/2^interpfactor:sizex_2, 
1+offset_y/2^interpfactor:sizey_2, 1:sizez_2); 
     
    [sizex_2, sizey_2, sizez_2]=size(cube2); 
     
elseif offset_x < 0 && offset_y < 0 
     
    cube2_expand=zeros(sizex, sizey, sizez); 
     
    cube2_expand(1:sizex_2, 1:sizey_2, :)=cube2; 
     
    cube2=cube2_expand; 
     
    [sizex_2, sizey_2, sizez_2]=size(cube2); 
     
end 
 
eval_cube1=zeros(sizex + search_dist_x*2, sizey + search_dist_y*2, sizez + 
search_dist_z*2); 
eval_cube1(:,:,:)=-10^8; 
eval_cube1(search_dist_x + 1 : search_dist_x + sizex,... 
    search_dist_y + 1: search_dist_y + sizey, ... 
    search_dist_z + 1 : search_dist_z + sizez) = cube1; 
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gValue=zeros(search_dist_x * 2 + 1, search_dist_y * 2 + 1, search_dist_z * 2 + 
1); 
gValue(:,:,:)=100; 
distdiff=zeros(search_dist_x * 2 + 1, search_dist_y * 2 + 1, search_dist_z * 2 + 
1); 
gamma=zeros(sizex_2, sizey_2, sizez_2); 
 
for k=1:search_dist_z * 2 + 1 
     
    for i=1:search_dist_x * 2 + 1 
         
        for j=1:search_dist_y * 2 + 1 
             
            distdiff(i,j,k)=sqrt(sqrt((((i-search_dist_x-
1)*spacing_x_1))^2+(((j-search_dist_y-1)*spacing_y_1))^2)^2+((k-search_dist_z-
1)*slice_thickness)^2); 
             
        end 
         
    end 
     
end 
 
 
%######################## 3D vs 3D volume gamma analysis: Wendling proposal  
 
for slice_num=1:sizez_2 
     
    waitbar(slice_num/sizez_2,h); 
     
    if getappdata(h,'canceling') 
        break 
    end 
     
    for x=1:sizex_2 
         
         
        for y=1:sizey_2 
             
            testdose=eval_cube1(1+(x-1)*spacing_x_2/spacing_x_1:(x-
1)*spacing_x_2/spacing_x_1+search_dist_x*2+1,... 
                1+(y-1)*spacing_y_2/spacing_y_1:(y-
1)*spacing_y_2/spacing_y_1+search_dist_y*2+1, ... 
                slice_num*2^interpfactor-search_dist_z+search_dist_z-
(2^interpfactor-1): slice_num*2^interpfactor+search_dist_z+search_dist_z-
(2^interpfactor-1)); 
             
            if local_global==1, 
                 
                 
                test_dosediff=(cube2(x,y,slice_num)-testdose)/normDose; 
                 
            else 
                 
                test_dosediff=(cube2(x,y,slice_num)-testdose)./testdose; 
                 
            end 
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            gValue=sqrt((test_dosediff./doseCriterion).^2 + 
(distdiff./(distanceCriterion)).^2); 
             
            gamma(x,y,slice_num)=min(gValue(:)); 
             
        end 
         
    end 
     
end 
 
 
 
 
 
 
